Edgar Filing: HERCULES TECHNOLOGY GROWTH CAPITAL INC

Form 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 10-Q

(Mark One)

x	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES

EXCHANGE ACT OF 1934

For The Quarterly Period Ended March 31, 2013

¨	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES

EXCHANGE ACT OF 1934

Commission File Number: 814-00702

HERCULES TECHNOLOGY GROWTH

CAPITAL, INC.

(Exact Name of Registrant as Specified in its Charter)

Maryland

743113410

(State or Jurisdiction of

Incorporation or Organization)

(IRS Employer

Identification No.)

400 Hamilton Ave., Suite 310

Palo Alto, California

94301

(Address of Principal Executive Offices)

(Zip Code)

(650) 289-3060

(Registrant’s Telephone Number, Including Area Code)

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter periods that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this Chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ¨ No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.


Large Accelerated Filer	¨	Accelerated Filer	x

Non-Accelerated Filer	¨	Smaller Reporting Company	¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x

On April 30, 2013, there were 61,554,003 shares outstanding of the Registrant’s common stock, $0.001 par value.

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

FORM 10-Q TABLE OF CONTENTS


PART I. FINANCIAL INFORMATION		3

Item 1.	Consolidated Financial Statements	3

	Consolidated Statement of Assets and Liabilities as of March 31, 2013 (unaudited) and December 31, 2012	3

	Consolidated Statement of Operations for the three-month periods ended March 31, 2013 and 2012 (unaudited)	5

	Consolidated Statement of Changes in Net Assets for the three-month periods ended March 31, 2013 and 2012 (unaudited)	6

	Consolidated Statement of Cash Flows for the three-month periods ended March 31, 2013 and 2012 (unaudited)	7

	Consolidated Schedule of Investments as of March 31, 2013 (unaudited)	8

	Consolidated Schedule of Investments as of December 31, 2012	25

	Notes to Consolidated Financial Statements (unaudited)	40

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	64

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	92

Item 4.	Controls and Procedures	94

PART II. OTHER INFORMATION		95

Item 1.	Legal Proceedings	95

Item 1A.	Risk Factors	95

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	97

Item 3.	Defaults Upon Senior Securities	97

Item 4.	Mine Safety Disclosures	97

Item 5.	Other Information	97

Item 6.	Exhibits	97

SIGNATURES		98

PART I: FINANCIAL INFORMATION

In this Quarterly Report, the “Company,” “Hercules,” “we,” “us” and “our” refer to Hercules Technology Growth Capital, Inc. and its wholly owned subsidiaries and its affiliated securitization trusts unless the context otherwise requires.

ITEM 1.

CONSOLIDATED FINANCIAL STATEMENTS

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

CONSOLIDATED STATEMENT OF ASSETS AND LIABILITIES

(unaudited)

(dollars in thousands, except per share data)


	March 31, 2013			December 31, 2012
Assets
Investments:
Non-control/Non-affiliate investments (cost of $957,508 and $896,031, respectively)	$	953,788		$	894,428
Affiliate investments (cost of $20,196 and $18,307, respectively)		14,196			11,872

Total investments, at fair value (cost of $977,704 and $914,338, respectively)		967,984			906,300
Cash and cash equivalents		206,928			182,994
Restricted Cash		810			—
Interest receivable		9,674			9,635
Other assets		25,790			24,714

Total assets	$	1,211,186		$	1,123,643


Liabilities
Accounts payable and accrued liabilities	$	8,456		$	11,575
Long-term Liabilities (Convertible Senior Note)		71,707			71,436
Asset-Backed Notes		120,051			129,300
2019 Notes		170,364			170,364
Long-term SBA Debentures		225,000			225,000

Total liabilities	$	595,578		$	607,675
Commitments and Contingencies (Note 9)
Net assets consist of:
Common stock, par value		62			53
Capital in excess of par value		660,833			564,508
Unrealized depreciation on investments		(8,281	)		(7,947	)
Accumulated realized losses on investments		(34,925	)		(36,916	)
Distributions in excess of investment income		(2,081	)		(3,730	)

Total net assets	$	615,608		$	515,968

Total liabilities and net assets	$	1,211,186		$	1,123,643

Shares of common stock outstanding ($0.001 par value, 100,000,000 authorized)		61,554			52,925
Net asset value per share	$	10.00		$	9.75

See notes to consolidated financial statements.

The following table presents the assets and liabilities of our consolidated variable interest entity (“VIE”). The assets of the VIE can only be used to settle obligations of the consolidated VIE, and the creditors (or beneficial interest holders) do not have recourse to our general credit. These assets and liabilities are included in the Consolidated Statements of Assets and Liabilities above.


(Unaudited, in thousands)	March 31, 2013		December 31, 2012
ASSETS
Restricted Cash	$	810	$	—
Total investments, at fair value (cost of $219,853 and $0, respectively)		218,142		226,997

Total assets	$	218,952	$	226,997


LIABILITIES
Asset-Backed Notes	$	120,051	$	129,300

Total liabilities	$	120,051	$	129,300

See notes to consolidated financial statements.

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(unaudited)

(in thousands, except per share data)


	Three Months Ended March 31,
	2013			2012
Investment income:
Interest Income
Non-control/Non-affiliate investments	$	28,319		$	20,281
Affiliate investments		610			6
Control investments		—			13

Total interest income		28,929			20,300

Fees
Non-control/Non-affiliate investments		2,028			2,067

Total fees		2,028			2,067

Total investment income		30,957			22,367

Operating expenses:
Interest		7,631			3,896
Loan fees		1,079			1,076
General and administrative		2,252			1,817
Employee Compensation:
Compensation and benefits		3,798			3,395
Stock-based compensation		1,165			808

Total employee compensation		4,963			4,203

Total operating expenses		15,925			10,992

Net investment income		15,032			11,375
Net realized (losses) gains on investments
Non-control/Non-affiliate investments		1,991			2,877

Total net realized (loss) gain on investments		1,991			2,877
Net unrealized (depreciation) appreciation on investments
Non-control/Non-affiliate investments		(768	)		1,751
Affiliate investments		434			1,076
Control investments		—			26

Total net unrealized (depreciation) appreciation on investments		(334	)		2,853

Total net realized (unrealized) gain		1,657			5,730
Net increase in net assets resulting from operations	$	16,689		$	17,105
Net investment income before investment gains and losses per common share:
Basic	$	0.27		$	0.24
Change in net assets per common share:
Basic	$	0.30		$	0.36
Diluted	$	0.30		$	0.36
Weighted average shares outstanding
Basic		53,682			47,018
Diluted		53,823			47,210

See notes to consolidated financial statements.

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

CONSOLIDATED STATEMENT OF CHANGES IN NET ASSETS

(unaudited)

(dollars and shares in thousands)


	Common Stock					Capital in excess of par value			Unrealized Appreciation on Investments			Accumulated Realized Gains (Losses) on Investments			Distributions in Excess of Investment Income			Provision for Income Taxes on Investment Gains			Net Assets
	Shares			Par Value		Capital in excess of par value			Unrealized Appreciation on Investments			Accumulated Realized Gains (Losses) on Investments			Distributions in Excess of Investment Income						Net Assets
Balance at December 31, 2011		43,853		$	44	$	484,244		$	(3,431	)	$	(43,042	)	$	(6,432	)	$	(342	)	$	431,041

Net increase in net assets resulting from operations		—			—		—			2,853			2,877			11,375			—			17,105
Issuance of common stock		5,425			5		49,773			—			—			—			—			49,778
Issuance of common stock under restricted stock plan		620			1		—			—			—			—			—			1
Issuance of common stock as stock dividend		62			—		670			—			—			—			—			670
Retired shares from net issuance		(239	)		—		(2,562	)		—			—			—			—			(2,562	)
Dividends declared		—			—		—			—			—			(11,412	)		—			(11,412	)
Stock-based compensation		—			—		826			—			—			—			—			826

Balance at March 31, 2012		49,721		$	50	$	532,951		$	(578	)	$	(40,165	)	$	(6,469	)	$	(342	)	$	485,447


Balance at December 31, 2012		52,925		$	53	$	564,509		$	(7,947	)	$	(36,916	)	$	(3,389	)	$	(342	)	$	515,968

Net increase in net assets resulting from operations		—			—		—			(334	)		1,991			15,032			—			16,689
Issuance of common stock		80			—		910			—			—			—			—			910
Issuance of common stock under restricted stock plan		531			1		(1	)		—			—			—			—			—
Issuance of common stock as stock dividend		40			—		488			—			—			—			—			488
Retired shares from net issuance		(72	)		—		(1,808	)		—			—			—			—			(1,808	)
Public Offering		8,050			8		95,550			—			—			—			—			95,558
Dividends declared		—			—		—			—			—			(13,382	)		—			(13,382	)
Stock-based compensation		—			—		1,185			—			—			—			—			1,185

Balance at March 31, 2013		61,554		$	62	$	660,833		$	(8,281	)	$	(34,925	)	$	(1,739	)	$	(342	)	$	615,608

See notes to consolidated financial statements.

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(unaudited)

(dollars in thousands)


	For the Three Months Ended March 31,
	2013			2012
Cash flows from operating activities:
Net increase in net assets resulting from operations	$	16,689		$	17,105
Adjustments to reconcile net increase in net assets resulting from operations to net cash used in operating activities:
Purchase of investments		(139,095	)		(64,961	)
Principal payments received on investments		75,987			35,533
Proceeds from sale of investments		5,212			8,726
Net unrealized (appreciation) / depreciation on investments		334			(2,853	)
Net realized (gain) / loss on investments		(1,991	)		(2,877	)
Accretion of paid-in-kind principal		(555	)		(280	)
Accretion of loan discounts		(1,455	)		(916	)
Accretion of loan discount on Convertible Senior Notes		271			271
Accretion of loan exit fees		(1,819	)		(2,685	)
Change in deferred loan origination revenue		313			(198	)
Unearned fees related to unfunded commitments		(856	)		(2,360	)
Amortization of debt fees and issuance costs		938			913
Depreciation		68			71
Stock-based compensation and amortization of restricted stock grants		1,185			826
Change in operating assets and liabilities:
Interest and fees receivable		(41	)		(143	)
Prepaid expenses and other assets		33			(75	)
Accounts payable		(250	)		(51	)
Accrued liabilities		(2,682	)		(3,733	)


Net cash used in operating activities		(47,714	)		(17,687	)
Cash flows from investing activities:
Purchases of capital equipment		(24	)		(12	)
Investment in restricted cash		(810	)		—
Other long-term assets		(30	)		—


Net cash used in investing activities		(864	)		(12	)
Cash flows from financing activities:
Proceeds from issuance of common stock, net		94,660			47,218
Dividends paid		(12,894	)		(10,742	)
Repayments of credit facilities		(9,254	)		(34,818	)


Net cash provided by financing activities		72,512			1,658

Net increase / (decrease) in cash		23,934			(16,041	)
Cash and cash equivalents at beginning of year		182,994			64,474


Cash and cash equivalents at end of year	$	206,928		$	48,433

See notes to consolidated financial statements.

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

March 31, 2013

(unaudited)

(dollars in thousands)


Portfolio Company	Sub-Industry	Type of Investment⁽¹⁾	Principal Amount		Cost⁽²⁾		Value⁽³⁾
Maturity: Upon Liquidation
Paratek Pharmaceuticals, Inc.	Drug Discovery & Development	Senior Debt⁽⁹⁾
		Matures upon liquidation Interest rate Fixed 10.00%	$	45	$	45	$	45
		Senior Debt⁽⁹⁾
		Matures upon liquidation Interest rate Fixed 10.00%	$	36		31		31
		Senior Debt⁽⁹⁾
		Matures upon liquidation No initial interest rate	$	28		28		28

Total Paratek Pharmaceuticals, Inc.						104		104
Maturity: Under 1 Year Maturity
Chroma Therapeutics, Ltd.^(5)(10)	Drug Discovery & Development	Senior Debt
		Matures November 2013 Interest rate Prime + 7.75% or Floor rate of 12.00%	$	3,007		3,714		3,675
Maturity: 1-5 Years Maturity
ADMA Biologics, Inc.	Drug Discovery & Development	Senior Debt
		Matures April 2016 Interest rate Prime + 2.75% or Floor rate of 8.50%	$	5,000		4,844		4,844
Anthera Pharmaceuticals Inc.⁽³⁾	Drug Discovery & Development	Senior Debt⁽¹¹⁾
		Matures December 2014 Interest rate Prime + 7.30% or Floor rate of 10.55%	$	18,199		18,574		18,574
Aveo Pharmaceuticals, Inc.⁽³⁾	Drug Discovery & Development	Senior Debt⁽¹¹⁾
		Matures September 2015 Interest rate Prime + 7.15% or Floor rate of 11.90%	$	26,500		26,500		27,030
Cell Therapeutics, Inc.⁽³⁾	Drug Discovery & Development	Senior Debt
		Matures October 2016 Interest rate Prime + 9.00% or Floor rate of 12.25%	$	10,000		9,670		9,670
Cempra, Inc.⁽³⁾	Drug Discovery & Development	Senior Debt⁽¹¹⁾
		Matures December 2015 Interest rate Prime + 6.30% or Floor rate of 9.55%	$	10,000		9,898		9,815
Concert Pharmaceuticals, Inc.	Drug Discovery & Development	Senior Debt⁽⁴⁾
		Matures October 2015 Interest rate Prime + 3.25% or Floor rate of 8.50%	$	20,000		19,687		18,946
Coronado BioSciences, Inc.⁽³⁾	Drug Discovery & Development	Senior Debt⁽¹¹⁾
		Matures March 2016 Interest rate Prime + 6.00% or Floor rate of 9.25%	$	15,000		14,838		14,430
Dicerna Pharmaceuticals, Inc.	Drug Discovery & Development	Senior Debt
		Matures January 2015 Interest rate Prime + 4.40% or Floor rate of 10.15%	$	8,168		8,039		7,921
Insmed, Inc.	Drug Discovery & Development	Senior Debt⁽¹¹⁾
		Matures January 2016 Interest rate Prime + 4.75% or Floor rate of 9.25%	$	20,000		19,438		19,498
Merrimack Pharmaceuticals, Inc.	Drug Discovery & Development	Senior Debt
		Matures May 2016 Interest rate Prime + 5.30% or Floor rate of 10.55%	$	40,000		39,840		39,840

See notes to consolidated financial statements.

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS—(Continued)

March 31, 2013

(unaudited)

(dollars in thousands)


Portfolio Company	Sub-Industry	Type of Investment⁽¹⁾	Principal Amount		Cost⁽²⁾		Value⁽³⁾
Neuralstem, Inc.⁽³⁾	Drug Discovery & Development	Senior Debt
		Matures June 2016 Interest rate Prime + 7.75% or Floor rate of 11.00%	$	8,000	$	7,654	$	7,654
NeurogesX, Inc.⁽³⁾	Drug Discovery & Development	Senior Debt
		Matures February 2015 Interest rate Prime + 7.50% or Floor rate of 10.75%	$	4,041		4,429		4,397

Total Debt Drug Discovery & Development (30.28%)*						187,229		186,398

Maturity: Under 1 Year Maturity
PeerApp, Inc.	Communications & Networking	Senior Debt⁽⁴⁾
		Matures April 2013 Interest rate Prime + 7.50% or Floor rate of 11.50%	$	159		248		248
Maturity: 1-5 Years Maturity
Bridgewave Communications	Communications & Networking	Senior Debt
		Matures March 2016 Interest rate Fixed 8.00%	$	7,500		7,163		4,369
OpenPeak, Inc.	Communications & Networking	Senior Debt⁽¹¹⁾
		Matures July 2015 Interest rate Prime + 8.75% or Floor rate of 12.00%	$	14,129		14,330		14,472
UPH Holdings, Inc.⁽⁸⁾	Communications & Networking	Senior Debt
		Matures April 2015 Interest rate Libor + 11.00% or Floor rate of 13.50%	$	6,600		6,489		3,478
		Senior Debt
		Matures September 2015 Interest rate Libor + 11.00% or Floor rate of 13.50%	$	338		333		178
		Senior Debt
		Matures January 2017 Interest rate Libor + 11.00% or Floor rate of 13.50%	$	3,594		3,594		1,894

Total UPH Holdings, Inc.						10,416		5,550

Total Debt Communications & Networking (4.00%)*						32,157		24,639

Maturity: 1-5 Years Maturity
Clustrix, Inc.	Electronics & Computer Hardware	Senior Debt
		Matures December 2015 Interest rate Prime + 6.50% or Floor rate of 9.75%	$	696		669		678
Identive Group, Inc.	Electronics & Computer Hardware	Senior Debt
		Matures November 2015 Interest rate Prime + 7.75% or Floor rate 11.00%	$	7,500		7,562		7,562
OCZ Technology Group, Inc.⁽³⁾	Electronics & Computer Hardware	Senior Debt
		Matures April 2016 Interest rate Prime + 8.75% or Floor rate of 12.50%, PIK Interest 3.00%	$	10,000		9,473		9,473

Total Debt Electronics & Computer Hardware (2.88%)						17,704		17,713

Maturity: Upon Liquidation
Tada Innovations, Inc.	Software	Senior Debt⁽⁹⁾
		Matures upon liquidation Interest rate Fixed 8.00%	$	100		100		—

See notes to consolidated financial statements.

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS—(Continued)

March 31, 2013

(unaudited)

(dollars in thousands)


Portfolio Company	Sub-Industry	Type of Investment⁽¹⁾	Principal Amount		Cost⁽²⁾		Value⁽³⁾
Maturity: 1-5 Years Maturity
Box, Inc.	Software	Senior Debt⁽⁴⁾
		Matures March 2016 Interest rate Prime + 3.75% or Floor rate of 7.50%	$	10,000	$	9,947	$	9,513
		Senior Debt⁽⁴⁾
		Matures July 2014 Interest rate Prime + 5.25% or Floor rate of 8.50%	$	866		930		919
		Senior Debt⁽¹¹⁾
		Matures July 2016 Interest rate Prime + 5.13% or Floor rate of 8.88%	$	20,000		20,211		19,574

Total Box, Inc.						31,088		30,006
Clickfox, Inc.	Software	Senior Debt
		Matures November 2015 Interest rate Prime + 8.25% or Floor rate of 11.50%	$	7,788		7,209		7,443
EndPlay,Inc.	Software	Senior Debt
		Matures August 2015 Interest rate Prime + 7.35% or Floor rate 10.6%	$	2,000		1,945		1,945
Hillcrest Laboratories, Inc	Software	Senior Debt
		Matures July 2015 Interest rate Prime + 7.50% or Floor rate of 10.75%	$	3,764		3,701		3,664
JackBe Corporation	Software	Senior Debt
		Matures January 2016 Interest rate Prime + 7.25% or Floor rate of 10.50%	$	3,000		2,922		2,929
Kxen, Inc.	Software	Senior Debt⁽⁴⁾
		Matures January 2015 Interest rate Prime + 5.08% or Floor rate of 8.33%	$	2,078		2,126		1,980
Neos Geosolutions, Inc.	Software	Senior Debt
		Matures May 2016 Interest rate Prime + 5.75% or Floor rate of 9.50%	$	4,000		3,955		3,955

Total Debt Software (8.44%)*						53,046		51,922

Maturity: Under 1 Year Maturity
Althea Technologies, Inc.	Specialty Pharmaceuticals	Senior Debt
		Matures October 2013 Interest rate Prime + 7.70% or Floor rate of 10.95%	$	6,933		7,285		7,285
Quatrx Pharmaceuticals Company	Specialty Pharmaceuticals	Senior Debt⁽⁹⁾
		Matures March 2014 Interest rate Fixed 8.00%	$	1,888		1,888		2,767

Total Debt Specialty Pharmaceuticals (1.63%)*						9,173		10,052

Maturity: 1-5 Years Maturity
Achronix Semiconductor Corporation	Semiconductors	Senior Debt
		Matures January 2015 Interest rate Prime + 10.60% or Floor rate of 13.85%	$	1,653		1,618		1,602

Total Debt Semiconductors (0.26%)*						1,618		1,602

See notes to consolidated financial statements.

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS—(Continued)

March 31, 2013

(unaudited)

(dollars in thousands)


Portfolio Company	Sub-Industry	Type of Investment⁽¹⁾	Principal Amount		Cost⁽²⁾		Value⁽³⁾
Maturity: Under 1 Year Maturity
Alexza Pharmaceuticals, Inc.⁽³⁾	Drug Delivery	Senior Debt⁽¹¹⁾
		Matures October 2013 Interest rate Prime + 6.50% or Floor rate of 10.75%	$	3,594	$	3,994	$	3,994
Maturity: 1-5 Years Maturity
AcelRX Pharmaceuticals, Inc.⁽³⁾	Drug Delivery	Senior Debt⁽¹¹⁾
		Matures December 2014 Interest rate Prime + 3.25% or Floor rate of 8.50%	$	14,452		14,402		14,108
BIND Therapeutics, Inc.	Drug Delivery	Senior Debt
		Matures July 2014 Interest rate Prime + 7.45% or Floor rate of 10.70%	$	2,838		2,875		2,926
Intelliject, Inc.	Drug Delivery	Senior Debt⁽¹¹⁾
		Matures June 2016 Interest rate Prime + 5.75% or Floor rate of 11.00%	$	15,000		14,705		15,155
Nupathe, Inc.⁽³⁾	Drug Delivery	Senior Debt
		Matures May 2016 Interest rate Prime - 3.25% or Floor rate of 9.85%	$	8,500		8,220		8,220
Revance Therapeutics, Inc.	Drug Delivery	Senior Debt
		Matures March 2015 Interest rate Prime + 6.60% or Floor rate of 9.85%	$	16,594		16,582		16,379

Total Debt Drug Delivery (9.87%)*						60,778		60,782

Maturity: Under 1 Year Maturity
Loku, Inc.	Internet Consumer & Business Services	Senior Debt⁽⁹⁾
		Matures June 2013 Interest rate Fixed 6.00%	$	100		100		100
Tectura Corporation	Internet Consumer & Business Services	Revolving Line of Credit
		Matures July 2013 Interest rate LIBOR + 8.00% or Floor rate of 11.00%	$	16,340		18,033		17,663
		Senior Debt
		Matures April 2013 Interest rate LIBOR + 10.00% or Floor rate of 13.00%	$	563		553		553
		Senior Debt
		Matures July 2013 Interest rate LIBOR + 10.00% or Floor rate of 13.00%	$	1,000		1,000		1,000

Total Tectura Corporation						19,586		19,216
Maturity: 1-5 Years Maturity
Ahhha, Inc.⁽⁸⁾	Internet Consumer & Business Services	Senior Debt
		Matures January 2015 Interest rate Fixed 12.00%	$	350		347		—
Blurb, Inc.	Internet Consumer & Business Services	Senior Debt
		Matures December 2015 Interest rate Prime + 5.25% or Floor rate 8.50%	$	8,000		7,749		7,547
Education Dynamics, LLC	Internet Consumer & Business Services	Senior Debt
		Matures March 2016 Interest rate Fixed 12.50%, PIK Interest 1.50%	$	26,750		26,386		25,563

See notes to consolidated financial statements.

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS—(Continued)

March 31, 2013

(unaudited)

(dollars in thousands)


Portfolio Company	Sub-Industry	Type of Investment⁽¹⁾	Principal Amount		Cost⁽²⁾		Value⁽³⁾
Just.Me, Inc.	Internet Consumer & Business Services	Senior Debt
		Matures June 2015 Interest rate Prime + 2.50% or Floor rate 5.75%	$	750	$	737	$	689
		Senior Debt
		Matures June 2015 Interest rate Prime + 5.00% or Floor rate 8.25%	$	750		732		709

Total Just.Me, Inc.						1,469		1,398
NetPlenish, Inc.	Internet Consumer & Business Services	Senior Debt
		Matures April 2015 Interest rate Fixed 10.00%	$	500		492		460
Reply! Inc.	Internet Consumer & Business Services	Senior Debt⁽¹¹⁾
		Matures September 2015 Interest rate Prime + 6.875% or Floor rate of 10.125%	$	11,749		11,638		11,525
		Senior Debt⁽¹¹⁾
		Matures September 2015 Interest rate Prime + 7.25% or Floor rate of 11.00%	$	2,000		1,957		2,005
		Senior Debt
		Matures February 2016 Interest rate Prime + 7.25% or Floor rate of 10.50%	$	3,000		2,977		2,977

Total Reply! Inc.						16,572		16,507
Second Rotation, Inc.	Internet Consumer & Business Services	Senior Debt
		Matures April 2016 Interest rate Prime + 7.00% or Floor rate of 10.25%, PIK interest 2.50%	$	12,142		12,013		12,013
ShareThis, Inc.	Internet Consumer & Business Services	Senior Debt
		Matures June 2016 Interest rate Prime + 7.50% or Floor rate of 10.75%	$	15,000		14,349		14,349
Tectura Corporation	Internet Consumer & Business Services	Senior Debt
		Matures December 2014 Interest rate LIBOR + 10.00% or Floor rate of 13.00%	$	6,468		6,412		6,230
Trulia, Inc.⁽³⁾	Internet Consumer & Business Services	Senior Debt⁽¹¹⁾
		Matures September 2015 Interest rate Prime + 2.75% or Floor rate of 6.00%	$	5,000		4,934		4,794
		Senior Debt⁽¹¹⁾
		Matures September 2015 Interest rate Prime + 5.50% or Floor rate of 8.75%	$	5,000		4,933		4,640

Total Trulia, Inc.						9,867		9,434
Vaultlogix, Inc.	Internet Consumer & Business Services	Senior Debt
		Matures September 2016 Interest rate LIBOR + 8.50% or Floor rate of 10.00%, PIK interest 2.50%	$	7,500		7,740		7,680
		Senior Debt
		Matures September 2015 Interest rate LIBOR + 7.00% or Floor rate of 8.50%	$	9,903		9,864		9,580

Total Vaultlogix, Inc.						17,604		17,260

See notes to consolidated financial statements.

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS—(Continued)

March 31, 2013

(unaudited)

(dollars in thousands)


Portfolio Company	Sub-Industry	Type of Investment⁽¹⁾	Principal Amount		Cost⁽²⁾		Value⁽³⁾
Wavemarket, Inc.	Internet Consumer & Business Services	Senior Debt⁽¹¹⁾
		Matures September 2015 Interest rate Prime + 5.75% or Floor rate of 9.50%	$	10,000	$	9,876	$	9,458

Total Debt Internet Consumer & Business Services (22.67%)*						142,822		139,535

Maturity: Under 1 Year Maturity
InXpo, Inc.	Information Services	Senior Debt
		Matures March 2014 Interest rate Prime + 7.50% or Floor rate of 10.75%	$	2,550		2,432		2,316
Maturity: 1-5 Years Maturity
Cha Cha Search, Inc.	Information Services	Senior Debt
		Matures February 2015 Interest rate Prime + 6.25% or Floor rate of 9.50%	$	2,364		2,334		2,277
Eccentex Corporation	Information Services	Senior Debt⁽¹¹⁾
		Matures May 2015 Interest rate Prime + 7.00% or Floor rate of 10.25%	$	966		949		449
Jab Wireless, Inc.	Information Services	Senior Debt
		Matures November 2017 Interest rate Prime + 6.75% or Floor rate of 8.00%	$	30,000		29,861		29,850
RichRelevance, Inc.	Information Services	Senior Debt
		Matures January 2015 Interest rate Prime + 3.25% or Floor rate of 7.50%	$	3,778		3,762		3,661
Womensforum.com, Inc.	Information Services	Senior Debt⁽¹¹⁾
		Matures October 2016 Interest rate LIBOR + 6.50% or Floor rate of 9.25%	$	8,000		7,853		7,853
		Senior Debt⁽¹¹⁾
		Matures October 2016 Interest rate LIBOR + 7.50% or Floor rate of 10.25%	$	4,500		4,451		4,451

Total Womensforum.com, Inc.						12,304		12,304

Total Debt Information Services (8.26%)*						51,642		50,857

Maturity: Upon Liquidation
Novasys Medical, Inc.	Medical Device & Equipment	Senior Debt⁽⁹⁾
		Matures upon liquidation Interest rate Fixed 8.00%	$	65		65		65
Maturity: Under 1 Year Maturity
Gynesonics, Inc.	Medical Device & Equipment	Senior Debt
		Matures October 2013 Interest rate Prime + 8.25% or Floor rate of 11.50%	$	3,073		3,178		3,178
Optiscan Biomedical, Corp.⁽⁶⁾	Medical Device & Equipment	Senior Debt
		Matures December 2013 Interest rate Prime + 8.20% or Floor rate of 11.45%	$	8,260		9,101		9,265
Oraya Therapeutics, Inc.	Medical Device & Equipment	Senior Debt⁽⁹⁾
		Matures December 2013 Interest rate Fixed 7.00%	$	500		500		500

See notes to consolidated financial statements.

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS—(Continued)

March 31, 2013

(unaudited)

(dollars in thousands)


Portfolio Company	Sub-Industry	Type of Investment⁽¹⁾	Principal Amount		Cost⁽²⁾		Value⁽³⁾
Maturity: 1-5 Years Maturity
Lanx, Inc.	Medical Device & Equipment	Senior Debt
		Matures October 2016 Interest rate Prime + 8.00% or Floor rate of 11.75%	$	15,000	$	14,651	$	15,101
		Revolving Line of Credit
		Matures October 2015 Interest rate Prime + 6.75% or Floor rate of 10.50%	$	5,500		5,313		5,276

Total Lanx, Inc.						19,964		20,377
Medrobotics Corporation	Medical Device & Equipment	Senior Debt
		Matures March 2016 Interest rate Prime + 7.85% or Floor rate of 11.10%	$	5,000		4,766		4,766
MELA Sciences, Inc.	Medical Device & Equipment	Senior Debt
		Matures November 2016 Interest rate Prime + 7.20% or Floor rate of 10.45%	$	6,000		5,919		5,919
NinePoint Medical, Inc.	Medical Device & Equipment	Senior Debt
		Matures January 2016 Interest rate Prime + 5.85% or Floor rate of 9.10%	$	7,000		6,805		6,805
Oraya Therapeutics, Inc.	Medical Device & Equipment	Senior Debt⁽¹¹⁾
		Matures September 2015 Interest rate Prime + 5.50% or Floor rate of 10.25%	$	9,711		9,542		9,678
United Orthopedic Group, Inc.	Medical Device & Equipment	Senior Debt
		Matures July 2016 Interest rate Prime + 8.60% or Floor rate of 11.85%	$	25,000		24,215		24,215
SonaCare Medical, LLC	Medical Device & Equipment	Senior Debt⁽¹¹⁾
		Matures April 2016 Interest rate Prime + 7.75% or Floor rate of 11.00%	$	6,000		5,919		5,855

Total Debt Medical Device & Equipment (14.72%)*						89,974		90,623

Maturity: 1-5 Years Maturity
Navidea Biopharmaceuticals, Inc. (pka Neoprobe)⁽³⁾	Diagnostic	Senior Debt
		Matures December 2014 Interest rate Prime + 6.75% or Floor rate of 10.00%	$	5,086		5,086		5,147
Tethys Bioscience Inc.	Diagnostic	Senior Debt⁽¹¹⁾
		Matures December 2015 Interest rate Prime + 8.40% or Floor rate of 11.65%	$	10,000		10,057		9,614

Total Debt Diagnostic (2.40%)*						15,143		14,761

See notes to consolidated financial statements.

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS—(Continued)

March 31, 2013

(unaudited)

(dollars in thousands)


Portfolio Company	Sub-Industry	Type of Investment⁽¹⁾	Principal Amount		Cost⁽²⁾		Value⁽³⁾
Maturity: Under 1 Year Maturity
Labcyte, Inc.	Biotechnology Tools	Senior Debt
		Matures May 2013 Interest rate Prime + 8.60% or Floor rate of 11.85%	$	315	$	394	$	394
Maturity: 1-5 Years Maturity
Labcyte, Inc.	Biotechnology Tools	Senior Debt⁽¹¹⁾
		Matures June 2016 Interest rate Prime + 6.70% or Floor rate of 9.95%	$	5,000		4,932		4,980

Total Debt Biotechnology Tools (0.87%)*						5,326		5,374

Maturity: 1-5 Years Maturity
MedCall, LLC	Healthcare Services, Other	Senior Debt
		Matures January 2016 Interest rate 7.79% or Floor rate of 9.50%	$	4,778		4,727		4,606
		Senior Debt
		Matures January 2016 Interest rate LIBOR +8.00% or Floor rate of 10.00%	$	3,931		3,873		3,801

Total MedCall, LLC						8,600		8,407
Pacific Child & Family Associates, LLC	Healthcare Services, Other	Senior Debt
		Matures January 2015 Interest rate LIBOR + 8.00% or Floor rate of 11.50%	$	2,737		2,741		2,686
		Senior Debt
		Matures January 2015 Interest rate LIBOR + 11.00% or Floor rate of 14.00%, PIK interest 3.75%	$	5,900		6,641		6,382

Total Pacific Child & Family Associates, LLC						9,382		9,068
ScriptSave (Medical Security Card Company, LLC)	Healthcare Services, Other	Senior Debt
		Matures February 2016 Interest rate LIBOR + 8.75% or Floor rate of 11.25%	$	14,067		13,893		13,941

Total Debt Health Services, Other (5.10%)*						31,875		31,416

Maturity: 1-5 Years Maturity
Entrigue Surgical, Inc.	Surgical Devices	Senior Debt
		Matures December 2014 Interest rate Prime + 5.90% or Floor rate of 9.65%	$	2,183		2,168		2,171
Transmedics, Inc.	Surgical Devices	Senior Debt⁽¹¹⁾
		Matures November 2015 Interest rate Fixed 12.95%	$	7,250		7,097		7,097

Total Debt Surgical Devices (1.51%)*						9,265		9,268

Maturity: 1-5 Years Maturity
Westwood One Communications	Media/Content/ Info	Senior Debt
		Matures October 2016 Interest rate LIBOR + 6.50% or Floor rate of 8.00%	$	19,614		18,253		17,890
Women’s Marketing, Inc.	Media/Content/ Info	Senior Debt
		Matures May 2016 Interest rate Libor + 9.50% or Floor rate of 12.00%, PIK interest 3.00%	$	9,681		10,092		10,189
		Senior Debt⁽¹¹⁾
		Matures November 2015 Interest rate Libor + 7.50% or Floor rate of 10.00%	$	15,612		15,389		15,175

Total Women’s Marketing, Inc.						25,481		25,364

See notes to consolidated financial statements.

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS—(Continued)

March 31, 2013

(unaudited)

(dollars in thousands)


Portfolio Company	Sub-Industry	Type of Investment⁽¹⁾	Principal Amount		Cost⁽²⁾		Value⁽³⁾
Zoom Media Corporation	Media/Content/ Info	Senior Debt
		Matures December 2015 Interest rate Prime + 7.25% or Floor rate of 10.50%, PIK interest 3.75%	$	5,000	$	4,738	$	4,738
	Media/Content/ Info	Revolving Line of Credit
		Matures December 2014 Interest rate Prime + 5.25% or Floor rate of 8.50%	$	3,500		3,238		3,238

Total Zoom Media Corporation						7,976		7,976

Total Debt Media/Content/Info (8.32%)*						51,710		51,230

Maturity: Under 1 Year Maturity
BrightSource Energy, Inc.	Clean Tech	Senior Debt
		Matures January 2014 Interest rate Prime + 8.25% or Floor rate of 11.50%	$	35,000		34,645		34,645
Solexel, Inc.	Clean Tech	Senior Debt
		Matures June 2013 Interest rate Prime + 8.25% or Floor rate of 11.50%	$	1,476		1,474		1,474
		Senior Debt
		Matures June 2013 Interest rate Prime + 7.25% or Floor rate of 10.50%	$	169		169		169

Total Solexel, Inc.						1,643		1,643
Maturity: 1-5 Years Maturity
Alphabet Energy, Inc.	Clean Tech	Senior Debt
		Matures February 2015 Interest rate Prime + 5.75% or Floor rate of 9.00%	$	1,772		1,679		1,679
American Supercondutor Corporation⁽³⁾	Clean Tech	Senior Debt⁽¹¹⁾
		Matures December 2014 Interest rate Prime + 7.25% or Floor rate of 11.00%	$	8,077		8,139		8,344
Comverge, Inc.	Clean Tech	Senior Debt
		Matures November 2017 Interest rate LIBOR + 8.00% or Floor rate of 9.50%	$	20,000		19,605		19,605
	Clean Tech	Senior Debt
		Matures November 2017 Interest rate LIBOR + 9.50% or Floor rate of 11.00%	$	14,000		13,754		13,754

Total Comverge, Inc.						33,359		33,359
Enphase Energy, Inc.⁽³⁾	Clean Tech	Senior Debt⁽¹¹⁾
		Matures June 2014 Interest rate Prime + 5.75% or Floor rate of 9.00%	$	3,167		3,169		3,135
	Clean Tech	Senior Debt
		Matures August 2016 Interest rate Prime + 8.25% or Floor rate of 11.50%	$	7,400		7,353		7,353

Total Enphase Energy, Inc.						10,522		10,488
Glori Energy, Inc.	Clean Tech	Senior Debt⁽¹¹⁾
		Matures June 2015 Interest rate Prime + 6.75% or Floor rate of 10.00%	$	8,000		7,913		7,961
Integrated Photovoltaics, Inc.	Clean Tech	Senior Debt
		Matures February 2015 Interest rate Prime + 7.38% or Floor rate of 10.63%	$	2,305		2,239		2,237

See notes to consolidated financial statements.

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS—(Continued)

March 31, 2013

(unaudited)

(dollars in thousands)


Portfolio Company	Sub-Industry	Type of Investment⁽¹⁾	Principal Amount		Cost⁽²⁾		Value⁽³⁾
Polyera Corporation	Clean Tech	Senior Debt
		Matures June 2016 Interest rate Prime + 6.75% or Floor rate of 10.00%	$	3,000	$	2,971	$	2,971
Redwood Systems, Inc.	Clean Tech	Senior Debt
		Matures February 2016 Interest rate Prime + 6.50% or Floor rate of 9.75%	$	5,000		4,993		4,993
SCIenergy, Inc.	Clean Tech	Senior Debt⁽⁴⁾
		Matures September 2015 Interest rate Prime + 8.75% or Floor rate 12.00%	$	5,296		5,194		5,353
Stion Corporation	Clean Tech	Senior Debt⁽⁴⁾
		Matures February 2015 Interest rate Prime + 6.75% or Floor rate of 10.00%	$	6,732		6,765		6,754
TAS Energy, Inc.	Clean Tech	Senior Debt
		Matures February 2015 Interest rate Prime + 7.75% or Floor rate of 11.00%	$	10,000		9,630		9,630
		Senior Debt
		Matures February 2015 Interest rate Prime + 6.25% or Floor rate of 9.50%	$	5,000		4,782		4,782

Total TAS Energy, Inc.						14,412		14,412

Total Debt Clean Tech (21.90%)*						134,474		134,839



Total Debt (143.11%)					$	893,936	$	881,011

See notes to consolidated financial statements.

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS—(Continued)

March 31, 2013

(unaudited)

(dollars in thousands)



Portfolio Company	Sub-Industry	Type of Investment⁽¹⁾	Series	Shares		Cost⁽²⁾		Value⁽³⁾
ADMA Biologics, Inc.	Drug Discovery & Development	Common Stock Warrants			25,000	$	129	$	115
Acceleron Pharmaceuticals, Inc.	Drug Discovery & Development	Common Stock Warrants			46,446		39		55
		Preferred Stock Warrants	Series B		110,270		35		45

Total Warrants Acceleron Pharmaceuticals, Inc.					156,716		74		100
Anthera Pharmaceuticals Inc.⁽³⁾	Drug Discovery & Development	Common Stock Warrants			321,429		984		61
Cell Therapeutics, Inc.⁽³⁾	Drug Discovery & Development	Common Stock Warrants			679,040		300		322
Cempra, Inc.⁽³⁾	Drug Discovery & Development	Common Stock Warrants			39,038		187		49
Chroma Therapeutics, Ltd.^(5)(10)	Drug Discovery & Development	Preferred Stock Warrants	Series D		325,261		490		500
Concert Pharmaceuticals, Inc.	Drug Discovery & Development	Preferred Stock Warrants	Series C		400,000		367		133
Coronado Biosciences, Inc.⁽³⁾	Drug Discovery & Development	Common Stock Warrants			73,009		142		292
Dicerna Pharmaceuticals, Inc.	Drug Discovery & Development	Common Stock Warrants			50,000		28		15
		Preferred Stock Warrants	Series A		525,000		236		161
		Preferred Stock Warrants	Series B		660,000		311		202

Total Warrants Dicerna Pharmaceuticals, Inc.					1,235,000		575		378

See notes to consolidated financial statements.

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS—(Continued)

March 31, 2013

(unaudited)

(dollars in thousands)



Portfolio Company	Sub-Industry	Type of Investment⁽¹⁾	Series	Shares		Cost⁽²⁾		Value⁽³⁾
EpiCept Corporation⁽³⁾	Drug Discovery & Development	Common Stock Warrants			325,204	$	4	$	—
Horizon Pharma, Inc.⁽³⁾	Drug Discovery & Development	Common Stock Warrants			22,408		231		—
Insmed, Incorporated⁽³⁾	Drug Discovery & Development	Common Stock Warrants			329,931		570		1,482
Merrimack Pharmaceuticals, Inc.⁽³⁾	Drug Discovery & Development	Common Stock Warrants			302,143		155		644
Neuralstem, Inc.⁽³⁾	Drug Discovery & Development	Common Stock Warrants			608,695		295		291
NeurogesX, Inc.⁽³⁾	Drug Discovery & Development	Common Stock Warrants			3,421,500		503		71
Portola Pharmaceuticals, Inc.	Drug Discovery & Development	Preferred Stock Warrants	Series B		687,023		151		268

Total Warrants Drug Discovery & Development (0.76%)*							5,157		4,706

Bridgewave Communications	Communications & Networking	Preferred Stock Warrants	Series 5		2,942,618		753		—
Intelepeer, Inc.	Communications & Networking	Preferred Stock Warrants	Series C		117,958		102		184
Neonova Holding Company	Communications & Networking	Preferred Stock Warrants	Series A		450,000		94		21
OpenPeak, Inc.	Communications & Networking	Preferred Stock Warrants	Series E		25,646		149		11
PeerApp, Inc.	Communications & Networking	Preferred Stock Warrants	Series B		298,779		61		64
Peerless Network, Inc.	Communications & Networking	Preferred Stock Warrants	Series A		135,000		94		384
Ping Identity Corporation	Communications & Networking	Preferred Stock Warrants	Series B		1,136,277		52		118
UPH Holdings, Inc.⁽⁸⁾	Communications & Networking	Common Stock Warrants			145,877		131		—
Purcell Systems, Inc.	Communications & Networking	Preferred Stock Warrants	Series B		110,000		123		69
Stoke, Inc.	Communications & Networking	Preferred Stock Warrants	Series C		158,536		53		184
		Preferred Stock Warrants	Series D		72,727		65		80

Total Stoke, Inc.					231,263		118		264

Total Warrants Communications & Networking (0.18%)*							1,677		1,115

Atrenta, Inc.	Software	Preferred Stock Warrants	Series D		392,670		121		325
Box, Inc.	Software	Preferred Stock Warrants	Series C		271,070		117		2,380
		Preferred Stock Warrants	Series B		199,219		73		3,408
		Preferred Stock Warrants	Series D-1		62,255		193		319

Total Box, Inc.					532,544		383		6,107
Braxton Technologies, LLC.	Software	Preferred Stock Warrants	Series A		168,750		188		—
Central Desktop, Inc.	Software	Preferred Stock Warrants	Series B		522,823		108		186
Clickfox, Inc.	Software	Preferred Stock Warrants	Series B		1,038,563		329		364
		Preferred Stock Warrants	Series C		592,019		730		234

Total Clickfox, Inc.					1,630,582		1,059		598
Daegis Inc. (pka Unify Corporation)⁽³⁾	Software	Common Stock Warrants			718,860		1,434		77
Endplay, Inc.	Software	Preferred Stock Warrants	Series B		180,000		67		21
Forescout Technologies, Inc.	Software	Preferred Stock Warrants	Series D		399,687		99		348
Hillcrest Laboratories, Inc.	Software	Preferred Stock Warrants	Series E		1,865,650		55		54
JackBe Corporation	Software	Preferred Stock Warrants	Series C		180,000		73		56
Kxen, Inc.	Software	Preferred Stock Warrants	Series D		184,614		47		7
Neos Geosolutions, Inc.	Software	Preferred Stock Warrants	Series 3		221,150		22		23
Rockyou, Inc.	Software	Preferred Stock Warrants	Series B		41,266		117		—
SugarSync Inc.	Software	Preferred Stock Warrants	Series CC		332,726		78		168
		Preferred Stock Warrants	Series DD		107,526		34		41

Total SugarSync Inc.					440,252		112		209
Tada Innovations, Inc.	Software	Preferred Stock Warrants	Series A		20,833		25		—
White Sky, Inc.	Software	Preferred Stock Warrants	Series B-2		124,295		54		3
WildTangent, Inc.	Software	Preferred Stock Warrants	Series 3A		100,000		238		55

Total Warrants Software (1.31%)*							4,202		8,069

See notes to consolidated financial statements.

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS—(Continued)

March 31, 2013

(unaudited)

(dollars in thousands)


Portfolio Company	Sub-Industry	Type of Investment⁽¹⁾	Series	Shares		Cost⁽²⁾		Value⁽³⁾
Clustrix, Inc.	Electronics & Computer Hardware	Preferred Stock Warrants	Series B		49,732	$	12	$	6
OCZ Technology Group, Inc.⁽³⁾	Electronics & Computer Hardware	Common Stock Warrants			688,073		619		648
Shocking Technologies, Inc.	Electronics & Computer Hardware	Preferred Stock Warrants	Series A-1		181,818		63		201

Total Warrant Electronics & Computer Hardware (0.14%)*							694		855

Althea Technologies, Inc.	Specialty Pharmaceuticals	Preferred Stock Warrants	Series D		502,273		309		4,237
Quatrx Pharmaceuticals Company	Specialty Pharmaceuticals	Preferred Stock Warrants	Series E		340,534		308		—

Total Warrants Specialty Pharmaceuticals (0.69%)*							617		4,237

IPA Holdings, LLC	Consumer & Business Products	Common Stock Warrants			650,000		275		368
Market Force Information, Inc.	Consumer & Business Products	Preferred Stock Warrants	Series A		99,286		24		87
Seven Networks, Inc.	Consumer & Business Products	Preferred Stock Warrants	Series C		1,821,429		174		80
ShareThis, Inc.	Consumer & Business Products	Preferred Stock Warrants	Series B		535,905		547		498
Wavemarket, Inc.	Consumer & Business Products	Preferred Stock Warrants	Series E		1,083,333		106		62

Total Warrant Consumer & Business Products (0.18%)*							1,126		1,095

Achronix Semiconductor Corporation	Semiconductors	Preferred Stock Warrants	Series D		360,000		160		105
Enpirion, Inc.	Semiconductors	Preferred Stock Warrants	Series D		239,872		157		—
iWatt, Inc.	Semiconductors	Preferred Stock Warrants	Series C		558,748		46		16
		Preferred Stock Warrants	Series D		1,954,762		582		316

Total iWatt, Inc.					2,513,510		628		332
Kovio Inc.	Semiconductors	Preferred Stock Warrants	Series B		319,352		92		30

Total Warrants Semiconductors (0.07%)*							1,037		437

AcelRX Pharmaceuticals, Inc.⁽³⁾	Drug Delivery	Common Stock Warrants			274,508		356		564
Alexza Pharmaceuticals, Inc.⁽³⁾	Drug Delivery	Common Stock Warrants			37,639		645		2
BIND Therapeutics, Inc.	Drug Delivery	Preferred Stock Warrants	Series C-1		150,000		291		422
Intelliject, Inc.	Drug Delivery	Preferred Stock Warrants	Series B		82,500		594		965
NuPathe, Inc.⁽³⁾	Drug Delivery	Common Stock Warrants			106,631		139		166
Revance Therapeutics, Inc.	Drug Delivery	Preferred Stock Warrants	Series D		269,663		557		577
Transcept Pharmaceuticals, Inc.⁽³⁾	Drug Delivery	Common Stock Warrants			61,452		87		55

Total Warrant Drug Delivery (0.45%)*							2,669		2,751

Blurb, Inc.	Internet Consumer & Business Services	Preferred Stock Warrants	Series B		439,336		323		318
		Preferred Stock Warrants	Series C		234,280		636		505

Total Blurb, Inc.					673,616		959		823
Invoke Solutions, Inc.	Internet Consumer & Business Services	Common Stock Warrants			53,084		38		—
Just.Me	Internet Consumer & Business Services	Preferred Stock Warrants	Series A		102,299		20		29
Prism Education Group, Inc.	Internet Consumer & Business Services	Preferred Stock Warrants	Series B		200,000		43		—
Reply! Inc.	Internet Consumer & Business Services	Preferred Stock Warrants	Series B		137,225		320		769
Second Rotation, Inc.	Internet Consumer & Business Services	Preferred Stock Warrants	Series D		151,827		165		202
Tectura Corporation	Internet Consumer & Business Services	Preferred Stock Warrants	Series B-1		253,378		51		—

Total Warrants Internet Consumer & Business Services (0.30%)*							1,596		1,823

See notes to consolidated financial statements.

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS—(Continued)

March 31, 2013

(unaudited)

(dollars in thousands)


Portfolio Company	Sub-Industry	Type of Investment⁽¹⁾	Series	Shares		Cost⁽²⁾		Value⁽³⁾
Buzznet, Inc.	Information Services	Preferred Stock Warrants	Series B		19,962	$	9	$	—
Cha Cha Search, Inc.	Information Services	Preferred Stock Warrants	Series F		48,232		58		7
Eccentex Corporation	Information Services	Preferred Stock Warrants	Series A		408,719		31		—
Intelligent Beauty, Inc.	Information Services	Preferred Stock Warrants	Series B		190,234		230		611
InXpo, Inc.	Information Services	Preferred Stock Warrants	Series C		648,400		98		32
		Preferred Stock Warrants	Series C-1		582,015		48		43

Total InXpo, Inc.					1,230,415		146		75
Jab Wireless, Inc.	Information Services	Preferred Stock Warrants	Series A		266,567		265		343
RichRelevance, Inc.	Information Services	Preferred Stock Warrants	Series D		112,749		98		39
Solutionary, Inc.	Information Services	Preferred Stock Warrants	Series A-2		111,311		96		62

Total Warrants Information Services (0.18%)*							933		1,137

EKOS Corporation	Medical Device & Equipment	Preferred Stock Warrants	Series C		4,448,135		327		—
Gelesis, Inc.⁽⁶⁾	Medical Device & Equipment		LLC Interest		263,688		78		108
Lanx, Inc.	Medical Device & Equipment	Preferred Stock Warrants	Series C		1,203,369		441		755
Medrobotics Corporation	Medical Device & Equipment	Preferred Stock Warrants	Series D		424,008		343		404
NinePoint Medical, Inc.	Medical Device & Equipment	Preferred Stock Warrants	Series A		350,000		170		204
Novasys Medical, Inc.	Medical Device & Equipment	Preferred Stock Warrants	Series D		580,447		131		—
		Common Stock Warrants			109,449		2		—

Total Novasys Medical, Inc.					689,896		133		—
Optiscan Biomedical, Corp.⁽⁶⁾	Medical Device & Equipment	Preferred Stock Warrants	Series D		6,206,187		1,252		432
Oraya Therapeutics, Inc.	Medical Device & Equipment	Preferred Stock Warrants	Series C		716,948		676		266
		Common Stock Warrants			95,498		66		47

Total Oraya Therapeutics, Inc.					812,446		742		313
United Orthopedic Group, Inc.	Medical Device & Equipment	Preferred Stock Warrants	Series A		423,076		608		599
SonaCare Medical, LLC	Medical Device & Equipment	Preferred Stock Warrants	Series G		141,388		188		110

Total Warrants Medical Device & Equipment (0.47%)*							4,282		2,925

Navidea Biopharmaceuticals, Inc. (pka Neoprobe)⁽³⁾	Diagnostic	Common Stock Warrants			333,333		244		318
Tethys Bioscience, Inc.	Diagnostic	Preferred Stock Warrants	Series E		617,683		147		117

Total Warrants Diagnostic (0.07%)*							391		435

Labcyte, Inc.	Biotechnology Tools	Preferred Stock Warrants	Series C		1,127,624		323		254
NuGEN Technologies, Inc.	Biotechnology Tools	Preferred Stock Warrants	Series B		204,545		45		202
		Preferred Stock Warrants	Series C		30,114		33		11

Total NuGEN Technologies, Inc.					234,659		78		213

Total Warrants Biotechnology Tools (0.08%)*							401		467

Entrigue Surgical, Inc.	Surgical Devices	Preferred Stock Warrants	Series B		62,500		87		—
Transmedics, Inc.	Surgical Devices	Preferred Stock Warrants	Series B		40,436		225		—
		Preferred Stock Warrants	Series D		175,000		100		227

Total Transmedics, Inc.					215,436		325		227
Gynesonics, Inc.	Surgical Devices	Preferred Stock Warrants	Series C		1,756,444		412		343

Total Warrants Surgical Devices (0.09%)*							824		570

Everyday Health, Inc. (pka Waterfront Media, Inc.)	Media/Content/ Info	Preferred Stock Warrants	Series C		110,018		60		76
Glam Media, Inc.	Media/Content/ Info	Preferred Stock Warrants	Series D		407,457		482		—
Zoom Media Group, Inc.	Media/Content/ Info	Preferred Stock Warrants	n/a		1,204		348		337

Total Warrants Media/Content/Info (0.07%)*							890		413

See notes to consolidated financial statements.

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS—(Continued)

March 31, 2013

(unaudited)

(dollars in thousands)


Portfolio Company	Sub-Industry	Type of Investment⁽¹⁾	Series	Shares		Cost⁽²⁾		Value⁽³⁾
Alphabet Energy, Inc.	Clean Tech	Preferred Stock Warrants	Series A		86,328	$	83	$	141
American Supercondutor Corporation⁽³⁾	Clean Tech	Common Stock Warrants			139,275		244		123
BrightSource Energy, Inc.	Clean Tech	Preferred Stock Warrants	Series D		174,999		779		156
Calera, Inc.	Clean Tech	Preferred Stock Warrants	Series C		44,529		513		—
EcoMotors, Inc.	Clean Tech	Preferred Stock Warrants	Series B		437,500		308		490
Enphase Energy, Inc.⁽³⁾	Clean Tech	Common Stock Warrants			37,500		102		55
Fulcrum Bioenergy, Inc.	Clean Tech	Preferred Stock Warrants	Series C-1		187,265		211		133
Glori Energy, Inc.	Clean Tech	Preferred Stock Warrants	Series C		145,932		165		71
GreatPoint Energy, Inc.	Clean Tech	Preferred Stock Warrants	Series D-1		393,212		548		—
Integrated Photovoltaics, Inc.	Clean Tech	Preferred Stock Warrants	Series A-1		390,000		82		108
Polyera Corporation	Clean Tech	Preferred Stock Warrants	Series C		161,575		69		70
Propel Biofuels, Inc.	Clean Tech	Preferred Stock Warrants	Series C		3,200,000		211		227
Redwood Systems, Inc.	Clean Tech	Preferred Stock Warrants	Series C		331,250		3		—
SCIenergy, Inc.	Clean Tech	Preferred Stock Warrants	Series D		1,061,168		361		163
Solexel, Inc.	Clean Tech	Preferred Stock Warrants	Series B		245,682		1,161		9
Stion Corporation	Clean Tech	Preferred Stock Warrants	Series E		110,226		317		142
TAS Energy, Inc.	Clean Tech	Preferred Stock Warrants	Series A		37,406		299		272
Trilliant, Inc.	Clean Tech	Preferred Stock Warrants	Series A		320,000		162		54

Total Warrants Clean Tech (0.36%)*							5,618		2,214



Total Warrants (5.40%)						$	32,114	$	33,249

Aveo Pharmaceuticals, Inc.⁽³⁾	Drug Discovery & Development	Common Stock			167,864		842		1,234
Dicerna Pharmaceuticals, Inc.	Drug Discovery & Development	Preferred Stock	Series B		502,684		502		454
Inotek Pharmaceuticals Corp.	Drug Discovery & Development	Preferred Stock	Series C		15,334		1,500		—
Merrimack Pharmaceuticals, Inc.⁽³⁾	Drug Discovery & Development	Common Stock			546,448		2,000		3,333
Paratek Pharmaceuticals, Inc.	Drug Discovery & Development	Preferred Stock	Series H		244,158		1,000		376
		Common Stock			47,471		5		5

Total Paratek Pharmaceuticals, Inc.					291,629		1,005		381

Total Equity Drug Discovery & Development (0.88%)*							5,849		5,402

Acceleron Pharmaceuticals, Inc.	Drug Delivery	Preferred Stock	Series B		186,674		69		239
		Preferred Stock	Series B		600,601		243		227
		Preferred Stock	Series C		93,456		97		226
		Preferred Stock	Series E		43,488		61		63
		Preferred Stock	Series F		19,268		1,000		1,011

Total Acceleron Pharmaceuticals, Inc.					756,813		1,470		1,766
Merrion Pharma, Plc.^(3)(5)(10)	Drug Delivery	Common Stock			20,000		9		—
Nupathe, Inc.	Drug Delivery	Common Stock			50,000		146		162
Transcept Pharmaceuticals, Inc.⁽³⁾	Drug Delivery	Common Stock			41,570		500		199

Total Equity Drug Delivery (0.35%)*							2,125		2,127

Trulia, Inc.	Internet Consumer & Business Services	Common Stock			29,740		141		1,005
Philotic, Inc.	Internet Consumer & Business Services	Common Stock			8,121		93		—

Total Equity Internet Consumers & Business Services (0.16%)*							234		1,005

E-band Communications, Corp.⁽⁶⁾	Communications & Networking	Preferred Stock	Series B		564,972		2,000		—
		Preferred Stock	Series C		649,998		372		—
		Preferred Stock	Series D		847,544		508		—
		Preferred Stock	Series E		1,987,605		374		—

See notes to consolidated financial statements.

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS—(Continued)

March 31, 2013

(unaudited)

(dollars in thousands)


Portfolio Company	Sub-Industry	Type of Investment⁽¹⁾	Series	Shares		Cost⁽²⁾		Value⁽³⁾
Total E-band Communications, Corp.					4,050,119	$	3,254	$	—
Glowpoint, Inc.⁽³⁾	Communications & Networking	Common Stock			114,192		101		168
Neonova Holding Company	Communications & Networking	Preferred Stock	Series A		500,000		250		190
Peerless Network, Inc.	Communications & Networking	Preferred Stock	Series A		1,000,000		1,000		4,031
Stoke, Inc.	Communications & Networking	Preferred Stock	Series E		152,905		500		538

Total Equity Communications & Networking (0.80%)*							5,105		4,927

Atrenta, Inc.	Software	Preferred Stock	Series C		1,196,845		508		1,058
		Preferred Stock	Series D		635,513		986		1,622

Total Atrenta, Inc.					1,832,358		1,494		2,680
Box, Inc.	Software	Preferred Stock	Series C		390,625		500		5,172
		Preferred Stock	Series D		158,127		500		2,094
		Preferred Stock	Series D-1		124,511		1,000		1,648
		Preferred Stock	Series D-2		220,751		2,001		2,923
		Preferred Stock	Series E		38,183		500		505

Total Box, Inc.					932,197		4,501		12,342
Caplinked, Inc.	Software	Preferred Stock	Series A-3		53,614		52		73
Highroads, Inc.	Software	Preferred Stock	Series A-3		190,170		307		297

Total Equity Software (2.50%)*							6,354		15,392

Virident Systems	Electronics & Computer Hardware	Preferred Stock	Series D		6,546,217		5,000		5,001

Total Equity Electronics & Computer Hardware (0.81%)*							5,000		5,001

Quatrx Pharmaceuticals Company	Specialty Pharmaceuticals	Preferred Stock	Series E		166,419		750		—

Total Equity Specialty Pharmaceuticals (0.00%)*							750		—

Caivis Acquisition Corporation	Consumer & Business Products	Common Stock	Series A		295,861		819		598
Facebook, Inc.⁽³⁾	Consumer & Business Products	Common Stock	Series B		307,500		9,558		7,517
IPA Holdings, LLC	Consumer & Business Products	Preferred Stock	LLC interest		500,000		500		539
Market Force Information, Inc.	Consumer & Business Products	Preferred Stock	Series B		187,970		500		682

Total Equity Consumer & Business Products (1.52%)*							11,377		9,336

iWatt, Inc.	Semiconductors	Preferred Stock	Series E		2,412,864		490		823

Total Equity Semiconductors (0.13%)*							490		823

Buzznet, Inc.	Information Services	Preferred Stock	Series C		263,158		250		—
Good Technologies, Inc. (pka Visto Corporation)	Information Services	Common Stock			500,000		603		—
Solutionary, Inc.	Information Services	Preferred Stock	Series A-1		189,495		17		158
		Preferred Stock	Series A-2		65,834		326		189

Total Solutionary, Inc.					255,329		343		347

Total Equity Information Services (0.06%)*							1,196		347

Gelesis, Inc.⁽⁶⁾	Medical Device & Equipment		LLC Interest		674,208		—		493
			LLC Interest		674,208		425		691
			LLC Interest		675,676		500		596

Total Gelesis, Inc.					2,024,092		925		1,780

See notes to consolidated financial statements.

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS—(Continued)

March 31, 2013

(unaudited)

(dollars in thousands)


Portfolio Company	Sub-Industry	Type of Investment⁽¹⁾	Series	Shares		Cost⁽²⁾		Value⁽³⁾
Lanx, Inc.	Medical Device & Equipment	Preferred Stock	Series C		1,203,369	$	1,000	$	1,958
Novasys Medical, Inc.	Medical Device & Equipment	Preferred Stock	Series D-1		4,118,444		1,000		—
Optiscan Biomedical, Corp.⁽⁶⁾	Medical Device & Equipment	Preferred Stock	Series B		6,185,567		3,000		476
		Preferred Stock	Series C-2		1,927,309		655		156
		Preferred Stock	Series D		20,251,220		1,932		1,978

Total Optiscan Biomedical, Corp.					28,364,096		5,587		2,610

Total Equity Medical Device & Equipment (1.03%)*							8,512		6,348

NuGEN Technologies, Inc.	Biotechnology Tools	Preferred Stock	Series C		189,394		500		756

Total Equity Biotechnology Tools (0.12%)*							500		756

Transmedics, Inc.	Surgical Devices	Preferred Stock	Series B		88,961		1,100		53
		Preferred Stock	Series C		119,999		300		131
		Preferred Stock	Series D		260,000		650		720

Total Transmedics, Inc.					468,960		2,050		904
Gynesonics, Inc.	Surgical Devices	Preferred Stock	Series B		219,298		250		62
		Preferred Stock	Series C		656,512		282		117
		Preferred Stock	Series C		1,621,553		580		605

Total Gynesonics, Inc.					875,810		1,112		784

Total Equity Surgical Devices (0.28%)*							3,162		1,688

Everyday Health, Inc. (pka Waterfront Media, Inc.)	Media/Content/ Info	Preferred Stock	Series D		145,590		1,000		572

Total Equity Media/Content/Info (0.09%)*							1,000		572



Total Equity (8.73%)						$	51,654	$	53,724



Total Investments (157.24%)						$	977,704	$	967,984

*	Value as a percent of net assets

(1)	Preferred and common stock, warrants, and equity interests are generally non-income producing.

(2)	Gross unrealized appreciation, gross unrealized depreciation, and net depreciation for federal income tax purposes totaled $39,533 million, $48,528 million and $8,995 million respectively. The tax cost of investments is $978,533 million

(3)

Except for warrants in nineteen publicly traded companies and common stock in eight publicly traded companies, all investments are restricted at March 31, 2013 and were valued at fair value as determined in good faith by the Board of Directors. No unrestricted securities of the same issuer are outstanding. The Company uses the Standard Industrial Code for classifying the industry grouping of its portfolio companies.

(4)	Debt investments of this portfolio company have been pledged as collateral under the Wells Facility.

(5)	Non-U.S. company or the company’s principal place of business is outside the United States.

(6)	Affiliate investment that is defined under the Investment Company Act of 1940 as a company in which HTGC owns as least 5% but not more than 25% of the voting securities of the Company.

(7)	Control investment that is defined under the Investment Company Act of 1940 as a company in which HTGC owners as least 25% but not more than 50% of the voting securities of the Company.

(8)	Debt is on non-accrual status at March 31, 2013, and is therefore considered non-income producing.

(9)	Convertible Senior Debt

(10)	Indicates assets that the Company deems not “qualifying assets” under section 55(a) of the Investment Company Act of 1940, as amended. Qualifying assets must represent at least 70% of the Company’s total assets at the time of acquisition of any additional non-qualifying assets.

(11)	Denotes that all or a portion of the loan secures the notes offered in the Debt Securitization (as defined in Note 4).

See notes to consolidated financial statements.

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2012

(dollars in thousands)


Portfolio Company	Sub-Industry	Type of Investment⁽¹⁾	Principal Amount		Cost⁽²⁾		Value⁽³⁾
Anthera Pharmaceuticals Inc.⁽³⁾	Drug Discovery & Development	Senior Debt⁽¹¹⁾
		Matures December 2014 Interest rate Prime + 7.30% or Floor rate of 10.55%	$	20,532	$	20,745	$	21,007
Aveo Pharmaceuticals, Inc.⁽³⁾	Drug Discovery & Development	Senior Debt⁽¹¹⁾
		Matures September 2015 Interest rate Prime + 7.15% or Floor rate of 11.90%	$	26,500		26,500		27,030
Cempra, Inc.⁽³⁾	Drug Discovery & Development	Senior Debt⁽¹¹⁾
		Matures December 2015 Interest rate Prime + 6.30% or Floor rate of 9.55%	$	10,000		9,862		9,902
Chroma Therapeutics, Ltd.^(5)(10)	Drug Discovery & Development	Senior Debt
		Matures November 2013 Interest rate Prime + 7.75% or Floor rate of 12.00%	$	4,111		4,718		4,759
Concert Pharmaceuticals, Inc.⁽⁴⁾	Drug Discovery & Development	Senior Debt
		Matures October 2015 Interest rate Prime + 3.25% or Floor rate of 8.50%	$	20,000		19,633		18,983
Coronado BioSciences, Inc.⁽³⁾	Drug Discovery & Development	Senior Debt⁽¹¹⁾
		Matures March 2016 Interest rate Prime + 6.00% or Floor rate of 9.25%	$	15,000		14,761		14,761
Dicerna Pharmaceuticals, Inc.	Drug Discovery & Development	Senior Debt
		Matures January 2015 Interest rate Prime + 4.40% or Floor rate of 10.15%	$	9,166		8,996		8,929
Insmed, Inc.	Drug Discovery & Development	Senior Debt⁽¹¹⁾
		Matures January 2016 Interest rate Prime + 4.75% or Floor rate of 9.25%	$	20,000		19,305		19,674
Merrimack Pharmaceuticals, Inc.	Drug Discovery & Development	Senior Debt
		Matures May 2016 Interest rate Prime + 5.30% or Floor rate of 10.55%	$	40,000		39,670		39,670
NeurogesX, Inc.⁽³⁾	Drug Discovery & Development	Senior Debt
		Matures February 2015 Interest rate Prime + 7.50% or Floor rate of 10.75%	$	13,662		13,645		13,884
Paratek Pharmaceuticals, Inc.	Drug Discovery & Development	Senior Debt⁽⁹⁾
		Matures upon liquidation Interest rate Fixed 10.00%	$	45		45		45
		Senior Debt⁽⁹⁾
		Matures upon liquidation Interest rate Fixed 10.00%	$	36		31		31

Total Paratek Pharmaceuticals, Inc.						76		76

Total Debt Drug Discovery & Development (34.63%)*						177,911		178,675

See notes to consolidated financial statements.

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS—(Continued)

December 31, 2012

(dollars in thousands)


Portfolio Company	Sub-Industry	Type of Investment⁽¹⁾	Principal Amount		Cost⁽²⁾		Value⁽³⁾
Bridgewave Communications	Communications & Networking	Senior Debt
		Matures March 2016 Interest rate Prime + 8.75% or Floor rate of 12.00%	$	7,500	$	7,003	$	4,896
OpenPeak, Inc.	Communications & Networking	Senior Debt⁽¹¹⁾
		Matures July 2015 Interest rate Prime + 8.75% or Floor rate of 12.00%	$	15,000		15,008		15,158
PeerApp, Inc.⁽⁴⁾	Communications & Networking	Senior Debt
		Matures April 2013 Interest rate Prime + 7.50% or Floor rate of 11.50%	$	501		588		588
UPH Holdings, Inc.	Communications & Networking	Senior Debt
		Matures April 2015 Interest rate Libor + 11.00% or Floor rate of 13.50%	$	7,000		6,880		6,772
		Senior Debt
		Matures September 2015 Interest rate Libor + 11.00% or Floor rate of 13.50%	$	347		343		333
		Senior Debt
		Matures December 2016 Interest rate Libor + 11.00% or Floor rate of 13.50%	$	3,594		3,594		3,400

Total UPH Holdings, Inc.						10,817		10,505

Total Debt Communications & Networking (6.04%)*						33,416		31,147

Clustrix, Inc.	Electronics & Computer Hardware	Senior Debt
		Matures December 2015 Interest rate Prime + 6.50% or Floor rate of 9.75%	$	235		227		227
Identive Group, Inc.	Electronics & Computer Hardware	Senior Debt
		Matures November 2015 Interest rate Prime + 7.75% or Floor rate 11.00%	$	7,500		7,447		7,447

Total Debt Electronics & Computer Hardware (1.49%)						7,674		7,674

Box, Inc.⁽⁴⁾	Software	Senior Debt
		Matures March 2016 Interest rate Prime + 3.75% or Floor rate of 7.50%	$	10,000		9,910		9,353
		Senior Debt
		Matures July 2014 Interest rate Prime + 5.25% or Floor rate of 8.50%	$	1,018		1,075		1,060
		Senior Debt⁽¹¹⁾
		Matures July 2016 Interest rate Prime + 5.13% or Floor rate of 8.88%	$	20,000		20,138		19,274

Total Box, Inc.						31,123		29,687

See notes to consolidated financial statements.

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS—(Continued)

December 31, 2012

(dollars in thousands)


Portfolio Company	Sub-Industry	Type of Investment⁽¹⁾	Principal Amount		Cost⁽²⁾		Value⁽³⁾
Clickfox, Inc.	Software	Senior Debt
		Matures November 2015 Interest rate Prime + 8.25% or Floor rate of 11.50%	$	8,000	$	7,318	$	7,558
EndPlay,Inc.	Software	Senior Debt
		Matures August 2015 Interest rate Prime + 7.35% or Floor rate 10.6%	$	2,000		1,930		1,930
Hillcrest Laboratories, Inc	Software	Senior Debt
		Matures July 2015 Interest rate Prime + 7.50% or Floor rate of 10.75%	$	4,000		3,923		3,860
JackBe Corporation	Software	Senior Debt
		Matures January 2016 Interest rate Prime + 7.25% or Floor rate of 10.50%	$	3,000		2,900		2,900
Kxen, Inc.⁽⁴⁾	Software	Senior Debt
		Matures January 2015 Interest rate Prime + 5.08% or Floor rate of 8.33%	$	2,337		2,371		2,192
Tada Innovations, Inc.	Software	Senior Debt⁽⁹⁾
		Matures November 2012 Interest rate Fixed 8.00%	$	100		100		—

Total Debt Software (9.33%)*						49,665		48,127

Althea Technologies, Inc.	Specialty Pharmaceuticals	Senior Debt
		Matures October 2013 Interest rate Prime + 7.70% or Floor rate of 10.95%	$	7,659		7,927		7,927
Quatrx Pharmaceuticals Company	Specialty Pharmaceuticals	Senior Debt⁽⁹⁾
		Matures March 2014 Interest rate Fixed 8.00%	$	1,888		1,888		2,394

Total Debt Specialty Pharmaceuticals (2.00%)*						9,815		10,321

Achronix Semiconductor Corporation	Semiconductors	Senior Debt
		Matures January 2015 Interest rate Prime + 10.60% or Floor rate of 13.85%	$	1,847		1,803		1,783

Total Debt Semiconductors (0.34%)*						1,803		1,783

AcelRX Pharmaceuticals, Inc.⁽³⁾	Drug Delivery	Senior Debt⁽¹¹⁾
		Matures December 2014 Interest rate Prime + 3.25% or Floor rate of 8.50%	$	16,345		16,222		15,983
ADMA Biologics, Inc.	Drug Delivery	Senior Debt
		Matures February 2016 Interest rate Prime + 2.75% or Floor rate of 8.50%	$	4,000		3,857		3,857
Alexza Pharmaceuticals, Inc.⁽³⁾	Drug Delivery	Senior Debt⁽¹¹⁾
		Matures October 2013 Interest rate Prime + 6.50% or Floor rate of 10.75%	$	5,052		5,410		5,410
BIND Therapeutics, Inc.	Drug Delivery	Senior Debt
		Matures July 2014 Interest rate Prime + 7.45% or Floor rate of 10.70%	$	3,326		3,320		3,387

See notes to consolidated financial statements.

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS—(Continued)

December 31, 2012

(dollars in thousands)


Portfolio Company	Sub-Industry	Type of Investment⁽¹⁾	Principal Amount		Cost⁽²⁾		Value⁽³⁾
Intelliject, Inc.	Drug Delivery	Senior Debt⁽¹¹⁾
		Matures June 2016 Interest rate Prime + 5.75% or Floor rate of 11.00%	$	15,000	$	14,615	$	15,065
Nupathe, Inc.⁽³⁾	Drug Delivery	Senior Debt
		Matures May 2016 Interest rate Prime - 3.25% or Floor rate of 9.85%	$	8,500		8,166		8,166
Revance Therapeutics, Inc.	Drug Delivery	Senior Debt
		Matures March 2015 Interest rate Prime + 6.60% or Floor rate of 9.85%	$	18,446	$	18,330	$	18,263

Total Debt Drug Delivery (13.59%)*						69,920		70,131

Ahhha, Inc.⁽⁸⁾	Internet Consumer & Business Services	Senior Debt
		Matures January 2015 Interest rate Fixed 12.00%	$	350		347		—
Blurb, Inc.	Internet Consumer & Business Services	Senior Debt
		Matures December 2015 Interest rate Prime + 5.25% or Floor rate 8.50%	$	8,000		7,708		7,429
Education Dynamics, LLC	Internet Consumer & Business Services	Senior Debt
		Matures March 2016 Interest rate Fixed 12.50%, PIK Interest 1.50%	$	27,500		26,976		26,976
Just.Me, Inc.	Internet Consumer & Business Services	Senior Debt
		Matures June 2015 Interest rate Prime + 2.50% or Floor rate 5.75%	$	750		732		680
		Senior Debt
		Matures June 2015 Interest rate Prime + 5.00% or Floor rate 8.25%	$	750		727		704

Total Just.Me, Inc.						1,459		1,384
Loku, Inc.	Internet Consumer & Business Services	Senior Debt⁽⁹⁾
		Matures June 2013 Interest rate Fixed 6.00%	$	100		100		100
NetPlenish, Inc.	Internet Consumer & Business Services	Senior Debt
		Matures April 2015 Interest rate Fixed 10.00%	$	500		490		452
Reply! Inc.	Internet Consumer & Business Services	Senior Debt⁽¹¹⁾
		Matures September 2015 Interest rate Prime + 6.875% or Floor rate of 10.125%	$	11,749		11,624		11,337
		Senior Debt⁽¹¹⁾
		Matures September 2015 Interest rate Prime + 7.25% or Floor rate of 11.00%	$	2,000		1,946		1,971

Total Reply! Inc.						13,570		13,308
Second Rotation, Inc.	Internet Consumer & Business Services	Senior Debt
		Matures August 2015 Interest rate Prime + 6.50% or Floor rate of 10.25% , PIK Interest 2.50%	$	5,843		5,860		5,880

See notes to consolidated financial statements.

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS—(Continued)

December 31, 2012

(dollars in thousands)


Portfolio Company	Sub-Industry	Type of Investment⁽¹⁾	Principal Amount		Cost⁽²⁾		Value⁽³⁾
		Senior Debt
		Matures August 2015 Interest rate Prime + 6.50% or Floor rate of 10.25% , PIK Interest 1.50%	$	1,947	$	1,888	$	1,909
		Revolving Line of Credit
		Matures January 2013 Interest rate Fixed 10.50%, PIK Interest 0.25%	$	327		313		313

Total Second Rotation, Inc.						8,061		8,102
ShareThis, Inc.	Internet Consumer & Business Services	Senior Debt
		Matures June 2016 Interest rate Prime + 7.50% or Floor rate of 10.75%	$	15,000		14,268		14,268
Tectura Corporation	Internet Consumer & Business Services	Revolving Line of Credit
		Matures July 2013 Interest rate Libor + 8.00% or Floor rate of 11.00%	$	16,340		17,850		17,797
		Senior Debt
		Matures December 2014 Interest rate Libor + 10.00% or Floor rate of 13.00%	$	6,978		6,908		6,827
		Senior Debt
		Matures April 2013 Interest rate Libor + 10.00% or Floor rate of 13.00%	$	1,390		1,325		1,325

Total Tectura Corporation						26,083		25,949
Trulia, Inc.⁽³⁾	Internet Consumer & Business Services	Senior Debt⁽¹¹⁾
		Matures September 2015 Interest rate Prime + 2.75% or Floor rate of 6.00%	$	5,000		4,921		4,729
		Senior Debt⁽¹¹⁾
		Matures September 2015 Interest rate Prime + 5.50% or Floor rate of 8.75%	$	5,000		4,920		4,547

Total Trulia, Inc.						9,841		9,276
Vaultlogix, Inc.	Internet Consumer & Business Services	Senior Debt
		Matures September 2016 Interest rate LIBOR + 8.50% or Floor rate of 10.00%, PIK interest 2.50%	$	7,500		7,681		7,721
		Senior Debt
		Matures September 2015 Interest rate LIBOR + 7.00% or Floor rate of 8.50%	$	10,253		10,190		9,854

Total Vaultlogix, Inc.						17,871		17,575
Votizen, Inc.	Internet Consumer & Business Services	Senior Debt⁽⁹⁾
		Matures February 2013 Interest rate Fixed 5.00%	$	100		100		6
Wavemarket, Inc.	Internet Consumer & Business Services	Senior Debt⁽¹¹⁾
		Matures September 2015 Interest rate Prime + 5.75% or Floor rate of 9.50%	$	10,000		9,840		9,444

Total Debt Internet Consumer & Business Services (26.02%)*						136,714		134,269

See notes to consolidated financial statements.

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS—(Continued)

December 31, 2012

(dollars in thousands)


Portfolio Company	Sub-Industry	Type of Investment⁽¹⁾	Principal Amount		Cost⁽²⁾		Value⁽³⁾
Cha Cha Search, Inc.	Information Services	Senior Debt
		Matures February 2015 Interest rate Prime + 6.25% or Floor rate of 9.50%	$	2,641	$	2,604	$	2,522
Eccentex Corporation	Information Services	Senior Debt⁽¹¹⁾
		Matures May 2015 Interest rate Prime + 7.00% or Floor rate of 10.25%	$	1,000		977		965
InXpo, Inc.	Information Services	Senior Debt
		Matures March 2014 Interest rate Prime + 7.50% or Floor rate of 10.75%	$	2,550		2,466		2,434
Jab Wireless, Inc.	Information Services	Senior Debt
		Matures November 2017 Interest rate Prime + 6.75% or Floor rate of 8.00%	$	30,000		29,852		29,850
RichRelevance, Inc.	Information Services	Senior Debt
		Matures January 2015 Interest rate Prime + 3.25% or Floor rate of 7.50%	$	4,245		4,210		4,068
Womensforum.com, Inc.	Information Services	Senior Debt⁽¹¹⁾
		Matures October 2016 Interest rate LIBOR + 6.50% or Floor rate of 9.25%	$	8,000		7,838		7,838
		Senior Debt⁽¹¹⁾
		Matures October 2016 Interest rate LIBOR + 7.50% or Floor rate of 10.25%	$	4,500		4,422		4,422

Total Womensforum.com, Inc.						12,260		12,260

Total Debt Information Services (10.10%)*						52,369		52,099

Gynesonics, Inc.	Medical Device & Equipment	Senior Debt
		Matures October 2013 Interest rate Prime + 8.25% or Floor rate of 11.50%	$	3,912		3,975		4,014
		Senior Debt
		Matures February 2013 Interest rate Fixed 8.00%	$	253		247		247
		Senior Debt
		Matures September 2013 Interest rate Fixed 8.00%	$	36		30		30

Total Gynesonics, Inc.						4,252		4,291
Lanx, Inc.	Medical Device & Equipment	Senior Debt
		Matures October 2016 Interest rate Prime + 6.50% or Floor rate of 10.25%	$	15,000		14,428		14,428
		Revolving Line of Credit
		Matures October 2015 Interest rate Prime + 5.25% or Floor rate of 9.00%	$	5,500		5,300		5,300

Total Lanx, Inc.						19,728		19,728
Novasys Medical, Inc.	Medical Device & Equipment	Senior Debt⁽⁹⁾
		Matures January 2013 Interest rate Fixed 8.00%	$	65		65		65
		Senior Debt⁽⁹⁾
		Matures August 2013 Interest rate Fixed 8.00%	$	22		20		20

Total Novasys Medical, Inc.						85		85

See notes to consolidated financial statements.

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS—(Continued)

December 31, 2012

(dollars in thousands)


Portfolio Company	Sub-Industry	Type of Investment⁽¹⁾	Principal Amount		Cost⁽²⁾		Value⁽³⁾
Optiscan Biomedical, Corp.⁽⁶⁾	Medical Device & Equipment	Senior Debt
		Matures December 2013 Interest rate Prime + 8.20% or Floor rate of 11.45%	$	8,260	$	8,915	$	9,080
		Senior Debt⁽⁹⁾
		Matures April 2013 Interest rate Fixed 8.00%	$	288		288		288
		Senior Debt⁽⁹⁾
		Matures September 2013 Interest rate Fixed 8.00%	$	123		123		123

Total Optiscan Biomedical, Corp.						9,326		9,491
Oraya Therapeutics, Inc.	Medical Device & Equipment	Senior Debt⁽⁹⁾
		Matures December 2013 Interest rate Fixed 7.00%	$	500		500		500
		Senior Debt⁽¹¹⁾
		Matures September 2015 Interest rate Prime + 5.50% or Floor rate of 10.25%	$	10,000		9,798		10,079

Total Oraya Therapeutics, Inc.						10,298		10,579
USHIFU, LLC	Medical Device & Equipment	Senior Debt⁽¹¹⁾
		Matures April 2016 Interest rate Prime + 7.75% or Floor rate of 11.00%	$	6,000		5,856		5,856

Total Debt Medical Device & Equipment (9.69%)*						49,545		50,030

Navidea Biopharmaceuticals, Inc. (pka Neoprobe)⁽³⁾	Diagnostic	Senior Debt
		Matures December 2014 Interest rate Prime + 6.75% or Floor rate of 10.00%	$	5,741		5,691		5,752
Tethys Bioscience Inc.	Diagnostic	Senior Debt⁽¹¹⁾
		Matures December 2015 Interest rate Prime + 8.40% or Floor rate of 11.65%	$	10,000		9,940		10,026

Total Debt Diagnostic (3.06%)*						15,631		15,778

Labcyte, Inc.	Biotechnology Tools	Senior Debt
		Matures May 2013 Interest rate Prime + 8.60% or Floor rate of 11.85%	$	761		834		834
		Senior Debt⁽¹¹⁾
		Matures June 2016 Interest rate Prime + 6.70% or Floor rate of 9.95%	$	5,000		4,890		4,995

Total Labcyte, Inc.						5,724		5,829

Total Debt Biotechnology Tools (1.13%)*						5,724		5,829

MedCall, LLC	Healthcare Services, Other	Senior Debt
		Matures January 2016 Interest rate 7.79% or Floor rate of 9.50%	$	4,908		4,844		4,695
		Senior Debt
		Matures January 2016 Interest rate LIBOR +8.00% or Floor rate of 10.00%	$	4,037		3,972		3,871

Total MedCall, LLC						8,816		8,566

See notes to consolidated financial statements.

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS—(Continued)

December 31, 2012

(dollars in thousands)


Portfolio Company	Sub-Industry	Type of Investment⁽¹⁾	Principal Amount		Cost⁽²⁾		Value⁽³⁾
Pacific Child & Family Associates, LLC	Healthcare Services, Other	Senior Debt
		Matures January 2015 Interest rate LIBOR + 9.00% or Floor rate of 11.50%	$	3,661	$	3,713	$	3,713
		Revolving Line of Credit
		Matures January 2015 Interest rate LIBOR + 7.50% or Floor rate of 10.00%	$	1,500		1,490		1,490
		Senior Debt
		Matures January 2015 Interest rate LIBOR + 11.50% or Floor rate of 14.00%, PIK interest 3.75%	$	5,900		6,562		6,562

Total Pacific Child & Family Associates, LLC						11,765		11,765
ScriptSave (Medical Security Card Company, LLC)	Healthcare Services, Other	Senior Debt
		Matures February 2016 Interest rate LIBOR + 8.75% or Floor rate of 11.25%	$	16,375		16,168		16,150

Total Debt Health Services, Other (7.07%)*						36,749		36,481

Entrigue Surgical, Inc.	Surgical Devices	Senior Debt
		Matures December 2014 Interest rate Prime + 5.90% or Floor rate of 9.65%	$	2,463		2,431		2,427
Transmedics, Inc.	Surgical Devices	Senior Debt⁽¹¹⁾
		Matures November 2015 Interest rate Fixed 12.95%	$	7,250		7,464		7,464

Total Debt Surgical Devices (1.92%)*						9,895		9,891

Westwood One Communications	Media/Content/ Info	Senior Debt
		Matures October 2016 Interest rate LIBOR + 6.50% or Floor rate of 8.00%	$	20,475		18,994		17,575
Women’s Marketing, Inc.	Media/Content/ Info	Senior Debt
		Matures May 2016 Interest rate Libor + 9.50% or Floor rate of 12.00%, PIK interest 3.00%	$	9,681		10,002		10,002
		Senior Debt⁽¹¹⁾
		Matures November 2015 Interest rate Libor + 7.50% or Floor rate of 10.00%	$	16,362		16,105		15,787

Total Women’s Marketing, Inc.						26,107		25,789
Zoom Media Corporation	Media/Content/ Info	Senior Debt
		Matures December 2015 Interest rate Prime + 7.25% or Floor rate of 10.50%, PIK 3.75%	$	5,000		4,657		4,657
	Media/Content/ Info	Revolving Line of Credit
		Matures December 2014 Interest rate Prime + 5.25% or Floor rate of 8.50%	$	3,000		2,700		2,700

Total Zoom Media Corporation						7,357		7,357

Total Debt Media/Content/Info (9.83%)*						52,458		50,721

See notes to consolidated financial statements.

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS—(Continued)

December 31, 2012

(dollars in thousands)


Portfolio Company	Sub-Industry	Type of Investment⁽¹⁾	Principal Amount		Cost⁽²⁾		Value⁽³⁾
Alphabet Energy, Inc.	Clean Tech	Senior Debt
		Matures February 2015 Interest rate Prime + 5.75% or Floor rate of 9.00%	$	1,614	$	1,531	$	1,531
American Supercondutor Corporation⁽³⁾	Clean Tech	Senior Debt⁽¹¹⁾
		Matures December 2014 Interest rate Prime + 7.25% or Floor rate of 11.00%	$	9,231		9,161		9,438
BrightSource Energy, Inc.	Clean Tech	Revolving Line of Credit
		Matures January 2013 Interest rate Prime + 7.25% or Floor rate of 10.50%	$	35,000		34,870		34,870
Comverge, Inc.	Clean Tech	Senior Debt
		Matures November 2017 Interest rate LIBOR + 8.00% or Floor rate of 9.50%	$	20,000		19,577		19,577
	Clean Tech	Senior Debt
		Matures November 2017 Interest rate LIBOR + 9.50% or Floor rate of 11.00%	$	14,000		13,704		13,704

Total Comverge, Inc.						33,281		33,281
Enphase Energy, Inc.⁽³⁾	Clean Tech	Senior Debt⁽¹¹⁾
		Matures June 2014 Interest rate Prime + 5.75% or Floor rate of 9.00%	$	3,758		3,739		3,716
	Clean Tech	Senior Debt
		Matures August 2016 Interest rate Prime + 8.25% or Floor rate of 11.50%	$	7,400		7,321		7,321

Total Enphase Energy, Inc.						11,060		11,037
Glori Energy, Inc.	Clean Tech	Senior Debt⁽¹¹⁾
		Matures June 2015 Interest rate Prime + 6.75% or Floor rate of 10.00%	$	8,000		7,832		7,988
Integrated Photovoltaics, Inc.	Clean Tech	Senior Debt
		Matures February 2015 Interest rate Prime + 7.38% or Floor rate of 10.63%	$	2,572		2,494		2,508
Polyera Corporation	Clean Tech	Senior Debt
		Matures June 2016 Interest rate Prime + 6.75% or Floor rate of 10.00%	$	3,000		2,952		2,952
Redwood Systems, Inc.	Clean Tech	Senior Debt
		Matures February 2016 Interest rate Prime + 6.50% or Floor rate of 9.75%	$	5,000		4,965		4,965
SCIenergy, Inc.⁽⁴⁾	Clean Tech	Senior Debt
		Matures September 2015 Interest rate Prime + 8.75% or Floor rate 12.00%	$	5,296		5,103		5,262
Solexel, Inc.	Clean Tech	Senior Debt
		Matures June 2013 Interest rate Prime + 8.25% or Floor rate of 11.50%	$	2,884		2,877		2,877
		Senior Debt
		Matures June 2013 Interest rate Prime + 7.25% or Floor rate of 10.50%	$	331		330		330

Total Solexel, Inc.						3,207		3,207
Stion Corporation⁽⁴⁾	Clean Tech	Senior Debt
		Matures February 2015 Interest rate Prime + 6.75% or Floor rate of 10.00%	$	7,519		7,483		7,545

Total Debt Clean Tech (24.14%)*						123,938		124,584



Total Debt (160.38%)					$	833,228	$	827,540

See notes to consolidated financial statements.

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS—(Continued)

December 31, 2012

(dollars in thousands)


Portfolio Company	Sub-Industry	Type of Investment⁽¹⁾	Series	Shares		Cost⁽²⁾		Value⁽³⁾
Acceleron Pharmaceuticals, Inc.	Drug Discovery & Development	Common Stock Warrants			46,446	$	39	$	53
		Preferred Stock Warrants	Series A		426,000		69		345
		Preferred Stock Warrants	Series B		110,270		35		64

Total Warrants Acceleron Pharmaceuticals, Inc.					582,716		143		462
Anthera Pharmaceuticals Inc.⁽³⁾	Drug Discovery & Development	Common Stock Warrants			321,429		984		66
Cempra, Inc.⁽³⁾	Drug Discovery & Development	Common Stock Warrants			39,038		187		46
Chroma Therapeutics, Ltd.^(5)(10)	Drug Discovery & Development	Preferred Stock Warrants	Series D		325,261		490		500
Concert Pharmaceuticals, Inc.⁽⁴⁾	Drug Discovery & Development	Preferred Stock Warrants	Series C		400,000		367		126
Coronado Biosciences, Inc.⁽³⁾	Drug Discovery & Development	Common Stock Warrants			73,009		142		81
Dicerna Pharmaceuticals, Inc.	Drug Discovery & Development	Common Stock Warrants			50,000		28		16
		Preferred Stock Warrants	Series A		525,000		236		173
		Preferred Stock Warrants	Series B		660,000		311		217

Total Warrants Dicerna Pharmaceuticals, Inc.					1,235,000		575		406
EpiCept Corporation⁽³⁾	Drug Discovery & Development	Common Stock Warrants			325,204		4		—
Horizon Pharma, Inc.⁽³⁾	Drug Discovery & Development	Common Stock Warrants			22,408		231		—
Insmed, Incorporated⁽³⁾	Drug Discovery & Development	Common Stock Warrants			329,931		570		1,316
Merrimack Pharmaceuticals, Inc.⁽³⁾	Drug Discovery & Development	Common Stock Warrants			302,143		155		641
NeurogesX, Inc.⁽³⁾	Drug Discovery & Development	Common Stock Warrants			3,421,500		503		400
PolyMedix, Inc.⁽³⁾	Drug Discovery & Development	Common Stock Warrants			627,586		480		9
Portola Pharmaceuticals, Inc.	Drug Discovery & Development	Preferred Stock Warrants	Series B		687,023		152		298

Total Warrants Drug Discovery & Development (0.84%)*							4,983		4,351

Bridgewave Communications	Communications & Networking	Preferred Stock Warrants	Series 5		2,942,618		753		—
Intelepeer, Inc.	Communications & Networking	Preferred Stock Warrants	Series C		117,958		101		190
Neonova Holding Company	Communications & Networking	Preferred Stock Warrants	Series A		450,000		94		23
OpenPeak, Inc.	Communications & Networking	Preferred Stock Warrants	Series E		25,646		149		9
PeerApp, Inc.⁽⁴⁾	Communications & Networking	Preferred Stock Warrants	Series B		298,779		61		47
Peerless Network, Inc.	Communications & Networking	Preferred Stock Warrants	Series A		135,000		95		352
Ping Identity Corporation	Communications & Networking	Preferred Stock Warrants	Series B		1,136,277		52		112
UPH Holdings, Inc.	Communications & Networking	Common Stock Warrants			145,877		131		52
Purcell Systems, Inc.	Communications & Networking	Preferred Stock Warrants	Series B		110,000		123		62
Stoke, Inc.	Communications & Networking	Preferred Stock Warrants	Series C		158,536		53		135
		Preferred Stock Warrants	Series D		72,727		65		57

Total Stoke, Inc.					231,263		118		192

Total Warrants Communications & Networking (0.20%)*							1,677		1,039

See notes to consolidated financial statements.

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS—(Continued)

December 31, 2012

(dollars in thousands)


Portfolio Company	Sub-Industry	Type of Investment⁽¹⁾	Series	Shares		Cost⁽²⁾		Value⁽³⁾
Atrenta, Inc.	Software	Preferred Stock Warrants	Series D		392,670	$	121	$	322
Box, Inc.⁽⁴⁾	Software	Preferred Stock Warrants	Series C		271,070		117		2,235
		Preferred Stock Warrants	Series B		199,219		73		3,242
		Preferred Stock Warrants	Series D-1		62,255		194		566

Total Box, Inc.					532,544		384		6,043
Braxton Technologies, LLC.	Software	Preferred Stock Warrants	Series A		168,750		188		—
Central Desktop, Inc.	Software	Preferred Stock Warrants	Series B		522,823		108		166
Clickfox, Inc.	Software	Preferred Stock Warrants	Series B		1,038,563		329		332
		Preferred Stock Warrants	Series C		592,019		730		213

Total Clickfox, Inc.					1,630,582		1,059		545
Daegis Inc. (pka Unify Corporation)⁽³⁾	Software	Common Stock Warrants			718,860		1,434		75
Endplay, Inc.	Software	Preferred Stock Warrants	Series B		180,000		67		39
Forescout Technologies, Inc.	Software	Preferred Stock Warrants	Series D		399,687		99		202
HighRoads, Inc.	Software	Preferred Stock Warrants	Series B		190,176		44		9
Hillcrest Laboratories, Inc.	Software	Preferred Stock Warrants	Series E		1,865,650		55		70
JackBe Corporation	Software	Preferred Stock Warrants	Series C		180,000		73		54
Kxen, Inc.⁽⁴⁾	Software	Preferred Stock Warrants	Series D		184,614		47		13
Rockyou, Inc.	Software	Preferred Stock Warrants	Series B		41,266		117		—
SugarSync Inc.	Software	Preferred Stock Warrants	Series CC		332,726		78		123
		Preferred Stock Warrants	Series DD		107,526		34		30

Total SugarSync Inc.					440,252		112		153
Tada Innovations, Inc.	Software	Preferred Stock Warrants	Series A		20,833		25		—
White Sky, Inc.	Software	Preferred Stock Warrants	Series B-2		124,295		54		3
WildTangent, Inc.	Software	Preferred Stock Warrants	Series 3A		100,000		238		82

Total Warrants Software (1.51%)*							4,225		7,776

Clustrix, Inc.	Electronics & Computer Hardware	Preferred Stock Warrants	Series B		49,732		12		13
Luminus Devices, Inc.	Electronics & Computer Hardware	Common Stock Warrants			26,386		600		—
Shocking Technologies, Inc.	Electronics & Computer Hardware	Preferred Stock Warrants	Series A-1		181,818		63		106

Total Warrant Electronics & Computer Hardware (0.02%)*							675		119

Althea Technologies, Inc.	Specialty Pharmaceuticals	Preferred Stock Warrants	Series D		502,273		309		889
Pacira Pharmaceuticals, Inc.⁽³⁾	Specialty Pharmaceuticals	Common Stock Warrants			178,987		1,086		1,263
Quatrx Pharmaceuticals Company	Specialty Pharmaceuticals	Preferred Stock Warrants	Series E		340,534		528		—

Total Warrants Specialty Pharmaceuticals (0.42%)*							1,923		2,152

IPA Holdings, LLC	Consumer & Business Products	Common Stock Warrants			650,000		275		485
Market Force Information, Inc.	Consumer & Business Products	Preferred Stock Warrants	Series A		99,286		24		84
Seven Networks, Inc.	Consumer & Business Products	Preferred Stock Warrants	Series C		1,821,429		174		130
ShareThis, Inc.	Consumer & Business Products	Preferred Stock Warrants	Series B		535,905		547		543
Wageworks, Inc.⁽³⁾	Consumer & Business Products	Common Stock Warrants			211,765		252		2,023
Wavemarket, Inc.	Consumer & Business Products	Preferred Stock Warrants	Series E		1,083,333		106		61

Total Warrant Consumer & Business Products (0.64%)*							1,378		3,326

Achronix Semiconductor Corporation	Semiconductors	Preferred Stock Warrants	Series D		360,000		160		84
Enpirion, Inc.	Semiconductors	Preferred Stock Warrants	Series D		239,872		157		—
iWatt, Inc.	Semiconductors	Preferred Stock Warrants	Series C		558,748		45		14
		Preferred Stock Warrants	Series D		1,954,762		583		289

Total iWatt, Inc.					2,513,510		628		303
Kovio Inc.	Semiconductors	Preferred Stock Warrants	Series B		319,352		92		—
Quartics, Inc.	Semiconductors	Preferred Stock Warrants	Series C		69,139		53		—

Total Warrants Semiconductors (0.08%)*							1,090		387

See notes to consolidated financial statements.

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS—(Continued)

December 31, 2012

(dollars in thousands)


Portfolio Company	Sub-Industry	Type of Investment⁽¹⁾	Series	Shares		Cost⁽²⁾		Value⁽³⁾
AcelRX Pharmaceuticals, Inc.⁽³⁾	Drug Delivery	Common Stock Warrants			274,508	$	356	$	406
ADMA Biologics, Inc.	Drug Delivery	Common Stock Warrants			25,000		129		128
Alexza Pharmaceuticals, Inc.⁽³⁾	Drug Delivery	Common Stock Warrants			37,639		645		8
BIND Biosciences, Inc.	Drug Delivery	Preferred Stock Warrants	Series C-1		150,000		291		446
Intelliject, Inc.	Drug Delivery	Preferred Stock Warrants	Series B		82,500		594		574
NuPathe, Inc.⁽³⁾	Drug Delivery	Common Stock Warrants			106,631		139		165
Revance Therapeutics, Inc.	Drug Delivery	Preferred Stock Warrants	Series D		269,663		557		618
Transcept Pharmaceuticals, Inc.⁽³⁾	Drug Delivery	Common Stock Warrants			61,452		87		44

Total Warrant Drug Delivery (0.46%)*							2,798		2,389

Blurb, Inc.	Internet Consumer & Business Services	Preferred Stock Warrants	Series B		439,336		323		347
		Preferred Stock Warrants	Series C		234,280		636		218

Total Blurb, Inc.					673,616		959		565
Invoke Solutions, Inc.	Internet Consumer & Business Services	Common Stock Warrants			53,084		38		—
Just.Me	Internet Consumer & Business Services	Preferred Stock Warrants	Series A		102,299		20		20
Prism Education Group, Inc.	Internet Consumer & Business Services	Preferred Stock Warrants	Series B		200,000		43		—
Reply! Inc.	Internet Consumer & Business Services	Preferred Stock Warrants	Series B		137,225		320		802
Second Rotation	Internet Consumer & Business Services	Preferred Stock Warrants	Series D		105,819		105		113
Tectura Corporation	Internet Consumer & Business Services	Preferred Stock Warrants	Series B-1		253,378		51		12
Trulia, Inc.⁽³⁾	Internet Consumer & Business Services	Common Stock Warrants			56,053		188		368

Total Warrants Internet Consumer & Business Services (0.37%)*							1,724		1,880

Buzznet, Inc.	Information Services	Preferred Stock Warrants	Series B		19,962		9		—
Cha Cha Search, Inc.	Information Services	Preferred Stock Warrants	Series F		48,232		58		5
Eccentex Corporation	Information Services	Preferred Stock Warrants	Series A		408,719		31		3
Intelligent Beauty, Inc.	Information Services	Preferred Stock Warrants	Series B		190,234		230		579
InXpo, Inc.	Information Services	Preferred Stock Warrants	Series C		648,400		98		43
	Information Services	Preferred Stock Warrants	Series C-1		267,049		25		24

Total InXpo, Inc.	Information Services				915,449		123		67
Jab Wireless, Inc.	Information Services	Preferred Stock Warrants	Series A		266,567		265		420
RichRelevance, Inc.	Information Services	Preferred Stock Warrants	Series D		112,749		98		28
Solutionary, Inc.	Information Services	Preferred Stock Warrants	Series A-2		111,311		96		5

Total Warrants Information Services (0.22%)*							910		1,107

EKOS Corporation	Medical Device & Equipment	Preferred Stock Warrants	Series C		4,448,135		327		—
Gelesis, Inc.⁽⁶⁾	Medical Device & Equipment		LLC Interest		263,688		78		95
Lanx, Inc.	Medical Device & Equipment	Preferred Stock Warrants	Series C		1,203,369		441		445
Novasys Medical, Inc.	Medical Device & Equipment	Preferred Stock Warrants	Series D		580,447		131		—
		Common Stock Warrants			109,449		2		—

Total Novasys Medical, Inc.					689,896		133		—
Optiscan Biomedical, Corp.⁽⁶⁾	Medical Device & Equipment	Preferred Stock Warrants	Series D		6,206,187		1,069		151
Oraya Therapeutics, Inc.	Medical Device & Equipment	Preferred Stock Warrants	Series C		716,948		676		314
		Common Stock Warrants			95,498		66		62

Total Oraya Therapeutics, Inc.					812,446		742		376
USHIFU, LLC	Medical Device & Equipment	Preferred Stock Warrants	Series G		141,388		188		188

Total Warrants Medical Device & Equipment (0.24%)*							2,978		1,255

See notes to consolidated financial statements.

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS—(Continued)

December 31, 2012

(dollars in thousands)


Portfolio Company	Sub-Industry	Type of Investment⁽¹⁾	Series	Shares		Cost⁽²⁾		Value⁽³⁾
Navidea Biopharmaceuticals, Inc. (pka Neoprobe)⁽³⁾	Diagnostic	Common Stock Warrants			333,333	$	244	$	360
Tethys Bioscience, Inc.	Diagnostic	Preferred Stock Warrants	Series E		617,683		148		169

Total Warrants Diagnostic (0.10%)*							392		529

Labcyte, Inc.	Biotechnology Tools	Preferred Stock Warrants	Series C		1,127,624		323		247
NuGEN Technologies, Inc.	Biotechnology Tools	Preferred Stock Warrants	Series B		204,545		45		161
		Preferred Stock Warrants	Series C		30,114		33		8

Total NuGEN Technologies, Inc.					234,659		78		169

Total Warrants Biotechnology Tools (0.08%)*							401		416

Entrigue Surgical, Inc.	Surgical Devices	Preferred Stock Warrants	Series B		62,500		87		2
Transmedics, Inc.	Surgical Devices	Preferred Stock Warrants	Series B		40,436		225		—
		Preferred Stock Warrants	Series D		175,000		100		100

Total Transmedics, Inc.							325		100
Gynesonics, Inc.	Surgical Devices	Preferred Stock Warrants	Series A		123,457		18		7
		Preferred Stock Warrants	Series C		1,474,261		387		298

Total Gynesonics, Inc.					1,597,718		405		305

Total Warrants Surgical Devices (0.08%)*							817		407

Everyday Health, Inc. (pka Waterfront Media, Inc.)	Media/Content/ Info	Preferred Stock Warrants	Series C		110,018		60		55
Glam Media, Inc.	Media/Content/ Info	Preferred Stock Warrants	Series D		407,457		482		—
Zoom Media Group, Inc.	Media/Content/ Info	Preferred Stock Warrants	n/a		1,204		348		346

Total Warrants Media/Content/Info (0.08%)*							890		401

Alphabet Energy, Inc.	Clean Tech	Preferred Stock Warrants	Series A		79,083		68		148
American Supercondutor Corporation⁽³⁾	Clean Tech	Common Stock Warrants			139,275		244		122
BrightSource Energy, Inc.	Clean Tech	Preferred Stock Warrants	Series D		58,333		675		248
Calera, Inc.	Clean Tech	Preferred Stock Warrants	Series C		44,529		513		—
EcoMotors, Inc.	Clean Tech	Preferred Stock Warrants	Series B		437,500		308		435
Enphase Energy, Inc.⁽³⁾	Clean Tech	Common Stock Warrants			37,500		102		17
Fulcrum Bioenergy, Inc.	Clean Tech	Preferred Stock Warrants	Series C-1		187,265		211		104
Glori Energy, Inc.	Clean Tech	Preferred Stock Warrants	Series C		145,932		165		62
GreatPoint Energy, Inc.	Clean Tech	Preferred Stock Warrants	Series D-1		393,212		548		1
Integrated Photovoltaics, Inc.	Clean Tech	Preferred Stock Warrants	Series A-1		390,000		82		119
Polyera Corporation	Clean Tech	Preferred Stock Warrants	Series C		161,575		69		68
Propel Biofuels, Inc.	Clean Tech	Preferred Stock Warrants	Series C		3,200,000		211		317
Redwood Systems, Inc.	Clean Tech	Preferred Stock Warrants	Series C		331,250		3		2
SCIenergy, Inc.⁽⁴⁾	Clean Tech	Preferred Stock Warrants	Series D		1,061,168		361		145
Solexel, Inc.	Clean Tech	Preferred Stock Warrants	Series B		245,682		1,161		7
Stion Corporation⁽⁴⁾	Clean Tech	Preferred Stock Warrants	Series E		110,226		317		167
Trilliant, Inc.	Clean Tech	Preferred Stock Warrants	Series A		320,000		161		54

Total Warrants Clean Tech (0.39%)*							5,199		2,016



Total Warrants (5.73%)						$	32,060	$	29,550

Aveo Pharmaceuticals, Inc.⁽³⁾	Drug Discovery & Development	Common Stock			167,864		842		1,351
Dicerna Pharmaceuticals, Inc.	Drug Discovery & Development	Preferred Stock	Series B		502,684		502		488
Inotek Pharmaceuticals Corp.	Drug Discovery & Development	Preferred Stock	Series C		15,334		1,500		—
Merrimack Pharmaceuticals, Inc.⁽³⁾	Drug Discovery & Development	Common Stock			546,448		2,000		3,328
Paratek Pharmaceuticals, Inc.	Drug Discovery & Development	Preferred Stock	Series H		244,158		1,000		283
		Common Stock			47,471		5		3

Total Paratek Pharmaceuticals, Inc.					291,629		1,005		286

Total Equity Drug Discovery & Development (1.06%)*							5,849		5,453

See notes to consolidated financial statements.

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS—(Continued)

December 31, 2012

(dollars in thousands)


Portfolio Company	Sub-Industry	Type of Investment⁽¹⁾	Series	Shares		Cost⁽²⁾		Value⁽³⁾
Acceleron Pharmaceuticals, Inc.	Drug Delivery	Preferred Stock	Series B		600,601	$	1,000	$	915
		Preferred Stock	Series C		93,456		242		205
		Preferred Stock	Series E		43,488		98		174
		Preferred Stock	Series F		19,268		61		77

Total Acceleron Pharmaceuticals, Inc.					756,813		1,401		1,371
Merrion Pharma, Plc.^(3)(5)(10)	Drug Delivery	Common Stock			20,000		9		—
Nupathe, Inc.	Drug Delivery	Common Stock			50,000		146		142
Transcept Pharmaceuticals, Inc.⁽³⁾	Drug Delivery	Common Stock			41,570		500		185

Total Equity Drug Delivery (0.33%)*							2,056		1,698

E-band Communications, Corp.⁽⁶⁾	Communications & Networking	Preferred Stock	Series B		564,972		2,000		—
		Preferred Stock	Series C		649,998		372		—
		Preferred Stock	Series D		847,544		508		—
		Preferred Stock	Series E		1,987,605		374		—

Total E-band Communications, Corp.					4,050,119		3,254		—
Glowpoint, Inc.⁽³⁾	Communications & Networking	Common Stock			114,192		101		227
Neonova Holding Company	Communications & Networking	Preferred Stock	Series A		500,000		250		200
Peerless Network, Inc.	Communications & Networking	Preferred Stock	Series A		1,000,000		1,000		3,692
Stoke, Inc.	Communications & Networking	Preferred Stock	Series E		152,905		500		631
UPH Holdings, Inc.	Communications & Networking	Common Stock			742,887		—		624

Total Equity Communications & Networking (1.04%)*							5,105		5,374

Atrenta, Inc.	Software	Preferred Stock	Series C		1,196,845		508		1,042
		Preferred Stock	Series D		635,513		986		1,604

Total Atrenta, Inc.					1,832,358		1,494		2,646
Box, Inc.⁽⁴⁾	Software	Preferred Stock	Series C		390,625		500		5,117
		Preferred Stock	Series D		158,127		500		2,071
		Preferred Stock	Series D-1		124,511		1,000		1,632
		Preferred Stock	Series D-2		220,751		2,001		2,892
		Preferred Stock	Series E		38,183		500		500

Total Box, Inc.					932,197		4,501		12,212
Caplinked, Inc.	Software	Preferred Stock	Series A-3		53,614		52		77

Total Equity Software (2.89%)*							6,047		14,935

Spatial Photonics, Inc.	Electronics & Computer Hardware	Preferred Stock	Series D		4,717,813		268		—
Virident Systems	Electronics & Computer Hardware	Preferred Stock	Series D		6,546,217		5,000		4,922

Total Equity Electronics & Computer Hardware (0.95%)*							5,268		4,922

Quatrx Pharmaceuticals Company	Specialty Pharmaceuticals	Preferred Stock	Series E		166,419		750		—

Total Equity Specialty Pharmaceuticals (0.00%)*							750		—

Caivis Acquisition Corporation	Consumer & Business Products	Common Stock	Series A		295,861		819		597
Facebook, Inc.⁽³⁾	Consumer & Business Products	Common Stock	Series B		307,500		9,558		8,089
IPA Holdings, LLC	Consumer & Business Products	Preferred Stock	LLC interest		500,000		500		711
Market Force Information, Inc.	Consumer & Business Products	Preferred Stock	Series B		187,970		500		657
Wageworks, Inc.⁽³⁾	Consumer & Business Products	Common Stock	Series D		19,260		250		343

Total Equity Consumer & Business Products (2.02%)*							11,627		10,397

iWatt, Inc.	Semiconductors	Preferred Stock	Series E		2,412,864		490		752

Total Equity Semiconductors (0.15%)*							490		752

See notes to consolidated financial statements.

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS—(Continued)

December 31, 2012

(dollars in thousands)


Portfolio Company	Sub-Industry	Type of Investment⁽¹⁾	Series	Shares		Cost⁽²⁾		Value⁽³⁾
Buzznet, Inc.	Information Services	Preferred Stock	Series C		263,158	$	250	$	—
Good Technologies, Inc. (pka Visto Corporation)	Information Services	Common Stock			500,000		603		—
Solutionary, Inc.	Information Services	Preferred Stock	Series A-1		189,495		18		235
		Preferred Stock	Series A-2		65,834		325		82

Total Solutionary, Inc.					255,329		343		317

Total Equity Information Services (0.06%)*							1,196		317

Gelesis, Inc.⁽⁶⁾	Medical Device & Equipment		LLC Interest		674,208		—		435
			LLC Interest		674,208		425		610
			LLC Interest		675,676		500		525
Total Gelesis, Inc.					2,024,092		925		1,570
Lanx, Inc.	Medical Device & Equipment	Preferred Stock	Series C		1,203,369		1,000		1,155
Novasys Medical, Inc.	Medical Device & Equipment	Preferred Stock	Series D-1		4,118,444		1,000		—
Optiscan Biomedical, Corp.⁽⁶⁾	Medical Device & Equipment	Preferred Stock	Series B		6,185,567		3,000		314
		Preferred Stock	Series C-2		1,927,309		655		251

Total Optiscan Biomedical, Corp.					8,112,876		3,655		565

Total Equity Medical Device & Equipment (0.64%)*							6,580		3,290

NuGEN Technologies, Inc.	Biotechnology Tools	Preferred Stock	Series C		189,394		500		600

Total Equity Biotechnology Tools (0.12%)*							500		600

Transmedics, Inc.	Surgical Devices	Preferred Stock	Series B		88,961		1,100		—
		Preferred Stock	Series C		119,999		300		—
		Preferred Stock	Series D		260,000		650		650

Total Transmedics, Inc.					468,960		2,050		650
Gynesonics, Inc.	Surgical Devices	Preferred Stock	Series B		219,298		250		159
		Preferred Stock	Series C		656,512		282		251

Total Gynesonics, Inc.					875,810		532		410

Total Equity Surgical Devices (0.20%)*							2,582		1,060

Everyday Health, Inc. (pka Waterfront Media, Inc.)	Media/Content/ Info	Preferred Stock	Series D		145,590		1,000		412

Total Equity Media/Content/Info (0.08%)*							1,000		412



Total Equity (9.54%)					45,081,540	$	49,050	$	49,210

							49,050		49,210

Total Investments (175.65%)						$	914,338	$	906,300

*	Value as a percent of net assets

(1)	Preferred and common stock, warrants, and equity interests are generally non-income producing.

(2)	Gross unrealized appreciation, gross unrealized depreciation, and net depreciation for federal income tax purposes totaled $19.9 million, $27.6 million and $7.8 million respectively. The tax cost of investments is $916.9 million

(3)

Except for warrants in twenty publicly traded companies and common stock in eight publicly traded companies, all investments are restricted at December 31, 2012 and were valued at fair value as determined in good faith by the Board of Directors. No unrestricted securities of the same issuer are outstanding. The Company uses the Standard Industrial Code for classifying the industry grouping of its portfolio companies.

(4)	Debt investments of this portfolio company have been pledged as collateral under the Wells Facility.

(5)	Non-U.S. company or the company’s principal place of business is outside the United States.

(6)	Affiliate investment that is defined under the Investment Company Act of 1940 as companies in which HTGC owns as least 5% but not more than 25% of the voting securities of the Company.

(7)	Control investment that is defined under the Investment Company Act of 1940 as companies in which HTGC owners as least 25% but not more than 50% of the voting securities of the Company.

(8)	Debt is on non-accrual status at December 31, 2012, and is therefore considered non-income producing.

(9)	Convertible Senior Debt

(10)	Indicates assets that the Company deems not “qualifying assets” under section 55(a) of the Investment Company Act of 1940, as amended. Qualifying assets must represent at least 70% of the Company’s total assets at the time of acquisition of any additional non-qualifying assets.

(11)	Denotes that all or a portion of the loan secures the notes offered in the Debt Securitization (as defined in Note 4).

See notes to consolidated financial statements.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(unaudited)

1. Description of Business and Unaudited Interim Consolidated Financial Statements Basis of Presentation

Hercules Technology Growth Capital, Inc. (the “Company”) is a specialty finance company focused on providing senior secured loans to venture capital-backed companies in technology-related markets, including technology, biotechnology, life science, and clean-technology industries at all stages of development. The Company sources its investments through its principal office located in Silicon Valley, as well as through its additional offices in Boston, MA, New York, NY, Chicago, IL, Boulder, CO and McLean, VA. The Company was incorporated under the General Corporation Law of the State of Maryland in December 2003.

The Company is an internally managed, non-diversified closed-end investment company that has elected to be regulated as a business development company (“BDC”) under the Investment Company Act of 1940, as amended (the “1940 Act”). From incorporation through December 31, 2005, the Company was taxed as a corporation under Subchapter C of the Internal Revenue Code of 1986, (the “Code”). Effective January 1, 2006, the Company has elected to be treated for tax purposes as a regulated investment company, or RIC, under the Code (see Note 5).

Hercules Technology II, L.P. (“HT II”), Hercules Technology III, L.P. (“HT III”), and Hercules Technology IV, L.P. (“HT IV”), are Delaware limited partnerships that were formed in January 2005, September 2009 and December 2010, respectively. HT II and HT III were licensed to operate as small business investment companies (“SBICs”), under the authority of the Small Business Administration (“SBA”), on September 27, 2006 and May 26, 2010, respectively. As SBICs, HT II and HT III are subject to a variety of regulations concerning, among other things, the size and nature of the companies in which they may invest and the structure of those investments. The Company also formed Hercules Technology SBIC Management, LLC, or (“HTM”), a limited liability company in November 2003. HTM is a wholly owned subsidiary of the Company and serves as the limited partner and general partner of HT II and HT III (see Note 4).

HT II and HT III hold approximately $152.7 million and $257.5 million in assets, respectively, and accounted for approximately 9.8% and 16.5% of our total assets prior to consolidation at March 31, 2013.

The Company also established wholly owned subsidiaries, all of which are structured as Delaware corporations and limited liability companies, to hold portfolio companies organized as limited liability companies, or LLCs (or other forms of pass-through entities). The Company currently qualifies as a RIC for federal income tax purposes, which allows the Company to avoid paying corporate income taxes on any income or gains that the Company distributes to our stockholders. The purpose of establishing these entities is to satisfy the RIC tax requirement that at least 90% of the Company’s gross income for income tax purposes is investment income.

The consolidated financial statements include the accounts of the Company and its subsidiaries. All inter-company accounts and transactions have been eliminated in consolidation. In accordance with Article 6 of Regulation S-X under the Securities Act of 1933 and the Securities and Exchange Act of 1934, the Company does not consolidate portfolio company investments. The accompanying consolidated interim financial statements are presented in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information, and pursuant to the requirements for reporting on Form 10-Q and Article 10 of Regulation S-X under the Securities Act of 1933 and the Securities Exchange Act of 1934. Accordingly, certain disclosures accompanying annual consolidated financial statements prepared in accordance with U.S. GAAP are omitted. In the opinion of management, all adjustments consisting solely of normal recurring accruals considered necessary for the fair presentation of consolidated financial statements for the interim periods have been included. The current period’s results of operations are not necessarily indicative of results that ultimately may be achieved for the year. Therefore, the interim unaudited consolidated financial statements and notes should be read in conjunction with the audited consolidated financial statements and notes thereto for the period ended December 31, 2012. The year-end consolidated statement of assets and liabilities data was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. Financial statements prepared on a U.S. GAAP basis require management to make estimates and assumptions that affect the amounts and disclosures reported in the consolidated financial statements and accompanying notes. Such estimates and assumptions could change in the future as more information becomes known, which could impact the amounts reported and disclosed herein.

2. Summary of Significant Accounting Policies

Principles of Consolidation

The Consolidated Financial Statements include the accounts of the Company and its subsidiaries and all variable interest entities of which the Company is the primary beneficiary. All intercompany accounts and transactions have been eliminated in consolidation.

A VIE is an entity that either (i) has insufficient equity to permit the entity to finance its activities without additional subordinated financial support or (ii) has equity investors who lack the characteristics of a controlling financial interest. The primary beneficiary of a VIE is the party with both the power to direct the activities of the VIE that most significantly impact the VIE’s economic performance and the obligation to absorb the losses or the right to receive benefits that could potentially be significant to the VIE.

To assess whether the Company has the power to direct the activities of a VIE that most significantly impact its economic performance, the Company considers all the facts and circumstances including its role in establishing the VIE and its ongoing rights and responsibilities. This assessment includes identifying the activities that most significantly impact the VIE’s economic performance and identifying which party, if any, has power over those activities. In general, the party that makes the most significant decisions affecting the VIE is determined to have the power to direct the activities of a VIE. To assess whether the Company has the obligation to absorb the losses or the right to receive benefits that could potentially be significant to the VIE, the Company considers all of its economic interests, including debt and equity interests, servicing rights and fee arrangements, and any other variable interests in the VIE. If the Company determines that it is the party with the power to make the most significant decisions affecting the VIE, and the Company has a potentially significant interest in the VIE, then its consolidates the VIE.

The Company performs ongoing reassessments, usually quarterly, of whether it is the primary beneficiary of a VIE. The reassessment process considers whether the Company has acquired or divested the power to direct the activities of the VIE through changes in governing documents or other circumstances. The Company also reconsiders whether entities previously determined not to be VIEs have become VIEs, based on certain events, and therefore are subject to the VIE consolidation framework.

Out-of-Period Items

During the three-month period ended March 31, 2013, the Company recorded an out-of-period adjustment related to 2012 unrecorded escrow balances which increased total assets and unrealized appreciation by approximately $1.2 million at March 31, 2013. The Company evaluated the total out-of-period adjustments in relation to the current period, which is when they were corrected, as well as the period in which they originated and concluded that these adjustments are not material to both the consolidated quarterly and annual financial statements for all impacted periods. There is no change to net investment income (and by definition, no change to net investment income per share).

Valuation of Investments

The Company’s investments are carried at fair value in accordance with the 1940 Act and Accounting Standards Codification (“ASC”) topic 820 Fair Value Measurements and Disclosures (formerly known as SFAS No. 157, Fair Value Measurements). At March 31, 2013, 79.9% of the Company’s total assets represented investments in portfolio companies that are valued at fair value by the Board of Directors. Value, as defined in Section 2(a)(41) of the 1940 Act, is (i) the market price for those securities for which a market quotation is readily available and (ii) for all other securities and assets, fair value is as determined in good faith by the Board of Directors. The Company’s debt securities are primarily invested in venture capital-backed companies in technology-related markets, including technology, biotechnology, life science and clean technology industries. Given the nature of lending to these types of businesses, the Company’s investments in these portfolio companies are considered Level 3 assets under ASC 820 because there is no known or accessible market or market indexes for these investment securities to be traded or exchanged. As such, the Company

values substantially all of its investments at fair value as determined in good faith pursuant to a consistent valuation policy and the Company’s Board of Directors in accordance with the provisions of ASC 820 and the 1940 Act. Due to the inherent uncertainty in determining the fair value of investments that do not have a readily available market value, the fair value of the Company’s investments determined in good faith by its Board may differ significantly from the value that would have been used had a readily available market existed for such investments, and the differences could be material.

Our Board of Directors may from time to time engage an independent valuation firm to provide the Company with valuation assistance with respect to certain portfolio investments on a quarterly basis. The Company intends to continue to engage an independent valuation firm to provide management with assistance regarding the Company’s determination of the fair value of selected portfolio investments each quarter unless directed by the Board of Directors to cancel such valuation services. The scope of services rendered by an independent valuation firm is at the discretion of the Board of Directors. The Company’s Board of Directors is ultimately and solely responsible for determining the fair value of the Company’s investments in good faith.

With respect to investments for which market quotations are not readily available or when such market quotations are deemed not to represent fair value, the Company’s Board of Directors has approved a multi-step valuation process each quarter, as described below:

(1) the Company’s quarterly valuation process begins with each portfolio company or investment being initially valued by the investment professionals responsible for the portfolio investment;

(2) preliminary valuation conclusions are then documented and business based assumptions are discussed with the Company’s investment committee;

(3) the valuation committee of the Board of Directors reviews the preliminary valuation of the investment committee which incorporates the results of the independent valuation firm as appropriate;

(4) the Board of Directors discusses valuations and determines the fair value of each investment in our portfolio in good faith based on the input of, where applicable, the respective independent valuation firm and the valuation committee.

The Company adopted ASC 820 on January 1, 2008. ASC 820 establishes a framework for measuring the fair value of the assets and liabilities and outlines a fair value hierarchy which prioritizes the inputs used to measure fair value and the effect of fair value measures on earnings. ASC 820 also enhances disclosure requirements for fair value measurements based on the level within the hierarchy of the information used in the valuation. ASC 820 applies whenever other standards require (or permit) assets or liabilities to be measured at fair value but does not expand the use of fair value in any new circumstances. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.

The Company has categorized all investments recorded at fair value in accordance with ASC 820 based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels, defined by ASC 820 and directly related to the amount of subjectivity associated with the inputs to fair valuation of these assets and liabilities, are as follows:

Level 1—Inputs are unadjusted, quoted prices in active markets for identical assets at the measurement date. The types of assets carried at Level 1 fair value generally are equities listed in active markets.

Level 2—Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the asset in connection with market data at the measurement date and for the extent of the instrument’s anticipated life. Fair valued assets that are generally included in this category are warrants held in a public company.

Level 3—Inputs reflect management’s best estimate of what market participants would use in pricing the asset at the measurement date. It includes prices or valuations that require inputs that are both significant to the fair value measurement and unobservable. Generally, assets carried at fair value and included in this category are the debt investments and warrants and equities held in a private company.

In accordance with ASU 2011-04, the following table provides quantitative information about the Company’s Level 3 fair value measurements of the Company’s investments as of March 31, 2013 (unaudited). In addition to the techniques and inputs noted in the table below, according to the Company’s valuation policy the Company may also use other valuation techniques and methodologies when determining the Company’s fair value measurements. The below table is not intended to be all-inclusive, but rather provides information on the significant Level 3 inputs as they relate to the Company’s fair value measurements.


Investment Type - Level Three Debt Investments	Fair Value at March 31, 2013		Valuation Techniques/ Methodologies	Unobservable Input^(a)	Range
	(in thousands)
Pharmaceuticals - Debt	$	264,707	Market Comparable Companies	Hypothetical Market Yield Premium/(Discount)	13.84% - 19.29% (2.0%) - 1.0%
			Option Pricing Model^(b)	Average Industry Volatility^(c) Risk Free Interest Rate Estimated Time to Exit (in months)	57.97% 0.170% 12.17
Medical Devices - Debt		60,674	Market Comparable Companies	Hypothetical Market Yield Premium	16.77% 0.00% - 1.00%
Technology - Debt		164,844	Market Comparable Companies	Hypothetical Market Yield Premium/(Discount)	12.36% - 19.30% (2.00%) - 2.00%
			Liquidation	Investment Collateral	$0.00 - $7.08 million
Clean Tech - Debt		105,436	Market Comparable Companies	Hypothetical Market Yield Premium	13.03% - 17.17% 0.00% - 1.00%
Lower Middle Market - Debt		285,350	Market Comparable Companies	Hypothetical Market Yield Premium	11.07% - 21.85% 0.00% - 1.00%
			Broker Quote^(d)	Price Quotes Market Comparable Index Yield Spreads	81.0% - 100% of par 3.50% - 5.93%
				Par Value	$30.0 million

Total Level Three Debt Investments	$	881,011

(a)

The significant unobservable inputs used in the fair value measurement of our debt securities are hypothetical market yields and premiums/(discounts). The hypothetical market yield is defined as the exit price of an investment in a hypothetical market to hypothetical market participants where buyers and sellers are willing participants. The premiums (discounts) relate to company specific characteristics such as underlying investment performance, security liens, and other characteristics of the investment. Significant increases (decreases) in the inputs in isolation would result in a significantly lower (higher) fair value measurement, depending on the materiality of the investment. Debt investments in the industries noted in our Schedule of Investments are included in the industries note above as follows:

Pharmaceuticals, above, is comprised of debt investments in the Therapeutic, Specialty Pharmaceuticals, Drug Discovery and Development, Drug Delivery, and Diagnostics and Biotechnology industries in the Schedule of Investments.

Medical Devices, above, is comprised of debt investments in the Therapeutic, Surgical Devices, Medical Devices and Equipment and Biotechnology Tools industries in the Schedule of Investments.

Technology, above, is comprised of debt investments in the Software, Semiconductors, Internet Consumer and Business Services, Information Services, and Communications and Networking industries in the Schedule of Investments.

Lower Middle Market, above, is comprised of debt investments in the Communications and Networking, Electronics and Computer Hardware, Healthcare Services - Other, Information Services, Internet Consumer and Business Services, Media/Content/Info, and Specialty Pharmaceuticals industries in the Schedule of Investments.

Clean Tech, above, aligns with the Clean Tech Industry in the Schedule of Investments.

(b)	An option pricing model valuation technique was used to derive the fair value of the conversion feature of convertible notes.

(c)	Represents the range of industry volatility used by market participants when pricing the investment.

(d)	A broker quote valuation technique was used to derive the fair value of loans which are part of a syndicated facility.


Investment Type -	Fair Value at March 31, 2013		Valuation Techniques/ Methodologies	Unobservable Input^(a)	Range
	(unaudited, in thousands)
Level Three Equity Investments	$	40,106	Market Comparable Companies	EBITDA Multiple^(b) Revenue Multiple^(b) Discount for Lack of Marketability^(c)	4.30x - 24.55x 0.59x - 16.29x 10.4% - 25.20%
Level Three Warrant Investments		28,030	Market Comparable Companies	EBITDA Multiple^(b) Revenue Multiple^(b) Discount for Lack of Marketability^(c)	4.30x - 24.55x 0.59x - 16.29x 10.4% - 25.20%
Warrant positions additionally subject to:			Option Pricing Model	Average Industry Volatility^(d) Risk-Free Interest Rate Estimated Time to Exit (in months)	43.53% - 140.36% 0.15% - 0.64% 12 - 48

Total Level Three Warrant and Equity Investments	$	68,136

(a)

The significant unobservable inputs used in the fair value measurement of the Company’s warrant and equity-related securities are revenue and/or EBITDA multiples and discounts for lack of marketability. Additional inputs used in the Black Scholes option pricing model include industry volatility, risk free interest rate and estimated time to exit. Significant increases (decreases) in the inputs in isolation would result in a significantly higher (lower) fair value measurement, depending on the materiality of the investment. For some investments, additional consideration may be given to data from the last round of financing or merger/acquisition events near the measurement date.

(b)	Represents amounts used when the Company has determined that market participants would use such multiples when pricing the investments.

(c)	Represents amounts used when the Company has determined market participants would take into account these discounts when pricing the investments.

(d)	Represents the range of industry volatility used by market participants when pricing the investment.

Debt Investments

The Company’s debt securities are primarily invested in venture capital-backed companies in technology-related markets, including technology, biotechnology, life science and clean technology industries. Given the nature of lending to these types of businesses, the Company’s investments in these portfolio companies are considered Level 3 assets under ASC 820 because there is no known or accessible market or market indexes for these investment securities to be traded or exchanged.

The Company applies a procedure that assumes a sale of investment in a hypothetical market to a hypothetical market participant where buyers and sellers are willing participants. The hypothetical market does not include scenarios where the underlying security was simply repaid or extinguished, but includes an exit concept. Under this process, the Company also evaluates the collateral for recoverability of the debt investments as well as applies all of its historical fair value analysis. The Company uses pricing on recently issued comparable debt securities to determine the baseline hypothetical market yields as of the measurement date. The Company considers each portfolio company’s credit rating, security liens and other characteristics of the investment to adjust the baseline yield to derive a hypothetical yield for each investment as of the measurement date. The anticipated future cash flows from each investment are then discounted at the hypothetical yield to estimate each investment’s fair value as of the measurement date.

The Company’s process includes, among other things, the underlying investment performance, the current portfolio company’s financial condition and market changing events that impact valuation, estimated remaining life, current market yield and interest rate spreads of similar securities as of the measurement date. The Company values its syndicated loans using broker quotes and bond indices amongst other factors. If there is a significant deterioration of the credit quality of a debt investment, the Company may consider other factors to estimate fair value, including the proceeds that would be received in a liquidation analysis.

The Company records unrealized depreciation on investments when it believes that an investment has decreased in value, including where collection of a loan is doubtful or if under the in exchange premise when the value of a debt security was to be less than amortized cost of the investment. Conversely, where appropriate, the Company records unrealized appreciation if it believes that the underlying portfolio company has appreciated in value and, therefore, that its investment has also appreciated in value or if under the in exchange premise the value of a debt security were to be greater than amortized cost.

When originating a debt instrument, the Company generally receives warrants or other equity-related securities from the borrower. The Company determines the cost basis of the warrants or other equity-related securities received based upon their respective fair values on the date of receipt in proportion to the total fair value of the debt and warrants or other equity-related securities received. Any resulting discount on the loan from recordation of the warrant or other equity instruments is accreted into interest income over the life of the loan.

Equity-Related Securities and Warrants

Securities that are traded in the over-the-counter markets or on a stock exchange will be valued at the prevailing bid price at period end. The Company has a limited number of equity securities in public companies. In accordance with the 1940 Act, unrestricted publicly traded securities for which market quotations are readily available are valued at the closing market quote on the measurement date.

The Company estimates the fair value of warrants using a Black Scholes pricing model. At each reporting date, privately held warrant and equity-related securities are valued based on an analysis of various factors including, but not limited to, the portfolio company’s operating performance and financial condition and general market conditions, price to enterprise value or price to equity ratios, discounted cash flow, valuation comparisons to comparable public companies or other industry benchmarks. When an external event occurs, such as a purchase transaction, public offering, or subsequent equity sale, the pricing indicated by that external event is utilized to corroborate the Company’s valuation of the warrant and equity-related securities. The Company periodically reviews the valuation of its portfolio companies that have not been involved in a qualifying external event to determine if the enterprise value of the portfolio company may have increased or decreased since the last valuation measurement date.

Investments measured at fair value on a recurring basis are categorized in the tables below based upon the lowest level of significant input to the valuations as of March 31, 2013 (unaudited) and as of December 31, 2012. The Company transfers investments in and out of Level 1, 2 and 3 securities as of the beginning balance sheet date, based on changes in the use of observable and unobservable inputs utilized to perform the valuation for the period. During the three-months ended March 31, 2013, there were no transfers in between Levels 1 or 2.


			Investments at Fair Value as of March 31, 2013
(in thousands) Description	3/31/2013		Quoted Prices In Active Markets For Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Senior secured debt	$	881,011	$	—	$	—	$	881,011
Preferred stock		39,016		—		—		39,016
Common stock		14,708		13,618		—		1,090
Warrants		33,249		—		5,219		28,030

	$	967,984	$	13,618	$	5,219	$	949,147


			Investments at Fair Value as of December 31, 2012
(in thousands) Description	12/31/2012		Quoted Prices In Active Markets For Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Senior secured debt	$	827,540	$	—	$	—	$	827,540
Preferred stock		33,889		—		—		33,889
Common stock		15,321		13,665		—		1,656
Warrants		29,550		—		7,410		22,140

	$	906,300	$	13,665	$	7,410	$	885,225

The table below presents reconciliation for all financial assets and liabilities measured at fair value on a recurring basis, excluding accrued interest components, using significant unobservable inputs (Level 3) for the three-months ended March 31, 2013 (unaudited) and December 31, 2012.


(in thousands)	Balance, January 1, 2013		Net Realized Gains (losses)⁽¹⁾			Net change in unrealized appreciation or (depreciation)⁽²⁾			Purchases		Sales			Repayments			Gross Transfers into Level 3⁽³⁾		Gross Transfers out of Level 3⁽³⁾			Balances, March 31, 2013
Senior Debt	$	827,540	$	—		$	(7,237	)	$	143,715	$	—		$	(82,171	)	$	—	$	(836	)	$	881,011
Preferred Stock		33,889		(268	)		2,507			2,112		—			—			776		—			39,016
Common Stock		1,656		188			(659	)		—		(188	)		—			93		—			1,090
Warrant	$	22,140		2,071			5,043			1,834		(3,058	)		—			—		—			28,030

Total	$	885,225	$	1,991		$	(346	)	$	147,661	$	(3,246	)	$	(82,171	)	$	869	$	(836	)	$	949,147


(in thousands)	Balance, January 1, 2012		Net Realized Gains (losses)⁽¹⁾			Net change in unrealized appreciation or depreciation⁽²⁾			Purchases		Sales			Repayments			Gross Transfers into Level 3		Gross Transfers out of Level 3			Balances, December 31, 2012
Senior Debt	$	585,767	$	(5,178	)	$	(2,262	)	$	545,913	$	(2,000.00	)	$	(294,294	)	$	—	$	(406	)	$	827,540
Preferred Stock		30,289		(733	)		4,112			10,562		(6,553	)		—			356		(4,144	)		33,889
Common Stock		90		(16	)		5,523			9,558		(45	)		—			—		(13,453	)		1,656
Warrants		26,284		4,413			(2,453	)		7,362		(9,211	)		—			—		(4,256	)		22,140

Total	$	642,430	$	(1,514	)	$	4,920		$	573,395	$	(17,809	)	$	(294,294	)	$	356	$	(22,259	)	$	885,225

⁽¹⁾	Includes net realized gains (losses) recorded as realized gains or losses in the accompanying consolidated statements of operations.

⁽²⁾	Included in change in net unrealized appreciation or depreciation in the accompanying consolidated statements of operations.

⁽³⁾	Transfers in/out of Level 3 relate to the conversion of Optiscan Biomedical, Inc., Gynesonics, Inc. and Philotic, Inc. debt to equity.

For the three months ended March 31, 2013, approximately $1.6 million and $4.4 million in unrealized appreciation was recorded for equity and warrant Level 3 investments, respectively, relating to assets still held at the reporting date. For the same period, approximately $7.2 million in unrealized depreciation was recorded for Level 3 debt investments relating to assets still held at the reporting date.

For the year ended December 31, 2012, approximately $3.8 million in unrealized appreciation and $2.2 million in unrealized depreciation was recorded for equity and warrant Level 3 investments, respectively, relating to assets still held at the reporting date. For the same period, approximately $2.3 million in unrealized depreciation was recorded for Level 3 debt investments relating to assets still held at the reporting date.

As required by the 1940 Act, the Company classifies its investments by level of control. “Control investments” are defined in the 1940 Act as investments in those companies that the Company is deemed to “control”. Generally, under the 1940 Act, the Company is deemed to “control” a company in which it has invested if it owns 25% or more of the voting securities of such company or has greater than 50% representation on its board. “Affiliate investments” are investments in those companies that are “affiliated companies” of the Company, as defined in the 1940 Act, which are not control investments. The Company is deemed to be an “affiliate” of a company in which it has invested if it owns 5% or more but less than 25% of the voting securities of such company. “Non-control/non-affiliate investments” are investments that are neither control investments nor affiliate investments.

The following table summarizes our realized and unrealized gain and loss and changes in our unrealized appreciation and depreciation on control and affiliate investments for the three-months ended March 31, 2013 and 2012 (unaudited):


(in thousands)	March 31, 2013
Portfolio Company	Type	Fair Value at March 31, 2013		Investment Income		Unrealized (Depreciation)/ Appreciation		Reversal of Unrealized (Depreciation)/ Appreciation		Realized Gain/ (Loss)
Gelesis, Inc.	Non-Controlled Affiliate	$	1,888	$	—	$	222	$	—	$	—
Optiscan BioMedical, Corp.	Non-Controlled Affiliate		12,308		610		212		—		—

Total		$	14,196	$	610	$	434	$	—	$	—


(in thousands)	March 31, 2012
Portfolio Company	Type	Fair Value at March 31, 2012		Investment Income		Unrealized (Depreciation)/ Appreciation		Reversal of Unrealized (Depreciation)/ Appreciation		Realized Gain/ (Loss)
MaxVision Holding, LLC.	Control	$	675	$	13	$	26	$	—	$	—
E-Band Communications, Corp.	Non-Controlled Affiliate		1,094		6		1,076		—		—

Total		$	1,769	$	19	$	1,102	$	—	$	—

At March 31, 2013, the Company did not hold any Control Investments. The Company’s investment in MaxVision Holding, L.L.C., a company that was a Control Investment as of March 31, 2012, was liquidated during the year ended December 31, 2012. On July 31, 2012, the Company received payment of $2.0 million for its total debt investments in Maxvision Holding, L.L.C. Approximately $8.7 million of realized losses and $10.5 million of net change in unrealized appreciation was recognized on this control debt and equity investment during the year ended December 31, 2012.

During the year ended December 31, 2012, Gelesis, Inc. and Optiscan BioMedical, Corp. became non-controlled affiliates as companies in which the Company owns 5% or more but less than 25% of the voting securities of the company.

The Company has one additional non-controlled affiliate investment, E-band Communications, Corp, that has a fair value of zero at March 31, 2013, and no investment income, unrealized depreciation, realized depreciation or realized loss for the three-month period ended March 31, 2013.

A summary of the composition of the Company’s investment portfolio as of March 31, 2013 (unaudited) and December 31, 2012 at fair value is shown as follows:


	March 31, 2013					December 31, 2012
(in thousands)	Investments at Fair Value		Percentage of Total Portfolio			Investments at Fair Value		Percentage of Total Portfolio
Senior secured debt with warrants	$	700,498		72.4	%	$	652,041		72.0	%
Senior secured debt		213,762		22.1	%		205,049		22.6	%
Preferred stock		39,504		4.1	%		33,885		3.7	%
Common Stock		14,220		1.4	%		15,325		1.7	%

	$	967,984		100.0	%	$	906,300		100.0	%

A summary of the Company’s investment portfolio, at value, by geographic location as of March 31, 2013 (unaudited) and December 31, 2012:


	March 31, 2013					December 31, 2012
(in thousands)	Investments at Fair Value		Percentage of Total Portfolio			Investments at Fair Value		Percentage of Total Portfolio
United States	$	963,809		99.6	%	$	901,041		99.4	%
England		4,175		0.4	%		5,259		0.6	%

	$	967,984		100.0	%	$	906,300		100.0	%

The following table shows the fair value the Company’s portfolio by industry sector at March 31, 2013 (unaudited) and December 31, 2012:


	March 31, 2013					December 31, 2012
(in thousands)	Investments at Fair Value		Percentage of Total Portfolio			Investments at Fair Value		Percentage of Total Portfolio
Drug Discovery & Development	$	196,506		20.3	%	$	188,479		20.8	%
Internet Consumer & Business Services		142,362		14.7	%		136,149		15.0	%
Clean Tech		137,054		14.1	%		126,600		14.0	%
Medical Device & Equipment		99,896		10.3	%		54,575		6.0	%
Software		75,383		7.8	%		70,838		7.8	%
Drug Delivery		65,660		6.8	%		74,218		8.2	%
Information Services		52,342		5.4	%		53,523		5.9	%
Media/Content/Info		52,215		5.4	%		51,534		5.7	%
Healthcare Services, Other		31,416		3.2	%		36,481		4.0	%
Communications & Networking		30,681		3.2	%		37,560		4.1	%
Electronics & Computer Hardware		23,569		2.4	%		12,715		1.4	%
Diagnostic		15,196		1.6	%		16,307		1.8	%
Specialty Pharma		14,289		1.5	%		12,473		1.4	%
Surgical Devices		11,527		1.2	%		11,358		1.3	%
Consumer & Business Products		10,430		1.1	%		13,723		1.5	%
Biotechnology Tools		6,596		0.7	%		6,845		0.8	%
Semiconductors		2,862		0.3	%		2,922		0.3	%

	$	967,984		100.0	%	$	906,300		100.0	%

During the three-months ended March 31, 2013, the Company funded investments in debt securities and equity investments, totaling approximately $136.3 million and $2.0 million, respectively. During the three-months ended March 31, 2013, the Company converted approximately $836,000 of debt to equity in three portfolio companies.

During the year ended December 31, 2012, the Company funded investments in debt securities and equity investments, totaling approximately $486.8 million and $9.7 million, respectively. During the year ended December 31 2012, the Company converted approximately $356,000 of debt to equity in one portfolio company.

No single portfolio investment represents more than 10% of the fair value of the investments as of March 31, 2013 and December 31, 2012.

During the three-month period ended March 31, 2013, the Company recognized net realized gains of approximately $2.0 million on the portfolio. During the three-month period ended March 31, 2013, the Company recorded gross realized gains of approximately $3.6 million from the sale of investments in three portfolio companies. These gains were partially offset by the liquidation of the Company’s investments in five portfolio companies of approximately $1.6 million in gross realized losses.

During the three months ended March 31, 2012, the Company recognized net realized gains of approximately $2.9 million on the portfolio. The Company recorded approximately $2.2 million and $1.3 million of realized gains from the sale of equity in BARRX Medical, Inc. and Aegerion Pharmaceuticals, Inc., respectively. These gains were partially offset by realized losses of approximately $460,000 from the sale of the Company’s common stock in two public portfolio companies and due to the complete write off of warrants in one private portfolio company that had a cost basis of approximately $355,000.

Loan origination and commitment fees received in full at the inception of a loan are deferred and amortized into fee income as an enhancement to the related loan’s yield over the contractual life of the loan. Loan exit fees to be paid at the termination of the loan are accreted into interest income over the contractual life of the loan. The Company had approximately $2.6 million and $2.0 million of unamortized fees at March 31, 2013 and December 31, 2012, respectively, and approximately $8.6 million and $6.8 million in exit fees receivable at March 31, 2013 and December 31, 2012, respectively.

The Company has loans in its portfolio that contain a payment-in-kind (“PIK”) provision. The PIK interest, computed at the contractual rate specified in each loan agreement, is added to the principal balance of the loan and recorded as interest income. To maintain the Company’s status as a RIC, this non-cash source of income must be paid out to stockholders in the form of dividends even though the Company has not yet collected the cash. Amounts necessary to pay these dividends may come from available cash or the liquidation of certain investments. The Company recorded approximately $779,000 and $298,000 in PIK income during the three-months ended March 31, 2013 and 2012, respectively.

In certain investment transactions, the Company may provide advisory services. For services that are separately identifiable and external evidence exists to substantiate fair value, income is recognized as earned, which is generally when the investment transaction closes. The Company had no income from advisory services in the three-month period ended March 31, 2013.

In some cases, the Company collateralizes its investments by obtaining a first priority security interest in a portfolio company’s assets, which may include their intellectual property. In other cases, the Company may obtain a negative pledge covering a company’s intellectual property. At March 31, 2013, approximately 63.9% of the Company’s portfolio company loans were secured by a first priority security in all of the assets of the portfolio company (including their intellectual property), 34.6% of portfolio company loans were to portfolio companies that were prohibited from pledging or encumbering their intellectual property and 1.5% of portfolio company loans had an equipment only lien.

3. Fair Value of Financial Instruments

Fair value estimates are made at discrete points in time based on relevant information. These estimates may be subjective in nature and involve uncertainties and matters of significant judgment and, therefore, cannot be determined with precision. The Company believes that the carrying amounts of its financial instruments, consisting of cash and cash equivalents, receivables, accounts payable and accrued liabilities approximate the fair values of such items due to the short maturity of such instruments. The Convertible Senior Notes, 2019 Notes payable (the “April 2019 Notes” and the “September 2019 Notes”, together the “2019 Notes”), the Asset-Backed Notes and the SBA debentures as sources of liquidity remain a strategic advantage due to their flexible structure, long-term duration, and low fixed interest rates. At March 31, 2013, the April 2019 Notes were trading on the New York Stock Exchange for $1.023 per dollar at par value, and the September 2019 Notes were trading on the New York Stock Exchange for $1.036 per dollar at par value. Based on market quotations on or around March 31, 2013, the Convertible Senior Notes were trading for $1.095 per dollar at par value and the Asset-Backed Notes were trading for $1.005 per dollar at par value. Calculated based on the net present value of payments over the term of the notes using estimated market rates for similar notes and remaining terms, the fair value of the SBA debentures would be approximately $240.0 million, compared to the carrying amount of $225.0 million as of March 31, 2013.

See the accompanying Consolidated Schedule of Investments for the fair value of the Company’s investments. The methodology for the determination of the fair value of the Company’s investments is discussed in Note 1.

The liabilities of the Company below are recorded at amortized cost and not at fair value on the Consolidated Statement of Assets and Liabilities. The following table provides additional information about the level in the fair value hierarchy of the Company’s liabilities:


(in thousands) Description	3/31/2013		Identical Assets (Level 1)		Observable Inputs (Level 2)		Unobservable Inputs (Level 3)
Convertible Senior Notes	$	82,125	$	—	$	82,125	$	—
April 2019 Notes	$	86,450	$	—	$	86,450	$	—
September 2019 Notes	$	88,967	$	—	$	88,967	$	—
Class A Notes	$	120,652	$	—	$	—	$	120,652
SBA Debentures	$	240,019	$	—	$	—	$	240,019

4. Borrowings Long-term

SBA Debentures

On September 27, 2006, HT II received a license to operate as a SBIC under the SBIC program and is able to borrow funds from the SBA against eligible investments and additional contributions to regulatory capital. With the Company’s net investment of $38.0 million in HT II as of March 31, 2013, HT II has the capacity to issue a total of $76.0 million of SBA guaranteed debentures, subject to SBA approval, of which $76.0 million was outstanding as of March 31, 2013. As of March 31, 2013, HT II has paid commitment fees of approximately $1.5 million. As of March 31, 2013, the Company held investments in HT II in 49 companies with a fair value of approximately $128.3 million, accounting for approximately 13.3% of the Company’s total portfolio.

On May 26, 2010, HT III received a license to operate as a SBIC under the SBIC program and is able to borrow funds from the SBA against eligible investments and additional contributions to regulatory capital. With the Company’s net investment of $74.5 million in HT III as of March 31, 2013, HT III has the capacity to issue a total of $149.0 million of SBA guaranteed debentures, subject to SBA approval, of which $149.0 million was outstanding as of March 31, 2013. As of March 31, 2013, HT III has paid commitment fees of approximately $1.5 million. As of March 31, 2013, the Company held investments in HT III in 37 companies with a fair value of approximately $222.9 million, accounting for approximately 23.0% of the Company’s total portfolio.

A smaller concern is one that has a tangible net worth not exceeding $6.0 million and has average annual fully taxed net income not exceeding $2.0 million for the two most recent fiscal years. SBA regulations also provide alternative size standard criteria to determine eligibility, which depend on the industry in which the business is engaged and are based on such factors as the number of employees and gross sales. According to SBA regulations, SBICs may make long-term loans to small businesses, invest in the equity securities of such businesses and provide them with consulting and advisory services. Through its wholly-owned subsidiaries HT II and HT III, the Company plans to provide long-term loans to qualifying small businesses, and in connection therewith, make equity investments.

HT II and HT III are periodically examined and audited by the SBA’s staff to determine their compliance with SBA regulations. If HT II or HT III fails to comply with applicable SBA regulations, the SBA could, depending on the severity of the violation, limit or prohibit HT II’s or HT III’s use of debentures, declare outstanding debentures immediately due and payable, and/or limit HT II or HT III from making new investments. In addition, HT II or HT III may also be limited in their ability to make distributions to the Company if they do not have sufficient capital in accordance with SBA regulations. Such actions by the SBA would, in turn, negatively affect the Company because HT II and III are the Company’s wholly owned subsidiaries. HT II and HT III were in compliance with the terms of the SBIC’s leverage as of March 31, 2013 as a result of having sufficient capital as defined under the SBA regulations.

The rates of borrowings under various draws from the SBA beginning in April 2007 are set semiannually in March and September and range from 2.25% to 5.73%. Interest payments on SBA debentures are payable semiannually. There are no principal payments required on these issues prior to maturity and no prepayment penalties. Debentures under the SBA generally mature ten years after being borrowed. Based on the initial draw down date of April 2007, the initial maturity of SBA debentures will occur in April 2017. In addition, the SBA charges a fee that is set annually, depending on the Federal fiscal year the leverage commitment was delegated by the SBA, regardless of the date that the leverage was drawn by the SBIC. The annual fees related to HT II debentures that pooled on September 22, 2010 were 0.406% and 0.285%, depending upon the year in which the underlying commitment was closed. The annual fees related to HT III debentures that pooled on March 27, 2013, were 0.804%. The annual fees on other debentures have been set at 0.906%. The average amount of debentures outstanding for the three-month period ended March 31, 2013 for HT II was approximately $76.0 million with an average interest rate of approximately 5.30%. The average amount of debentures outstanding for the three-month period ended March 31, 2013 for HT III was approximately $149.0 million with an average interest rate of approximately 3.26%.

HT II and HT III hold approximately $152.7 million and $257.5 million in assets, respectively, and accounted for approximately 9.8% and 16.5% of the Company’s total assets prior to consolidation at March 31, 2013.

In January 2011, the Company repaid $25.0 million of SBA debentures under HT II, priced at approximately 6.63%, including annual fees. In April 2011, the SBA approved a $25.0 million dollar commitment for HT III.

In February 2012, the Company repaid $24.25 million of SBA debentures under HT II, priced at 6.63%, including annual fees. In June 2012, the SBA approved a $24.25 million dollar commitment for HT III.

In August 2012, the Company repaid $24.75 million of SBA debentures under HT II, $12.0 million priced at 6.43%, including annual fees and $12.75 million priced at 6.38%, including annual fees.

As of March 31, 2013, the maximum statutory limit on the dollar amount of outstanding SBA guaranteed debentures issued by a single SBIC is $150.0 million, subject to periodic adjustments by the SBA, and a maximum amount of $225.0 million for funds under common control, subject to periodic adjustments by the SBA. In the aggregate, at March 31, 2013 there was $225.0 million principal amount of indebtedness outstanding incurred by our SBIC subsidiaries, the maximum statutory limit on the dollar amount of SBA guaranteed debentures under the SBIC program.

The Company reported the following SBA debentures outstanding on its Consolidated Statement of Assets and Liabilities as of March 31, 2013 (unaudited) and December 31, 2012:


(in thousands) Issuance/Pooling Date	Maturity Date	Interest Rate⁽¹⁾			March 31, 2013		December 31, 2012
SBA Debentures:
March 26, 2008	March 1, 2018		6.38	%	$	34,800	$	34,800
March 25, 2009	March 1, 2019		5.53	%		18,400		18,400
September 23, 2009	September 1, 2019		4.64	%		3,400		3,400
September 22, 2010	September 1, 2020		3.62	%		6,500		6,500
September 22, 2010	September 1, 2020		3.50	%		22,900		22,900
March 29, 2011	March 1, 2021		4.37	%		28,750		28,750
September 21, 2011	September 1, 2021		3.16	%		25,000		25,000
March 21, 2012	March 1, 2022		3.05	%		11,250		11,250
March 21, 2012	March 1, 2022		3.28	%		25,000		25,000
September 19, 2012	September 1, 2022		3.05	%		24,250		24,250
March 27, 2013	March 1, 2023		3.16	%		24,750		24,750

Total SBA Debentures					$	225,000	$	225,000

⁽¹⁾	Interest rate includes annual charge

Wells Facility

In August 2008, the Company entered into a $50.0 million two-year revolving senior secured credit facility with Wells Fargo Capital Finance (the “Wells Facility”). On June 20, 2011, the Company renewed the Wells Facility. Under this three-year senior secured facility, Wells Fargo Capital Finance has made commitments of $75.0 million. The facility contains an accordion feature, in which the Company can increase the credit line up to an aggregate of $300.0 million, funded by additional lenders and with the agreement of Wells Fargo Capital Finance and subject to other customary conditions. The Company expects to continue discussions with various other potential lenders to join the new facility; however, there can be no assurances that additional lenders will join the Wells Facility.

On August 1, 2012, the Company entered into an amendment to the Wells Facility. The amendment reduces the interest rate floor by 75 basis points to 4.25% and extends the maturity date by one year to August 2015. Additionally, an amortization period of 12 months was added to pay down the principal balance as of the maturity date, and the unused line fee was reduced.

Borrowings under the Wells Facility will generally bear interest at a rate per annum equal to LIBOR plus 3.50%, with a floor of 4.25% and an advance rate of 50% against eligible loans. The Wells Facility is secured by loans in the borrowing base. The Wells Facility requires payment of a non-use fee on a scale of 0.0% to 0.50% of the average monthly outstanding balance. The monthly payment of a non-use fee thereafter shall depend on the average balance that was outstanding on a scale between 0.0% and 0.50%. For the three-month period ended March 31, 2013, this non-use fee was approximately $94,000. On June 20, 2011 the Company paid an additional $1.1 million in structuring fees in connection with the Wells Facility which is being amortized through the end of the term. At March 31, 2013, there were no borrowings outstanding on this facility.

The Wells Facility includes various financial and operating covenants applicable to the Company and our subsidiaries, in addition to those applicable to Hercules Funding II, LLC. These covenants require the Company to maintain certain financial ratios and a minimum tangible net worth in an amount, when added to outstanding subordinated indebtedness, that is in excess of $362.0 million plus 90% of the cumulative amount of equity raised after June 30, 2012. In addition, the tangible net worth covenant will increase by 90 cents on the dollar for every dollar of equity capital that the Company subsequently raises. As of March 31, 2013, the minimum tangible net worth covenant has increased to $478.5 million as a result of the October 2012 follow-on public offering of 3.1 million shares of common stock for proceeds of approximately $33.6 million and the March 2013 follow-on public offering of 8.1 million shares of common stock for proceeds of approximately $95.8 million. The Wells Facility provides for customary events of default, including, but not limited to, payment defaults, breach of representations or covenants, bankruptcy events and change of control. The Company was in compliance with all covenants at March 31, 2013.

Union Bank Facility

On February 10, 2010, the Company entered a $20.0 million one-year revolving senior secured credit facility with Union Bank (the “Union Bank Facility”). On November 2, 2011, the Company renewed and amended the Union Bank Facility and added a new lender under the Union Bank Facility. Union Bank and RBC Capital Markets (“RBC”) have made commitments of $30.0 million and $25.0 million, respectively. The Union Bank Facility contains an accordion feature, in which the Company can increase the credit line up to an aggregate of $150.0 million, funded by additional lenders and with the agreement of Union Bank and subject to other customary conditions. The Company expects to continue discussions with various other potential lenders to join the new facility; however, there can be no assurances that additional lenders will join the Union Bank Facility.

On March 30, 2012, the Company entered into an amendment to the Union Bank Facility which permitted the Company to issue additional senior notes relating to the offer and sale of our 2019 Notes. On September 17, 2012, the Company entered into an amendment to the Union Bank Facility. Pursuant to the terms of the amendment, the Company is permitted to increase its unsecured indebtedness by an aggregate original principal amount not to exceed $200.0 million incurred after March 30, 2012 in one or more issuances, provided certain conditions are satisfied for each issuance.

On December 17, 2012, the Company further amended the Union Bank Facility to remove RBC from the Union Bank Facility. Following the removal of RBC, the Union Bank Facility consists solely of Union Bank’s commitment of $30.0 million. In connection with the amendment, the maximum availability under the Union Bank Facility, subject to a borrowing base, was reduced from $55.0 million to $30.0 million. The Union Bank Facility contains an accordion feature, in which the Company could increase the credit line by up to $95.0 million in the aggregate, funded by commitments from additional lenders and with the agreement of Union Bank and subject to other customary conditions. There can be no assurances that additional lenders will join the Union Bank Facility.

Borrowings under the Union Bank Facility will generally bear interest at a rate per annum equal to LIBOR plus 2.25% with a floor of 4.0%. The Union Bank Facility requires the payment of a non-use fee of 0.50% annually. For the three-month period ended March 31, 2013, this non-use fee was approximately $37,500. The Union Bank Facility is collateralized by debt investments in our portfolio companies, and includes an advance rate equal to 50.0% of eligible loans placed in the collateral pool. The Union Bank Facility generally requires payment of interest on a monthly basis. All outstanding principal is due upon maturity. At March 31, 2013, there were no borrowings outstanding on this facility.

The Union Bank Facility requires various financial and operating covenants. These covenants require the Company to maintain certain financial ratios and a minimum tangible net worth in an amount, when added to outstanding subordinated indebtedness, that is in excess of $314.0 million plus 90% of the amount of net cash proceeds received from the sale of common stock after March 31, 2011. As of March 31, 2013, the minimum tangible net worth covenant has increased to $472.8 million as a result of the January and October 2012 follow-on public offerings of 5.0 and 3.1 million shares of common stock, respectively, for total net proceeds of approximately $80.9 million and the March 2013 follow-on public offering of 8.1 million shares of common stock for total net proceeds of approximately $95.6 million. The Union Bank Facility will mature on November 1, 2014, approximately three years from the date of issuance, revolving through the first 24 months with a term out provision for the remaining 12 months. Union Bank Facility also provides for customary events of default, including, but not limited to, payment defaults, breach of representations or covenants, bankruptcy events and change of control. The Company was in compliance with all covenants at March 31, 2013.

Citibank Credit Facility

The Company, through Hercules Funding Trust I, an affiliated statutory trust, had a securitized credit facility (the “Citibank Credit Facility”) with Citigroup Global Markets Realty Corp. which expired under normal terms. During the first quarter of 2009, the Company paid off all principal and interest owed under the Citibank Credit Facility. Citigroup has an equity participation right through a warrant participation agreement on the pool of loans and warrants collateralized under the Citibank Credit Facility. Pursuant to the warrant participation agreement, the Company granted to Citigroup a 10% participation in all warrants held as collateral. However, no additional warrants were included in collateral subsequent to the facility amendment on May 2, 2007. As a result, Citigroup is entitled to 10% of the realized gains on the warrants until the realized gains paid to Citigroup pursuant to the agreement equal $3,750,000 (the “Maximum Participation Limit”). The obligations under the warrant participation agreement continue even after the Citibank Credit Facility is terminated until the Maximum Participation Limit has been reached.

During the three-months ended March 31, 2013, the Company reduced its realized gain by approximately $207,000 for Citigroup’s participation in the gain on sale of equity securities which were obtained from exercising a portfolio company warrant which was included in the collateral pool. The Company recorded a decrease on participation liability and an increase on unrealized appreciation by a net amount of approximately $181,000 as a result of current quarter depreciation of fair value on the pool of warrants collateralized under the warrant participation agreement. The value of their participation right on unrealized gains in the related equity investments was approximately $132,000 as of March 31, 2013 and is included in accrued liabilities. There can be no assurances that the unrealized appreciation of the warrants will not be higher or lower in future periods due to fluctuations in the value of the warrants, thereby increasing or reducing the effect on the cost of borrowing. Since inception of the agreement, the Company has paid Citigroup approximately $1.6 million under the warrant participation agreement thereby reducing realized gains by this amount. The Company will continue to pay Citigroup under the warrant participation agreement until the Maximum Participation Limit is reached or the warrants expire. Warrants subject to the Citigroup participation agreement are set to expire between April 2013 and January 2017.

Convertible Senior Notes

In April 2011, the Company issued $75.0 million in aggregate principal amount of its 6.00% convertible senior notes (the “Convertible Senior Notes”) due 2016.

The Convertible Senior Notes mature on April 15, 2016 (the “Maturity Date”), unless previously converted or repurchased in accordance with their terms. The Convertible Senior Notes bear interest at a rate of 6.00% per year payable semiannually in arrears on April 15 and October 15 of each year, commencing on October 15, 2011. The Convertible Senior Notes are the Company’s senior unsecured obligations and rank senior in right of payment to the Company’s existing and future indebtedness that is expressly subordinated in right of payment to the Convertible Senior Notes; equal in right of payment to the Company’s existing and future unsecured indebtedness that is not so subordinated; effectively junior in right of payment to any of the Company’s secured indebtedness (including unsecured indebtedness that the Company later secures) to the extent of the value of the assets securing such indebtedness; and structurally junior to all existing and future indebtedness (including trade payables) incurred by the Company’s subsidiaries, financing vehicles or similar facilities.

Prior to the close of business on the business day immediately preceding October 15, 2015, holders may convert their Convertible Senior Notes only under certain circumstances set forth in the Indenture. On or after October 15, 2015 until the close of business on the scheduled trading day immediately preceding the Maturity Date, holders may convert their Convertible Senior Notes at any time. Upon conversion, the Company will pay or deliver, as the case may be, at its election, cash, shares of its common stock or a combination of cash and shares of its common stock. The conversion rate will initially be 84.0972 shares of common stock per $1,000 principal amount of Convertible Senior Notes (equivalent to an initial conversion price of approximately $11.89 per share of common stock). The conversion rate will be subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest. In addition, if certain corporate events occur prior to the Maturity Date, the conversion rate will be increased for converting holders.

The Company may not redeem the Convertible Senior Notes prior to maturity. No sinking fund is provided for the Convertible Senior Notes. In addition, if certain corporate events occur, holders of the Convertible Senior Notes may require the Company to repurchase for cash all or part of their Convertible Senior Notes at a repurchase price equal to 100% of the principal amount of the Convertible Senior Notes to be repurchased, plus accrued and unpaid interest through, but excluding, the required repurchase date.

The Convertible Senior Notes are accounted for in accordance with ASC 470-20 (previously FASB Staff Position No. APB 14- 1, “Accounting for Convertible Debt Instruments That May Be Settled in Cash upon Conversion (Including Partial Cash Settlement)”). In accounting for the Convertible Senior Notes, the Company estimated at the time of issuance that the values of the debt and the embedded conversion feature of the Convertible Senior Notes were approximately 92.8% and 7.2%, respectively. The original issue discount of 7.2% attributable to the conversion feature of the Convertible Senior Notes was recorded in “capital in excess of par value” in the accompanying consolidated statement of assets and liabilities. As a result, the Company records interest expense comprised of both stated interest expense as well as accretion of the original issue discount. Additionally, the issuance costs associated with the Convertible Senior Notes were allocated to the debt and equity components in proportion to the allocation of the proceeds and accounted for as debt issuance costs and equity issuance costs, respectively. At the time of issuance, the debt issuance costs and equity issuance costs were approximately $2.9 million and $224,000, respectively. At the time of issuance and as of March 31, 2013, the equity component, net of issuance costs, as recorded in the “capital in excess of par value” in the balance sheet was approximately $5.2 million.

As of March 31, 2013 (unaudited) and December 31, 2012, the components of the carrying value of the Convertible Senior Notes were as follows:


(in thousands)	As of March 31, 2013			As of December 31, 2013
Principal amount of debt	$	75,000		$	75,000
Original issue discount, net of accretion		(3,294	)		(3,564	)

Carrying value of debt	$	71,706		$	71,436

For the three months ended March 31, 2013 and 2012, the components of interest expense, fees and cash paid for interest expense for the Convertible Senior Notes were as follows (unaudited):


	Three Months Ended March 31,
(in thousands)	2013		2012
Stated interest expense	$	1,125	$	1,125
Accretion of original issue discount		271		271
Amortization of debt issuance cost		144		144

Total interest expense	$	1,540	$	1,540

Cash paid for interest expense	$	—	$	—

The estimated effective interest rate of the debt component of the Convertible Senior Notes, equal to the stated interest of 6.0% plus the accretion of the original issue discount, was approximately 8.2% for the three months ended March 31, 2013. As of March 31, 2013, the Company is in compliance with the terms of the indentures governing the Convertible Senior Notes.

2019 Notes

On March 6, 2012, the Company and the Trustee entered into an indenture (the “Base Indenture”). On April 17, 2012, the Company and the Trustee entered into the First Supplemental Indenture to the Base Indenture, dated April 17, 2012, relating to the Company’s issuance, offer and sale of $43.0 million aggregate principal amount of 7.00% senior notes due 2019 (the “April 2019 Notes”). The sale of the April 2019 Notes generated net proceeds, before expenses, of approximately $41.7 million.

On September 24, 2012, the Company and the Trustee, entered into the Second Supplemental Indenture to the Base Indenture, dated as of September 24, 2012, relating to the Company’s issuance, offer and sale of $75.0 million aggregate principal amount of 7.00% senior notes due 2019 (the “September 2019 Notes”). The sale of the September 2019 Notes generated net proceeds, before expenses, of approximately $72.75 million.

2019 Notes payable is compromised of:


	As of
(in thousands)	March 31, 2013 (unaudited)		December 31, 2012
April 2019 Notes	$	84,490	$	84,490
September 2019 Notes		85,875		85,875

Carrying Value of Debt	$	170,365	$	170,365

April 2019 Notes

The April 2019 Notes will mature on April 30, 2019 and may be redeemed in whole or in part at the Company’s option at any time or from time to time on or after April 30, 2015, upon not less than 30 days nor more than 60 days written notice by mail prior to the date fixed for redemption thereof, at a redemption price of 100% of the outstanding principal amount thereof plus accrued and unpaid interest payments otherwise payable for the then-current quarterly interest period accrued to but not including the date fixed for redemption. The April 2019 Notes bear interest at a rate of 7.00% per year payable quarterly on January 30, April 30, July 30 and October 30 of each year, commencing on July 30, 2012, and trade on the New York Stock Exchange under the trading symbol “HTGZ.”

The April 2019 Notes are the Company’s direct unsecured obligations and rank: (i) pari passu with our other outstanding and future senior unsecured indebtedness, including without limitation, the $75 million in aggregate principal amount of the Convertible Senior Notes; (ii) senior to any of the Company’s future indebtedness that expressly provides it is subordinated to the April 2019 Notes; (iii) effectively subordinated to all the Company’s existing and future secured indebtedness (including indebtedness that is initially unsecured to which the Company subsequently grants security), to the extent of the value of the assets securing such indebtedness, including without limitation, borrowings under the Company’s credit facilities; (iv) structurally subordinated to all existing and future indebtedness and other obligations of any of the Company’s subsidiaries, including without limitation, the indebtedness of Hercules Technology II, L.P. and Hercules Technology III, L.P. and borrowings under the Company’s revolving senior secured credit facility with Wells Fargo Capital Finance.

The Base Indenture, as supplemented by the First Supplemental Indenture, contains certain covenants including covenants requiring the Company to comply with (regardless of whether it is subject to) the asset coverage requirements set forth in Section 18(a)(1)(A) as modified by Section 61(a)(1) of the 1940 Act to comply with the restrictions on dividends, distributions and purchase of capital stock set forth in Section 18(a)(1)(B) as modified by Section 61(a)(1) of the 1940 Act and to provide financial information to the holders of the April 2019 Notes and the Trustee if the Company should no longer be subject to the reporting requirements under the Securities Exchange Act of 1934. These covenants are subject to important limitations and exceptions that are described in the Indenture, as supplemented by the First Supplemental Indenture. The Indenture provides for customary events of default and further provides that the Trustee or the holders of 25% in aggregate principal amount of the outstanding April 2019 Notes in a series may declare such April 2019 Notes immediately due and payable upon the occurrence of any event of default after expiration of any applicable grace period.

The April 2019 Notes were sold pursuant to an underwriting agreement dated April 11, 2012 among the Company and Stifel, Nicolaus & Company, Incorporated, as representative of the several underwriters named in the underwriting agreement.

In July 2012, the Company re-opened our April 2019 Notes and issued an additional amount of approximately $41.5 million in aggregate principal amount of April 2019 Notes, which includes exercise of an over-allotment option, bringing the total amount of the April 2019 Notes issued to approximately $84.5 million in aggregate principal amount.

September 2019 Notes

The September 2019 Notes will mature on September 30, 2019 and may be redeemed in whole or in part at the Company’s option at any time or from time to time on or after September 30, 2015, upon not less than 30 days nor more than 60 days written notice by mail prior to the date fixed for redemption thereof, at a redemption price of 100% of the outstanding principal amount thereof plus accrued and unpaid interest payments otherwise payable for the then-current quarterly interest period accrued to but not including the date fixed for redemption. The September 2019 Notes bear interest at a rate of 7.00% per year payable quarterly on March 30, June 30, September 30 and December 30 of each year, commencing on December 30, 2012, and trade on the New York Stock Exchange under the trading symbol “HTGY.”

The September 2019 Notes are the Company’s direct unsecured obligations and rank: (i) pari passu with our other outstanding and future senior unsecured indebtedness, including without limitation, the $75 million in aggregate principal amount of the Convertible Senior Notes; (ii) senior to any of the Company’s future indebtedness that expressly provides it is subordinated to the September 2019 Notes; (iii) effectively subordinated to all the Company’s existing and future secured indebtedness (including indebtedness that is initially unsecured to which the Company subsequently grant security), to the extent of the value of the assets securing such indebtedness, including without limitation, borrowings under the Company’s credit facilities; (iv) structurally subordinated to all existing and future indebtedness and other obligations of any of our subsidiaries, including without limitation, the indebtedness of Hercules Technology II, L.P. and Hercules Technology III, L.P. and borrowings under the Company’s revolving senior secured credit facility with Wells Fargo Capital Finance.

The Base Indenture, as supplemented by the Second Supplemental Indenture, contains certain covenants including covenants requiring the Company to comply with (regardless of whether it is subject to) the asset coverage requirements set forth in Section 18(a) (1)(A) as modified by Section 61(a)(1) of the 1940 Act to comply with the restrictions on dividends, distributions and purchase of capital stock set forth in Section 18(a)(1)(B) as modified by Section 61(a)(1) of the 1940 Act and to provide financial information to the holders of the September 2019 Notes and the Trustee if the Company should no longer be subject to the reporting requirements under the Securities Exchange Act of 1934. These covenants are subject to important limitations and exceptions that are described in the Indenture, as supplemented by the Second Supplemental Indenture. The Indenture provides for customary events of default and further provides that the Trustee or the holders of 25% in aggregate principal amount of the outstanding September 2019 Notes in a series may declare such September 2019 Notes immediately due and payable upon the occurrence of any event of default after expiration of any applicable grace period.

The September 2019 Notes were sold pursuant to an underwriting agreement dated September 19, 2012 among the Company and Stifel, Nicolaus & Company, Incorporated, as representative of the several underwriters named in the underwriting agreement.

In October 2012, the underwriters exercised their over-allotment option for an additional $10.9 million of the September 2019 Notes, bringing the total amount of the September 2019 Notes issued to approximately $85.9 million in aggregate principal amount.

For the years ended March 31, 2013 and 2012, the components of interest expense and related fees and cash paid for interest expense and fees for the April 2019 and September 2019 Notes are as follows (unaudited):


	Three Months Ended March 31,
(in thousands)	2013		2012
Stated interest expense	$	2,981	$	—
Amortization of debt issuance cost		240		—

Total interest expense and fees	$	3,222	$	—

Cash paid for interest expense and fees	$	2,998	$	—

As of March 31, 2013, the Company is in compliance with the terms of the indenture governing the 2019 Notes.

Asset-Backed Notes

On December 19, 2012, the Company completed a $230.7 million term debt securitization in connection with which an affiliate of the Company made an offer of $129.3 million in aggregate principal amount of fixed-rate asset-backed notes (the “Asset-Backed Notes”), which Asset-Backed Notes were rated A2(sf) by Moody’s Investors Service, Inc. The Asset-Backed Notes were issued by Hercules Capital Funding Trust 2012-1 pursuant to a note purchase agreement, dated as of December 12, 2012, by and among the Company, Hercules Capital Funding 2012-1 LLC, as Trust Depositor (the “Trust Depositor”), Hercules Capital Funding Trust 2012-1, as Issuer (the “Issuer”), and Guggenheim Securities, LLC, as Initial Purchaser, and are backed by a pool of senior loans made to certain of our portfolio companies and secured by certain assets of those portfolio companies and are to be serviced by the Company. Interest on the Asset-Backed Notes will be paid, to the extent of funds available, at a fixed rate of 3.32% per annum. The Asset-Backed Notes have a stated maturity of December 16, 2017.

As part of this transaction, the Company entered into a sale and contribution agreement with the Trust Depositor under which the Company has agreed to sell or have contributed to the Trust Depositor certain senior loans made to certain of our portfolio companies (the “Loans”). The Company has made customary representations, warranties and covenants in the sale and contribution agreement with respect to the Loans as of the date of their transfer to the Trust Depositor.

In connection with the issuance and sale of the Asset-Backed Notes, the Company has made customary representations, warranties and covenants in the note purchase agreement. The Asset-Backed Notes are secured obligations of the Issuer and are non-recourse to the Company. The Issuer also entered into an indenture governing the Asset-Backed Notes, which indenture includes customary representations, warranties and covenants. The Asset-Backed Notes were sold without being registered under the Securities Act of 1933, as amended (the “Securities Act”), to “qualified institutional buyers” in compliance with the exemption from registration provided by Rule 144A under the Securities Act and to institutional “accredited investors” (as defined in Rule 501(a)(1), (2), (3) or (7) under the Securities Act) who in each case, are “qualified purchasers” for purposes of Section 3(c)(7) under the 1940 Act. In addition, the Trust Depositor entered into an amended and restated trust agreement, which includes customary representation, warranties and covenants.

The Loans are serviced by the Company pursuant to a sale and servicing agreement, which contains customary representations, warranties and covenants. The Company performs certain servicing and administrative functions with respect to the Loans. The Company is entitled to receive a monthly fee from the Issuer for servicing the Loans. This servicing fee is equal to the product of one-twelfth (or in the case of the first payment date, a fraction equal to the number of days from and including December 5, 2012 through and including January 15, 2013 over 360) of 2.00% and the aggregate outstanding principal balance of the Loans, excluding all defaulted Loans and all purchased Loans, as of the first day of the related collection period (the period from the 5th day of the immediately preceding calendar month through the 4th day of the calendar month in which a payment date occurs, and for the first payment date, the period from and including December 5, 2012, to the close of business on January 4, 2013).

The Company also serves as administrator to the Issuer under an administration agreement, which includes customary representations, warranties and covenants.

At March 31, 2013 (unaudited) and December 31, 2012, the Asset-Backed Notes had an outstanding balance of $120.1 million and $129.3 million, respectively.

Under the terms of the Asset Backed Notes, the Company is required to maintain a reserve cash balance, funded through interest and principal collections from the underlying securitized debt portfolio, which may be used to pay monthly interest and principal payments on the Asset-Backed Notes. The Company has segregated these funds and classified them as Restricted Cash. There was approximately $810,000 of Restricted Cash as of March 31, 2013 funded through interest collections. There was no cash segregated at December 31, 2012 due to immaterial monthly interest collections for the period ended December 31, 2012.

Outstanding Borrowings

At March 31, 2013 (unaudited) and December 31, 2012, the Company had the following borrowing capacity and outstanding borrowings:


	March 31, 2013				December 31, 2012
(in thousands)	Total Available		Carrying Value⁽¹⁾		Total Available		Carrying Value⁽¹⁾
Union Bank Facility	$	30,000	$	—	$	30,000	$	—
Wells Facility		75,000		—		75,000		—
Convertible Senior Notes⁽²⁾		75,000		71,707		75,000		71,436
2019 Notes		170,364		170,364		170,364		170,364
Asset-Backed Notes	$	120,051		120,051		129,300		129,300
SBA Debentures⁽³⁾		225,000		225,000		225,000		225,000

Total	$	695,415	$	587,122	$	704,664	$	596,100

⁽¹⁾	Except for the Convertible Senior Notes (as defined below), all carrying values are the same as the principal amount outstanding.

⁽²⁾

Represents the aggregate principal amount outstanding of the Convertible Senior Notes (as defined below) less the unaccreted discount initially recorded upon issuance of the Convertible Senior Notes. The total unaccreted discount for the Convertible Senior Notes was $3.3 million at March 31, 2013 and $3.6 million at December 31, 2012.

⁽³⁾	At March 31, 2013 and at December 31, 2012, the total available borrowings under the SBA was $225.0 million, of which 76.0 million was available in HT II and $149.0 million was available in HT III.

5. Income taxes

The Company has elected to be taxed as a RIC under Subchapter M of the Code and intends to continue to operate so as to qualify to be taxed as a RIC under Subchapter M of the Code and, as such, will not be subject to federal income tax on the portion of taxable income and gains distributed to stockholders.

To qualify as a RIC, the Company is required to meet certain income and asset diversification tests in addition to distributing at least 90% of its investment company taxable income, as defined by the Code. The amount to be paid out as a dividend is determined by the Board of Directors each quarter and is based upon the annual earnings estimated by the management of the Company. To the extent that the Company’s earnings fall below the amount of dividends declared, however, a portion of the total amount of the Company’s dividends for the fiscal year may be deemed a return of capital for tax purposes to the Company’s stockholders.

Taxable income includes the Company’s taxable interest, dividend and fee income, as well as taxable net capital gains. Taxable income generally differs from net income for financial reporting purposes due to temporary and permanent differences in the recognition of income and expenses, and generally excludes net unrealized appreciation or depreciation, as gains or losses are not included in taxable income until they are realized.

Taxable income includes non-cash income, such as changes in accrued and reinvested interest and dividends, which includes contractual payment-in-kind interest, and the amortization of discounts and fees. Cash collections of income resulting from contractual PIK interest or the amortization of discounts and fees generally occur upon the repayment of the loans or debt securities that include such items. Non-cash taxable income is reduced by non-cash expenses, such as realized losses and depreciation and amortization expense.

During the three-months ended March 31, 2013, the Company declared a distribution of $0.25 per share. The determination of the tax attributes of the Company’s distributions is made annually as of the end of the Company’s fiscal year based upon its taxable income for the full year and distributions paid for the full year. As a result, a determination made on a quarterly basis may not be representative of the actual tax attributes of the Company’s distributions for a full year. If the Company had determined the tax attributes of our distributions year-to-date as of March 31, 2013, approximately 100.0% would be from ordinary income and spillover earnings from 2012. However there can be no certainty to shareholders that this determination is representative of what the tax attributes of its 2013 distributions to shareholders will actually be.

As a RIC, the Company will be subject to a 4% nondeductible federal excise tax on certain undistributed income unless the Company distributes in a timely manner an amount at least equal to the sum of (1) 98% of its ordinary income for each calendar year, (2) 98.2% of its capital gain net income for the 1-year period ending October 31 in that calendar year and (3) any income realized, but not distributed, in the preceding year (the “Excise Tax Avoidance Requirements”). The Company will not be subject to excise taxes on amounts on which the Company is required to pay corporate income tax (such as retained net capital gains). Depending on the level of taxable income earned in a tax year, the Company may choose to carry over taxable income in excess of current year distributions from such taxable income into the next tax year and pay a 4% excise tax on such income, as required. The maximum amount of excess taxable income that may be carried over for distribution in the next year under the Code is the total amount of dividends paid in the following year, subject to certain declaration and payment guidelines. To the extent the Company chooses to carry over taxable income into the next tax year, dividends declared and paid by the Company in a year may differ from taxable income for that year as such dividends may include the distribution of current year taxable income, the distribution of prior year taxable income carried over into and distributed in the current year, or returns of capital.

Taxable income for the three-month period ended March 31, 2013 was approximately $14.7 million or $0.27 per share. Taxable net realized gains for the same period were $1.1 million or approximately $0.02 per share. Taxable income for the three-month period ended March 31, 2012 was approximately $10.7 million or $0.23 per share. Taxable net realized gains for the same period were $3.2 million or approximately $0.07 per share.

The Company intends to distribute approximately $1.5 million of spillover earnings from the year ended December 31, 2012 to our shareholders in 2013.

6. Shareholders’ Equity

On July 25, 2012, our Board of Directors approved an extension of the stock repurchase plan under the same terms and conditions that allowed the Company to repurchase up to $35.0 million of our common stock. The stock repurchase plan expired on February 26, 2013 and no shares were repurchased in 2013.

On March 13, 2013, the Company raised approximately $95.8 million, before deducting offering expenses, in a public offering of 8,050,000 shares of its common stock.

The Company has issued stock options for common stock subject to future issuance, of which 2,516,880 and 2,574,749 were outstanding at March 31, 2013 and December 31, 2012, respectively.

7. Equity Incentive Plan

The Company and its stockholders have authorized and adopted the 2004 Equity Incentive Plan (the “2004 Plan”) for purposes of attracting and retaining the services of its executive officers and key employees. Under the 2004 Plan, the Company is authorized to issue 7,000,000 shares of common stock. On June 1, 2011, stockholders approved an amended and restated plan and provided an increase of 1,000,000 shares, authorizing the Company to issue 8,000,000 shares of common stock under the 2004 Plan.

The Company and its stockholders have authorized and adopted the 2006 Non-Employee Director Plan (the “2006 Plan” and, together with the 2004 Plan, the “Plans”) for purposes of attracting and retaining the services of its Board of Directors. Under the 2006 Plan, the Company is authorized to issue 1,000,000 shares of common stock. Unless terminated earlier by the Company’s Board of Directors, the 2006 Plan will terminate on July 21, 2017 and no additional awards may be made under the 2006 Plan after that date. The Company filed an exemptive relief request with the Securities and Exchange Commission (“SEC”) to allow options to be issued under the 2006 Plan which was approved on October 10, 2007.

On June 21, 2007, the stockholders approved amendments to the 2004 Plan and the 2006 Plan allowing for the grant of restricted stock. The amended Plans limit the combined maximum amount of restricted stock that may be issued under both Plans to 10% of the outstanding shares of the Company’s stock on the effective date of the Plans plus 10% of the number of shares of stock issued or delivered by the Company during the terms of the Plans. The amendments further specify that no one person shall be granted awards of restricted stock relating to more than 25% of the shares available for issuance under the 2004 Plan. Further, the amount of voting securities that would result from the exercise of all of the Company’s outstanding warrants, options and rights, together with any restricted stock issued pursuant to the Plans, at the time of issuance shall not exceed 25% of its outstanding voting securities, except that if the amount of voting securities that would result from such exercise of all of the Company’s outstanding warrants, options and rights issued to the Company’s directors, officers and employees, together with any restricted stock issued pursuant to the Plans, would exceed 15% of the Company’s outstanding voting securities, then the total amount of voting securities that would result from the exercise of all outstanding warrants, options and rights, together with any restricted stock issued pursuant to the Plans, at the time of issuance shall not exceed 20% of our outstanding voting securities.

In conjunction with the amendment and in accordance with the exemptive order, on June 21, 2007 the Company made an automatic grant of shares of restricted common stock to Messrs. Badavas, Chow and Woodward, the independent members of its Board of Directors, in the amounts of 1,667, 1,667 and 3,334 shares, respectively. In May 2008, the Company issued restricted shares to Messrs. Badavas and Chow in the amount of 5,000 shares each. In June 2009, the Company issued 5,000 restricted stock shares to Mr. Woodward. The shares were issued pursuant to the 2006 Plan and vested 33% on an annual basis from the date of grant. Deferred compensation cost was recognized ratably over the three year vesting period.

The following table summarizes the common stock options activities for the three-months ended March 31, 2013 and 2012 (unaudited):


	For the Three Month Period Ended March 31,
	2013					2012
	Common Stock Options			Weighted Average Exercise Price		Common Stock Options			Weighted Average Exercise Price
Outstanding at December 31		2,574,749		$	12.00		4,213,604		$	11.40
Granted		27,000		$	12.16		18,000		$	11.01
Exercised		(80,256	)	$	11.31		(424,667	)	$	4.94
Cancelled / Forfeited		(4,613	)	$	9.65		(257,174	)	$	11.96

Outstanding at March 31		2,516,880		$	12.03		3,549,763		$	12.14

Shares Expected to Vest at March 31		408,065		$	12.03		484,462		$	12.14

Options generally vest 33% one year after the date of grant and ratably over the succeeding 24 months. All options may be exercised for a period ending seven years after the date of grant. At March 31, 2013, options for approximately 2.1 million shares were exercisable at a weighted average exercise price of approximately $12.31 per share with weighted average of remaining contractual term of 1.80 years.

The fair value of options granted is based upon a Black Scholes option pricing model using the assumptions in the following table for each of the three-month periods ended March 31, 2013 and 2012:


	For Three Months Ended March 31,
	2013	2012
Expected Volatility	46.90%	46.70%
Expected Dividends	10%	10%
Expected term (in years)	4.5	4.5
Risk-free rate	0.65% - 0.80%	0.61% - 1.07%

The following table summarizes stock options outstanding and exercisable at March 31, 2013 (unaudited):


(Dollars in thousands, except exercise price)	Options outstanding								Options exercisable
Range of exercise prices	Number of shares		Weighted average remaining contractual life		Aggregate intrinsic value		Weighted average exercise price		Number of shares		Weighted average remaining contractual life		Aggregate intrinsic value		Weighted average exercise price
$4.21 - $8.49		46,248		4.01	$	307,634	$	5.60		46,248		4.01	$	307,634	$	5.60
$8.67 - $13.40		1,806,632		3.11		1,465,249	$	11.46		1,398,567		2.21		771,543	$	11.72
$13.87 - $14.02		664,000		0.78		—	$	14.02		664,000		0.78		—	$	14.02

$4.21 - $14.02		2,516,880		2.51	$	1,772,883	$	12.03		2,108,815		1.80	$	1,079,177	$	12.31

During the three months ended March 31, 2013 and 2012, the Company granted approximately 606,001 shares and 672,000 shares, respectively, of restricted stock pursuant to the Plans. All restricted stock grants under the 2004 Plan made prior to March 4, 2013 will continue to vest on a monthly basis following their one year anniversary over the succeeding 36 months. During 2012, the Compensation Committee adopted a policy that provided for awards with different vesting schedules for short and long-term awards. Under the 2004 Plan, restricted stock awarded subsequent to March 3, 2013 will vest subject to continued employment based on two vesting schedules: short-term awards vest one-half on the one year anniversary of the date of the grant and quarterly over the succeeding 12 months, and long-term awards vest one-fourth on the one year anniversary of the date of grant and quarterly over the succeeding 36 months.

The Company determined that the fair value of restricted stock granted under the 2006 and 2004 Plans during the three-month periods ended March 31, 2013 and 2012 was approximately $7.7 million and $7.3 million, respectively. During the three-month periods ended March 31, 2013 and 2012, the Company expensed approximately $1.1 million and $722,000 of compensation expense related to restricted stock, respectively. As of March 31, 2013, there was approximately $14.8 million of total unrecognized compensation costs related to restricted stock. These costs are expected to be recognized over a weighted average period of 2.81 years.

The following table summarizes the activities for our unvested restricted stock for the three-months ended March 31, 2013 and 2012 (unaudited):


	For the Three Month Period Ended March 31,
	2013					2012
	Restricted Stock Units			Weighted Average Exercise Price		Restricted Stock Units			Weighted Average Exercise Price
Unvested at December 31		899,789		$	10.73		621,509		$	10.06
Granted		606,001		$	12.72		671,859		$	10.82
Vested		(201,263	)	$	10.39		(143,627	)	$	10.56
Forfeited		(6,076	)	$	10.54		—		$	—
Unvested at March 31		1,298,451		$	11.71		1,149,741		$	10.44

The SEC, through an exemptive order granted on June 22, 2010, approved amendments to the Plans which allow participants to elect to have the Company withhold shares of the Company’s common stock to pay for the exercise price and applicable taxes with respect to an option exercise (“net issuance exercise”). The exemptive order also permits the holders of restricted stock to elect to have the Company withhold shares of Hercules stock to pay the applicable taxes due on restricted stock at the time of vesting. Each individual can make, and does not preclude the participant from electing to make, a cash payment at the time of option exercise or to pay taxes on restricted stock.

8. Earnings Per Share

Shares used in the computation of the Company’s basic and diluted earnings per share are as follows (unaudited):


	Three Months Ended March 31,
(in thousands, except per share data)	2013			2012
Numerator
Net increase in net assets resulting from operations	$	16,689		$	17,105
Less: Dividends declared-common and restricted shares		(13,382	)		(11,412	)

Undistributed earnings		3,307			5,693

Undistributed earnings-common shares		3,307			5,693
Add: Dividend declared-common shares		13,051			11,136

Numerator for basic and diluted change in net assets per common share	$	16,358		$	16,829

Denominator

Basic weighted average common shares outstanding		53,682			47,018

Common shares issuable (including adjustment for dilutive effect of Convertible Senior Notes)		141			192

Weighted average common shares outstanding assuming dilution		53,823			47,210
Change in net assets per common share
Basic	$	0.30		$	0.36
Diluted	$	0.30		$	0.36

The Convertible Senior Notes may be surrendered for conversion during the five business day period after any five consecutive trading day period (the “measurement period”) in which the trading price per $1,000 principal amount of notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of our common stock and the conversion rate on each such trading day. For the purpose of calculating diluted earnings per share for the three-month period ended March 31, 2013, the underlying shares for the intrinsic value of the embedded options in the Convertible Senior Notes were included in this calculation because the trading price ($11.89) was less than the conversion price in effect for such period for the Convertible Senior Notes.

The calculation of change in net assets resulting from operations per common share—assuming dilution, excludes all anti-dilutive shares. For the three-months ended March 31, 2013 and 2012, the number of anti-dilutive shares, as calculated based on the weighted average closing price of the Company’s common stock for the periods, was approximately 2,630,003 and 2,616,129 shares, respectively.

9. Financial Highlights

Following is a schedule of financial highlights for the three-months ended March 31, 2013 and 2012:

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

FINANCIAL HIGHLIGHTS

(unaudited)

(dollars in thousands, except per share amounts)


	Three Months Ended March 31,
	2013			2012
Per share data:
Net asset value at beginning of period	$	9.75		$	9.83
Net investment income⁽¹⁾		0.28			0.24
Net realized gain (loss) on investments		0.03			0.06
Net unrealized appreciation (depreciation) on investments		(0.01	)		0.06

Total from investment operations		0.30			0.36
Net increase/(decrease) in net assets from capital share transactions		0.18			(0.21	)
Distributions		(0.25	)		(0.24	)
Stock-based compensation expense included in investment income⁽²⁾		0.02			0.02

Net asset value at end of period	$	10.00		$	9.76


Ratios and supplemental data:
Per share market value at end of period	$	12.25		$	11.08
Total return⁽³⁾		14.59	%		19.89	%
Shares outstanding at end of period		61,554			49,721
Weighted average number of common shares outstanding		53,682			47,018
Net assets at end of period	$	615,608		$	485,447
Ratio of operating expense to average net assets		12.23	%		9.41	%
Ratio of net investment income before provision for income tax expense and investment gains and losses to average net assets		11.54	%		9.73	%
Average debt outstanding	$	593,940		$	292,832
Weighted average debt per common share	$	11.06		$	6.23

(1)	Net investment income per share is calculated as net investment income divided by the weighted average shares outstanding.

(2)	Stock option expense is a non-cash expense that has no effect on net asset value. Pursuant to ASC 718, net investment loss includes the expense associated with the granting of stock options which is offset by a corresponding increase in paid-in capital.

(3)	The total return for the three-month periods ended March 31, 2013 and 2012 equals the change in the ending market value over the beginning of period price per share plus dividends paid per share during the period, divided by the beginning price.

10. Commitments and Contingencies

The Company’s commitments and contingencies consist primarily of unused commitments to extend credit, in the form of loans to the Company’s portfolio companies. The balance of unfunded commitments to extend credit at March 31, 2013 totaled approximately $137.1 million. Approximately $83.6 million of these unfunded origination activity commitments as of March 31, 2013 are dependent upon the portfolio company reaching certain milestones before the debt commitment becomes available. Since a portion of these commitments may expire without being drawn, unfunded commitments do not necessarily represent future cash requirements. In addition, the Company had approximately $93.0 million of non-binding term sheets outstanding at March 31, 2013. Non-binding outstanding term sheets are subject to completion of the Company’s due diligence and final approval process, as well as the negotiation of definitive documentation with the prospective portfolio companies. Not all non-binding term sheets are expected to close and do not necessarily represent future cash requirements.

Certain premises are leased under agreements which expire at various dates through March 2020. Total rent expense amounted to approximately $329,000 and $285,000 during the three-month periods ended March 31, 2013 and 2012, respectively.

Future commitments under the credit facility and operating leases were as follows at March 31, 2013:


	Payments due by period
	(in thousands)
Contractual Obligations⁽¹⁾⁽²⁾	Total		Less than 1 year		1 - 3 years		3 - 5 years		After 5 years
Borrowings⁽³⁾⁽⁴⁾	$	587,123	$	—	$	120,051	$	71,707	$	395,365
Operating Lease Obligations⁽⁵⁾		8,555		1,334		2,901		3,063		1,257

Total	$	595,678	$	1,334	$	122,952	$	74,770	$	396,622

⁽¹⁾	Excludes commitments to extend credit to our portfolio companies.

⁽²⁾	The Company also has a warrant participation agreement with Citigroup. See Note 4.

⁽³⁾	Includes $225.0 million in borrowings under the SBA debentures, $170.4 million of the 2019 Notes, $120.1 million in aggregate principal amount of the Asset-Backed Notes and $71.7 million of the Convertible Senior Notes.

⁽⁴⁾

Except for the Convertible Senior Notes, all carrying values are the same as the principal amount outstanding. The aggregate principal amount outstanding of the Convertible Senior Notes less the unaccreted discount initially recorded upon issuance of the Convertible Senior Notes was $3.3 million at March 31, 2013.

⁽⁵⁾	Long-term facility leases.

The Company may, from time to time, be involved in litigation arising out of its operations in the normal course of business or otherwise. Furthermore, third parties may try to seek to impose liability on the Company in connection with the activities of its portfolio companies. While the outcome of any current legal proceedings cannot at this time be predicted with certainty, the Company does not expect any current matters will materially affect the Company’s financial condition or results of operations; however, there can be no assurance whether any pending legal proceedings will have a material adverse effect on the Company’s financial condition or results of operations in any future reporting period.

11. Subsequent Events

Dividend Declaration

On April 29, 2013 the Board of Directors increased the quarterly dividend by $0.02, or approximately 8.0%, and declared a cash dividend of $0.27 per share to be paid on May 21, 2013 to shareholders of record as of May 14, 2013. This dividend will represent the Company’s thirty-first consecutive dividend declaration since its initial public offering, bringing the total cumulative dividend declared to date to $8.16 per share.

Company Developments

In April 2013, Kroll Bond Rating Agency (“KBRA”) assigned the Company an investment grade corporate rating of BBB+. In addition, the Company’s two outstanding bond issuances of 7.00% Senior Notes due 2019, which trade on the NYSE under the symbols “HTGZ” and “HTGY,” were assigned a rating of BBB+.

Portfolio Company Developments

In April 2013, Japanese company Ajinomoto Co., Inc. (TYO: 2802) completed its acquisition of the Company’s portfolio company Althea Technologies.

In April 2013, Omthera Pharmaceuticals, Inc., (“OMTH”) completed its initial public offering of 8,000,000 shares of its common stock at $8.00 per share.

In April 2013, Portola Pharmaceuticals, Inc. filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to a proposed initial public offering of its common stock. The number of shares to be offered and the price range for the offering have not yet been determined.

ITEM 2.

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Forward-Looking Statements

The matters discussed in this report, as well as in future oral and written statements by management of Hercules Technology Growth Capital, that are forward-looking statements are based on current management expectations that involve substantial risks and uncertainties which could cause actual results to differ materially from the results expressed in, or implied by, these forward-looking statements. Forward-looking statements relate to future events or our future financial performance. We generally identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other similar words. Important assumptions include our ability to originate new investments, achieve certain margins and levels of profitability, the availability of additional capital, and the ability to maintain certain debt to asset ratios. In light of these and other uncertainties, the inclusion of a projection or forward-looking statement in this report should not be regarded as a representation by us that our plans or objectives will be achieved. The forward-looking statements contained in this report include statements as to:

•

our future operating results;

•

our business prospects and the prospects of our prospective portfolio companies;

•

the impact of investments that we expect to make;

•

the impact of a protracted decline in the liquidity of credit markets on our business;

•

our informal relationships with third parties including in the venture capital industry;

•

the expected market for venture capital investments and our addressable market;

•

the dependence of our future success on the general economy and its impact on the industries in which we invest;

•

our ability to access debt markets and equity markets;

•

the ability of our portfolio companies to achieve their objectives;

•

our expected financings and investments;

•

our regulatory structure and tax status;

•

our ability to operate as a BDC, a SBIC and a RIC;

•

the adequacy of our cash resources and working capital;

•

the timing of cash flows, if any, from the operations of our portfolio companies;

•

the timing, form and amount of any dividend distributions;

•

the impact of fluctuations in interest rates on our business;

•

the valuation of any investments in portfolio companies, particularly those having no liquid trading market; and

•

our ability to recover unrealized losses.

For a discussion of factors that could cause our actual results to differ from forward-looking statements contained in this report, please see the discussion under Item 1A—“Risk Factors” of Part II of this quarterly report on Form 10-Q as well as Item 1A—“Risk Factors” of our annual report on Form 10-K. You should not place undue reliance on these forward-looking statements. The forward-looking statements made in this report relate only to events as of the date on which the statements are made. We undertake no obligation to update any forward-looking statement to reflect events or circumstances occurring after the date of this report.

The following discussion should be read in conjunction with our consolidated financial statements and related notes and other financial information appearing elsewhere in this report. In addition to historical information, the following discussion and other parts of this report contain forward-looking information that involves risks and uncertainties. Our actual results could differ materially from those anticipated by such forward-looking information due to the factors discussed under Item 1A—“Risk Factors” of Part II of this quarterly report on Form 10-Q, Item 1A—“Risk Factors” of our annual report on Form 10-K, and “Forward-Looking Statements” of this Item 2.

Overview

We are a specialty finance company focused on providing senior secured loans to venture capital-backed companies in technology-related markets, including technology, biotechnology, life science, and clean-technology industries at all stages of development. We source our investments through our principal office located in Silicon Valley, as well as through our additional offices in Boston, MA, New York, NY, Chicago, IL, Boulder, CO and McLean, VA.

Our goal is to be the leading structured debt financing provider of choice for venture capital-backed companies in technology-related markets requiring sophisticated and customized financing solutions. Our strategy is to evaluate and invest in a broad range of technology-related markets including technology, biotechnology, life science, and clean-technology industries and to offer a full suite of growth capital products up and down the capital structure. We invest primarily in structured debt with warrants and, to a lesser extent, in senior debt and equity investments. We invest primarily in private companies and to a lesser extent public companies. We use the term “structured debt with warrants” to refer to any debt investment, such as a senior or subordinated secured loan, that is coupled with an equity component, including warrants, options or rights to purchase common or preferred stock. Our structured debt with warrants investments will typically be secured by some or all of the assets of the portfolio company.

Our investment objective is to maximize our portfolio total return by generating current income from our debt investments and capital appreciation from our equity-related investments. Our primary business objectives are to increase our net income, net operating income and net asset value by investing in structured debt with warrants and equity of venture capital-backed companies in technology-related markets with attractive current yields and the potential for equity appreciation and realized gains. Our structured debt investments typically include warrants or other equity interests, giving us the potential to realize equity-like returns on a portion of our investments. Our equity ownership in our portfolio companies may represent a controlling interest. In some cases, we receive the right to make additional equity investments in our portfolio companies in connection with future equity financing rounds. Capital that we provide directly to venture capital-backed companies in technology-related markets is generally used for growth and general working capital purposes as well as in select cases for acquisitions or recapitalizations.

We also make investments in qualifying small businesses through two wholly-owned SBICs, HT II and HT III. HT II and HT III hold approximately $152.7 million and $257.5 million in assets, respectively, and accounted for approximately 9.8% and 16.5% of our total assets prior to consolidation at March 31, 2013. We have issued $225.0 million in SBA-guaranteed debentures in our SBIC subsidiaries, which is the maximum amount allowed for a group of SBICs under common control.

We are an internally managed, non-diversified closed-end investment company that has elected to be regulated as a business development company under the 1940 Act. As a business development company, we are required to comply with certain regulatory requirements. For instance, we generally have to invest at least 70% of our total assets in “qualifying assets,” including securities of private U.S. companies, cash, cash equivalents, and high-quality debt investments that mature in one year or less.

From incorporation through December 31, 2005, we were taxed as a corporation under Subchapter C of the Internal Revenue Code, or the Code. As of January 1, 2006, we have elected to be treated for federal income tax purposes as a regulated investment company, or a RIC, under Subchapter M of the Code. Pursuant to this election, we generally will not have to pay corporate-level taxes on any income that we distribute to our stockholders. However, such an election and qualification to be treated as a RIC requires that we comply with certain requirements contained in Subchapter M of the Code. For example, a RIC must meet certain requirements, including source-of income, asset diversification and income distribution requirements. The income source requirement mandates that we receive 90% or more of our income from qualified earnings, typically referred to as “good income.”

Our portfolio is comprised of, and we anticipate that our portfolio will continue to be comprised of, investments primarily in technology-related companies at various stages of their development. Consistent with regulatory requirements, we invest primarily in United States based companies and to a lesser extent in foreign companies.

We regularly engage in discussions with third parties with respect to various potential transactions. We may acquire an investment or a portfolio of investments or an entire company or sell a portion of our portfolio on an opportunistic basis. We or our subsidiaries may also agree to manage certain other funds that invest in debt, equity or provide other financing or services to companies in a variety of industries for which we may earn management or other fees for our services. We may also invest in the equity of these funds, along with other third parties, from which we would seek to earn a return and/or future incentive allocations. Some of these transactions could be material to our business. Consummation of any such transaction will be subject to completion of due diligence, finalization of key business and financial terms (including price) and negotiation of final definitive documentation as well as a number of other factors and conditions including, without limitation, the approval of our board of directors and required regulatory or third party consents and, in certain cases, the approval of our stockholders. Accordingly, there can be no assurance that any such transaction would be consummated. Any of these transactions or funds may require significant management resources either during the transaction phase or on an ongoing basis depending on the terms of the transaction.

Portfolio and Investment Activity

The total value of our investment portfolio was $968.0 million at March 31, 2013 as compared to $906.3 million at December 31, 2012.

The fair value of the loan portfolio at March 31, 2013 was approximately $881.0 million, compared to a fair value of approximately $827.5 million at December 31, 2012. The fair value of the equity portfolio at March 31, 2013 was approximately $53.7 million, compared to a fair value of approximately $49.2 million at December 31, 2012. The fair value of the warrant portfolio at March 31, 2013 was approximately $33.3 million, compared to a fair value of approximately $29.5 million at December 31, 2012.

Portfolio Activity

Our investments in portfolio companies take a variety of forms, including unfunded contractual commitments and funded investments. From time to time, unfunded contractual commitments are dependent upon a portfolio company reaching certain milestones before the debt commitment is available to the portfolio company. These commitments will be subject to the same underwriting and ongoing portfolio maintenance as the on-balance sheet financial instruments that we hold. Debt commitments generally fund over the two succeeding quarters from close. Not all debt investments represent our future cash requirements. Similarly, unfunded contractual commitments may expire without being drawn and do not represent our future cash requirements.

Prior to entering into a contractual commitment, we generally issue a non-binding term sheet to a prospective portfolio company. Non-binding terms sheets are subject to completion of our due diligence and final approval process, as well as the negotiation of definitive documentation with the prospective portfolio companies. Not all non-binding term sheets are expected to close and do not necessarily represent our future cash requirements.

Our portfolio activity for the three-month periods ended March 31, 2013 (unaudited) and December 31, 2012 was comprised of the following:


(in millions)	March 31, 2013		December 31, 2012
Debt Commitments ⁽¹⁾
New portfolio company	$	162.5	$	362.3
Existing portfolio company		58.5		274.3

Total	$	221.0	$	636.6
Funded Debt Investments
New portfolio company	$	46.3	$	267.9
Existing portfolio company		90.0		191.4

Total	$	136.3	$	459.3
Funded Equity Investments
New portfolio company	$	—	$	6.0
Existing portfolio company		2.0		3.7

Total	$	2.0	$	9.7
Unfunded Contractual Commitments ⁽²⁾
Total	$	137.1	$	61.9
Non-Binding Term Sheets
New portfolio company	$	89.0	$	70.0
Existing portfolio company		4.0		—

Total	$	93.0	$	70.0

(1)	Includes restructured loans and renewals.

(2)

Includes unfunded contractual commitments in 28 new and existing portfolio companies. Approximately $83.6 million of these unfunded origination activity commitments as of March 31, 2013 are dependent upon the portfolio company reaching certain milestones before the debt commitment becomes available.

We receive payments in our loan portfolio based on scheduled amortization of the outstanding balances. In addition, we receive repayments of some of our loans prior to their scheduled maturity date. The frequency or volume of these repayments may fluctuate significantly from period to period. During the three-month period ended March 31, 2013, we received approximately $76.0 million in principal repayments, including approximately $35.0 million of principal repayments related to a renewal of an existing debt investment, $9.1 million of early principal repayments and approximately $31.9 million in scheduled principal payments.

Total portfolio investment activity (inclusive of unearned income) for the three-month period ended March 31, 2013 (unaudited) and for the year ended December 31, 2012 was as follows:


(in millions)	March 31, 2013			December 31, 2012
Beginning Portfolio	$	906.3		$	652.9
New Fundings		138.3			469.9
Warrants not related to current period fudings		0.7			(0.2	)
Principal payments received on investments		(76.0	)		(120.7	)
Early payoffs		—			(125.1	)
Restructure payoffs		(9.7	)		(48.5	)
Restructure fundings		9.7			85.0
Accretion of loan discounts and paid-in-kind principal		5.6			21.3
New loan fees		(2.2	)		(12.8	)
Conversion of “Other Assets”		—			9.6
Debt Converted to Equity		—			0.6
Proceeds from sale of investments		(1.4	)		(7.2	)
Net realized (loss) gain on investments		(1.6	)		(14.1	)
Net change in unrealized appreciation (depreciation)		(1.7	)		(4.4	)

Ending Portfolio	$	968.0		$	906.3

The following table shows the fair value of our portfolio of investments by asset class as of March 31, 2013 (unaudited) and December 31, 2012.


	March 31, 2013					December 31, 2012
(in thousands)	Investments at Fair Value		Percentage of Total Portfolio			Investments at Fair Value		Percentage of Total Portfolio
Senior secured debt with warrants	$	700,498		72.4	%	$	652,041		72.0	%
Senior secured debt		213,762		22.1	%		205,049		22.6	%
Preferred stock		39,504		4.1	%		33,885		3.7	%
Common Stock		14,220		1.4	%		15,325		1.7	%

	$	967,984		100.0	%	$	906,300		100.0	%

A summary of our investment portfolio at value by geographic location is as follows:


	March 31, 2013					December 31, 2012
(in thousands)	Investments at Fair Value		Percentage of Total Portfolio			Investments at Fair Value		Percentage of Total Portfolio
United States	$	963,809		99.6	%	$	901,041		99.4	%
England		4,175		0.4	%		5,259		0.6	%

	$	967,984		100.0	%	$	906,300		100.0	%

As of March 31, 2013, we held warrants or equity positions in five companies which have filed registration statements on Form S-1 with the SEC in contemplation of potential initial public offerings, ADMA Biologics, Inc., iWatt, Inc., Omthera Pharmaceuticals, Inc., Paratek Pharmaceuticals, Inc. and one company filed a Form S-1 Registration confidentially under the JOBS Act. There can be no assurance that these companies will complete their initial public offerings in a timely manner or at all.

Changes in Portfolio

We generate revenue in the form of interest income, primarily from our investments in debt securities, and commitment and facility fees. Fees generated in connection with our debt investments are recognized over the life of the loan or, in some cases, recognized as earned. In addition, we generate revenue in the form of capital gains, if any, on warrants or other equity-related securities that we acquire from our portfolio companies. Our investments generally range from $1.0 million to $25.0 million. Our debt investments have a term of between two and seven years and typically bear interest at a rate ranging from Prime to approximately 14.0% as of March 31, 2013. In addition to the cash yields received on our loans, in some instances, our loans may also include any of the following: end-of-term payments, exit fees, balloon payment fees, commitment fees, success fees, PIK provisions or prepayment fees which may be required to be included in income prior to receipt. Loan origination and commitment fees received in full at the inception of a loan are deferred and amortized into fee income as an enhancement to the related loan’s yield over the contractual life of the loan. We recognize nonrecurring fees amortized over the remaining term of the loan commencing in the quarter relating to specific loan modifications. Loan exit fees to be paid at the termination of the loan are accreted into interest income over the contractual life of the loan. We had approximately $2.6 million and $2.0 million of unamortized fees at March 31, 2013 and December 31, 2012, respectively, and approximately $8.6 million and $6.8 million in exit fees receivable at March 31, 2013 and December 31, 2012, respectively.

We have loans in our portfolio that contain a PIK provision. The PIK interest, computed at the contractual rate specified in each loan agreement, is added to the principal balance of the loan and recorded as interest income. To maintain our status as a RIC, this non-cash source of income must be paid out to stockholders in the form of dividends even though we have not yet collected the cash. Amounts necessary to pay these dividends may come from available cash or the liquidation of certain investments. We recorded approximately $779,000 and $298,000 in PIK income in the three-month periods ended March 31, 2013 and 2012.

In some cases, we may collateralize our investments by obtaining a first priority security interest in a portfolio company’s assets, which may include their intellectual property. In other cases, we may obtain a negative pledge covering a company’s intellectual property.

At March 31, 2013, approximately 63.9% of our portfolio company loans were secured by a first priority security in all of the assets of the portfolio company, 34.6% of the loans were to portfolio companies that were prohibited from pledging or encumbering their intellectual property and 1.5% of portfolio company loans had an equipment only lien.

Interest on debt securities is generally payable monthly, with amortization of principal typically occurring over the term of the security for emerging-growth, expansion-stage and established-stage companies. In addition, certain loans may include an interest-only period ranging from three to eighteen months for emerging-growth and expansion-stage companies and longer for established-stage companies. In limited instances in which we choose to defer amortization of the loan for a period of time from the date of the initial investment, the principal amount of the debt securities and any accrued but unpaid interest become due at the maturity date.

The effective yield on our debt investments during the three-month periods ended March 31, 2013 and 2012 was 14.3% and 14.6%. Excluding the effect of fee accelerations that occurred from early payoffs and one-time events, the adjusted effective yield for the three-month period ended March 31, 2013 was 13.8%. The adjusted effective yield for the three-month period ended December 31, 2012 was 13.6%. The effective yield is derived by dividing total investment income by the weighted average earning investment portfolio assets outstanding during the quarter which exclude non-interest earning assets such as warrants and equity investments. The overall weighted average yield to maturity of our loan investments was approximately 13.01% at March 31, 2013, a slight increase compared to 12.91% at December 31, 2012. The weighted average yield to maturity is computed using the interest rates in effect at the inception of each of the loans, and includes amortization of the loan facility fees, commitment fees and market premiums or discounts over the expected life of the debt investments, weighted by their respective costs when averaged and based on the assumption that all contractual loan commitments have been fully funded and held to maturity.

Portfolio Composition

Our portfolio companies are primarily privately held companies and, to a lesser extent, public companies which are active in the drug discovery and development, internet consumer and business services, clean technology, software, drug delivery, medical device and equipment, media/content/info, communications and networking, information services, healthcare services, diagnostic, specialty pharmaceuticals, biotechnology tools, surgical devices, consumer and business products, semiconductors, electronics and computer hardware and therapeutic industry sectors. These sectors are characterized by high margins, high growth rates, consolidation and product and market extension opportunities. Value is often vested in intangible assets and intellectual property.

As of March 31, 2013, approximately 59.4% of the fair value of our portfolio was composed of investments in four industries: 20.3% was composed of investments in the drug discovery and development industry, 14.7% was composed of investments in the internet consumer and business services industry, 14.1% was composed of investments in the clean technology industry and 10.3% was composed of investments in the medical device and equipment industry.

The following table shows the fair value of our portfolio by industry sector at March 31, 2013 (unaudited) and December 31, 2012:


	March 31, 2013					December 31, 2012
(in thousands)	Investments at Fair Value		Percentage of Total Portfolio			Investments at Fair Value		Percentage of Total Portfolio
Drug Discovery & Development	$	196,506		20.3	%	$	188,479		20.8	%
Internet Consumer & Business Services		142,362		14.7	%		136,149		15.0	%
Clean Tech		137,054		14.1	%		126,600		14.0	%
Medical Device & Equipment		99,896		10.3	%		54,575		6.0	%
Software		75,383		7.8	%		70,838		7.8	%
Drug Delivery		65,660		6.8	%		74,218		8.2	%
Information Services		52,342		5.4	%		53,523		5.9	%
Media/Content/Info		52,215		5.4	%		51,534		5.7	%
Healthcare Services, Other		31,416		3.2	%		36,481		4.0	%
Communications & Networking		30,681		3.2	%		37,560		4.1	%
Electronics & Computer Hardware		23,569		2.4	%		12,715		1.4	%
Diagnostic		15,196		1.6	%		16,307		1.8	%
Specialty Pharma		14,289		1.5	%		12,473		1.4	%
Surgical Devices		11,527		1.2	%		11,358		1.3	%
Consumer & Business Products		10,430		1.1	%		13,723		1.5	%
Biotechnology Tools		6,596		0.7	%		6,845		0.8	%
Semiconductors		2,862		0.3	%		2,922		0.3	%

	$	967,984		100.0	%	$	906,300		100.0	%

Industry and sector concentrations vary as new loans are recorded and loans pay off. Loan revenue, consisting of interest, fees, and recognition of gains on equity interests, can fluctuate dramatically when a loan is paid off or a related warrant or equity interest is sold. Revenue recognition in any given year can be highly concentrated among several portfolio companies.

For the three-months ended March 31, 2013 and the year ended December 31 2012, our ten largest portfolio companies represented approximately 33.1% and 35.2% of the total fair value of our investments in portfolio companies, respectively. At March 31, 2013 and December 31, 2012, we had four and eight investments, respectively, that represented 5% or more of our net assets. At March 31, 2013, we had five equity investments representing approximately 60.0% of the total fair value of our equity investments, and each represented 5% or more of the total fair value of our equity investments. At December 31, 2012, we had six equity investments which represented approximately 70.9% of the total fair value of our equity investments, and each represented 5% or more of the total fair value of such investments.

As of March 31, 2013, over 98.5% of our debt investments were in a senior secured first lien position, and more than 98.8% of the debt investment portfolio was priced at floating interest rates or floating interest rates with a Prime or LIBOR based interest rate floor. As a result, we believe we are well positioned to benefit should market rates increase. Our investments in senior secured debt with warrants have equity enhancement features, typically in the form of warrants or other equity-related securities designed to provide us with an opportunity for capital appreciation. Our warrant coverage generally ranges from 3% to 20% of the principal amount invested in a portfolio company, with a strike price equal to the most recent equity financing round. As of March 31, 2013, we held warrants in 117 portfolio companies, with a fair value of approximately $33.3 million. The fair value of the warrant portfolio has increased by approximately 12.9% as compared to the fair value of $29.5 million at December 31, 2012. These warrant holdings would require us to invest approximately $72.7 million to exercise such warrants. Warrants may appreciate or depreciate in value depending largely upon the underlying portfolio company’s performance and overall market conditions. Of the warrants which have monetized since inception, we have realized warrant gain multiples in the range of approximately 1.04x to 10.20x based on the historical rate of return on our investments. However, these warrants may not appreciate in value and, in fact, may decline in value. Accordingly, we may not be able to realize gains from our warrant interests.

As required by the 1940 Act, we classify our investments by level of control. “Control investments” are defined in the 1940 Act as investments in those companies that we are deemed to “control”. Generally, under the 1940 Act, we are deemed to “control” a company in which we have invested if we own 25% or more of the voting securities of such company or have greater than 50% representation on its board. “Affiliate investments” are investments in those companies that are “affiliated companies” of ours, as defined in the 1940 Act, which are not control investments. We are deemed to be an “affiliate” of a company in which we have invested if we own 5% or more but less than 25% of the voting securities of such company. “Non-control/non-affiliate investments” are investments that are neither control investments nor affiliate investments.


(in thousands)	March 31, 2013
Portfolio Company	Type	Fair Value at March 31, 2013		Investment Income		Unrealized (Depreciation)/ Appreciation		Reversal of Unrealized (Depreciation)/ Appreciation		Realized Gain/ (Loss)
Gelesis, Inc.	Non-Controlled Affiliate		1,888		—		222		—		—
Optiscan BioMedical, Corp.	Non-Controlled Affiliate		12,308		610		212		—		—

Total		$	14,196	$	610	$	434	$	—	$	—


(in thousands)	March 31, 2012
Portfolio Company	Type	Fair Value at March 31, 2012		Investment Income		Unrealized (Depreciation)/ Appreciation		Reversal of Unrealized (Depreciation)/ Appreciation		Realized Gain/ (Loss)
MaxVision Holding, LLC.	Control	$	675	$	13	$	26	$	—	$	—
E-Band Communications, Corp.	Non-Controlled Affiliate		1,094		6		1,076		—		—

Total		$	1,769	$	19	$	1,102	$	—	$	—

At March 31, 2013, we did not hold any Control Investments. The Company’s investment in MaxVision Holding, L.L.C., a company that was a Control Investment as of March 31, 2012, was liquidated during the year ended December 31, 2012. On July 31, 2012, we received payment of $2.0 million for its total debt investments in Maxvision Holding, L.L.C. Approximately $8.7 million of realized losses and $10.5 million of net change in unrealized appreciation was recognized on this control debt and equity investment during the year ended December 31, 2012.

During the year ended December 31, 2012, Gelesis, Inc. and Optiscan BioMedical, Corp. became non-controlled affiliates because we own 5% or more but less than 25% of the voting securities of the company.

We have one additional non-controlled affiliate investment, E-band Communications, Corp, that has a fair value of zero at March 31, 2013, and no investment income, unrealized depreciation, realized depreciation or realized loss for the three-month period ended March 31, 2013.

Portfolio Grading

We use an investment grading system, which grades each debt investment on a scale of 1 to 5, to characterize and monitor our expected level of risk on the debt investments in our portfolio with 1 being the highest quality. The following table shows the distribution of our outstanding debt investments on the 1 to 5 investment grading scale at fair value as of March 31, 2013 (unaudited) and December 31, 2012, respectively:


	March 31, 2013							December 31, 2012
(in thousands)	Number of Companies		Investments at Fair Value		Percentage of Total Portfolio			Number of Companies		Investments at Fair Value		Percentage of Total Portfolio
Investment Grading
1		16	$	154,766		17.6	%		9	$	134,166		16.2	%
2		50		580,767		65.9	%		52		542,885		65.6	%
3		19		134,650		15.3	%		16		127,560		15.4	%
4		3		5,278		0.6	%		5		22,929		2.8	%
5		3		5,550		0.6	%		1		—		—

			$	881,011		100.0	%			$	827,540		100.0	%

As of March 31, 2013, our investments had a weighted average investment grading of 2.03 as compared to 2.06 at December 31, 2012. Our policy is to lower the grading on our portfolio companies as they approach the point in time when they will require additional equity capital. Additionally, we may downgrade our portfolio companies if they are not meeting our financing criteria and their respective business plans. Various companies in our portfolio will require additional funding in the near term or have not met their business plans and have therefore been downgraded until their funding is complete or their operations improve.

At March 31, 2013, we had two loans on non-accrual, one with a fair value of approximately $5.6 million and the other with no fair market value compared to one loan on non-accrual at December 31, 2012 with no fair market value.

Results of Operations

Comparison of the three-month period ended March 31, 2013 and 2012

Investment Income

Total investment income for the three-month period ended March 31, 2013 was approximately $31.0 million compared to $22.4 million in the first quarter of 2012.

Interest income for the three-month periods ended March 31, 2013 and 2012, totaled approximately $29.0 million compared to $20.3 million, respectively. The increase in interest income is attributable to an increase of loan interest income of approximately $7.0 million, back-end interest income of approximately $846,000, PIK interest income of approximately $481,000 and default interest income of approximately $461,000 for the three-month period ended March 31, 2013. The increase in interest income is attributable to growth in the overall loan portfolio.

Income from commitment, facility and loan related fees for the three-month periods ended March 31, 2013 and 2012, totaled approximately $2.0 million compared to $2.1 million, respectively. The decrease in fee income is attributable to fewer accelerations of fee income in the three-month period ended March 31, 2013.

The following table shows the PIK-related activity for the three-months ended March 31, 2013 and 2012, at cost (unaudited):


	Three months ended March 31, 2013
(in thousands)	2013			2012
Beginning PIK loan balance	$	3,309		$	2,041
PIK interest capitalized during the period		697			280
Payments received from PIK loans		(142	)		—

Ending PIK loan balance	$	3,864		$	2,321

The increase in payments received from PIK loans and PIK interest capitalized during the three-months ended March 31, 2013 is due to the addition of seven PIK loans and the payoff of one PIK loan during the period ended March 31, 2013.

In certain investment transactions, we may provide advisory services. For services that are separately identifiable and external evidence exists to substantiate fair value, income is recognized as earned, which is generally when the investment transaction closes. We had no income from advisory services in the three-month periods ended March 31, 2013 and 2012, respectively.

Operating Expenses

Operating expenses, which are comprised of interest and fees on borrowings, general and administrative and employee compensation, totaled approximately $15.9 million and $11.0 million during the three month periods ended March 31, 2013 and 2012, respectively.

Interest and fees on borrowings totaled approximately $8.7 million and $5.0 million during the three month periods ended March 31, 2013 and 2012, respectively. The increase is primarily attributed to interest and fee expenses of $3.2 million related to the 2019 Notes issued in April 2012 and September 2012 and $1.3 million related to the Asset-Backed Notes issued in December 2012. These expenses were partially offset by a decrease in interest and fees of approximately $710,000 associated with our SBA debentures due to the pay down in August 2012 of $12.0 million priced at 6.43%, including annual fees, and $12.75 million priced at 6.38%, including annual fees. Additional borrowings in November 2012 of SBA debentures priced on March 27, 2013 at 3.16%, including annual fees.

We had a weighted average cost of debt comprised of interest and fees of approximately 5.9% at March 31, 2013, as compared to 6.8% during March 31, 2012. The decrease was primarily driven by the Asset-Backed Notes issued in December 2012, which account for approximately 20.8% of our outstanding debt and accrue interest at 3.32%. As of March 31, 2013 the weighted average debt outstanding was approximately $593.9 million.

General and administrative expenses include legal fees, consulting fees, accounting fees, printer fees, insurance premiums, rent, workout and various other expenses. Expenses increased to $2.2 million from $1.8 million for the three month periods ended March 31, 2013 and 2012, respectively. These increases were primarily due to increases of approximately $127,000, $112,000 and $67,000 related to office, transportation and outside consulting services as a result of increased headcount partially offset by a decrease of approximately $70,000 for accounting expenses in the three-month period ended March 31, 2013.

Employee compensation and benefits totaled approximately $3.8 million and $3.4 million during the three-month periods ended March 31, 2013 and 2012, respectively. The increase was primarily attributable to additional headcount to 61 employees at March 31, 2013 from 52 employees at March 31, 2012. Stock-based compensation totaled approximately $1.2 million and $826,000 during the three-month periods ended March 31, 2013 and 2012, respectively. These increases were due primarily to the expense on restricted stock grants of approximately 606,001 shares issued in the first quarter of 2013. See “Financial Condition, Liquidity, and Capital Resources” for disclosure of additional expenses.

Net Investment Income Before Income Tax Expense and Investment Gains and Losses

Net investment income before income tax expense for the three-month period ended March 31, 2013 totaled approximately $15.0 million as compared to $11.4 million in the three-month period ended March 31, 2012. The changes are made up of the items described above under “Investment Income” and “Operating Expenses”.

Net Investment Realized Gains and Losses and Unrealized Appreciation and Depreciation

Realized gains or losses are measured by the difference between the net proceeds from the repayment or sale and the cost basis of the investment without regard to unrealized appreciation or depreciation previously recognized, and includes investments charged off during the period, net of recoveries. Net change in unrealized appreciation or depreciation primarily reflects the change in portfolio investment values during the reporting period, including the reversal of previously recorded unrealized appreciation or depreciation when gains or losses are realized.

A summary of realized gains and losses for the three-month periods ended March 31, 2013 and 2012 is as follows:


	March 31,
(in thousands)	2013			2012
Realized gains	$	3,613		$	3,690
Realized losses		(1,622	)		(813	)

Net realized gains (losses)	$	1,991		$	2,877

During the three-month period ended March 31, 2013, we recognized net realized gains of approximately $2.0 million on the portfolio. During the three-month period ended March 31, 2013, we recorded gross realized gains of approximately $3.6 million from the sale of investments in three portfolio companies. These gains were partially offset by the liquidation of our investments in five portfolio companies of approximately $1.6 million in gross realized losses.

During the three-month period ended March 31, 2012, we recognized net realized gains of approximately $2.9 million on the portfolio. We recorded approximately $2.2 million and $1.3 million of realized gains from the sale of equity in BARRX Medical, Inc. and Aegerion Pharmaceuticals, Inc., respectively. These gains were partially offset by realized losses of approximately $459,000 from the sale of our common stock in two public portfolio companies and due to the liquidation of our warrants in one private portfolio company that had a cost basis of approximately $355,000.

The net unrealized appreciation and depreciation of our investments is based on fair value of each investment determined in good faith by our Board of Directors. The following table itemizes the change in net unrealized appreciation/depreciation of investments for the three-month periods ended March 31, 2013 and 2012:


	March 31,
(in thousands)	2013			2012
Gross unrealized appreciation on portfolio investments	$	13,224		$	19,330
Gross unrealized depreciation on portfolio investments		(14,059	)		(12,502	)
Reversal of prior period net unrealized appreciation upon a realization event		(2,461	)		(4,508	)
Reversal of prior period net unrealized depreciation upon a realization event		1,613			429
Citigroup Warrant Participation		181			104

Net unrealized appreciation (depreciation) on portfolio investments	$	(1,502	)	$	2,853

During the three-months ended March 31, 2013, we recorded approximately $1.5 million of net unrealized depreciation from our debt, equity and warrant investments. Approximately $1.9 million is attributed to net unrealized appreciation on equity, of which approximately $93,000 is due to the reversal of prior period net unrealized appreciation upon being realized as a gain and $268,000 is due to the reversal of prior period net unrealized depreciation upon being realized as a loss. Approximately $3.8 million is attributed to net unrealized appreciation on our warrant investments, of which approximately $1.9 million is due to the reversal of prior period net unrealized appreciation upon being realized as a gain and $1.3 million is due to the reversal of prior period net unrealized depreciation upon being realized as a loss. We recorded approximately $7.2 million of net unrealized depreciation on our debt investments.

During the three-month period ended March 31, 2013, net unrealized investment appreciation recognized by us was increased by approximately $181,000 as a result of current quarter depreciation of fair value on the pool of warrants collateralized under the warrant participation agreement.

During the three-month period ended March 31, 2012, we recorded approximately $1.5 million of net unrealized depreciation on our debt investments and approximately $2.7 million and $1.5 million of net unrealized appreciation on our equity and warrant investments, respectively.

The following table itemizes the change in net unrealized appreciation/(depreciation) in the investment portfolio by category for the three-month periods ended March 31, 2013 and 2012.


	Three Months Ended March 31, 2013
(unaudited, in millions)	Loans			Equity			Warrants			Total
Collateral based impairments	$	(5.7	)	$	—		$	—		$	(5.7	)

Reversals due to Loan Payoffs & Warrant/Equity sales		—			0.2			(1.0	)		(0.8	)
Fair Value Market/Yield Adjustments*
Level 1 & 2 Assets		—			0.1			0.2			0.3
Level 3 Assets		(1.5	)		1.6			4.4			4.5

Total Fair Value Market/Yield Adjustments		(1.5	)		1.7			4.6			4.8


Total Unrealized Appreciation/(Depreciation)	$	(7.2	)	$	1.9		$	3.6		$	(1.7	)


	Three Months Ended March 31, 2012
(unaudited, in millions)	Loans			Equity			Warrants			Total
Reversals of Prior Period Collateral based impairments	$	1.3		$	—		$	—		$	1.3

Reversals due to Loan Payoffs & Warrant/Equity sales		—			(2.9	)		(1.2	)		(4.1	)
Fair Value Market/Yield Adjustments*
Level 1 & 2 Assets		—			(0.3	)		1.1			0.8
Level 3 Assets		(2.8	)		5.9			1.6			4.7

Total Fair Value Market/Yield Adjustments		(2.8	)		5.6			2.7			5.5


Total Unrealized Appreciation/(Depreciation)	$	(1.5	)	$	2.7		$	1.5		$	2.7

Level 1 assets are generally equities listed in active markets and level 2 assets are generally warrants held in a public company. Observable market prices are typically the primary input in valuing level 1 and 2 assets. Level 3 asset valuations require inputs that are both significant and unobservable. Generally, level 3 assets are debt investments and warrants and equities held in a private company. See Note 2 to the financial statements discussing ASC 820.

Income and Excise Taxes

We account for income taxes in accordance with the provisions of ASC 740, Income Taxes, which requires that deferred income taxes be determined based upon the estimated future tax effects of differences between the financial statement and tax basis of assets and liabilities given the provisions of the enacted tax law. Valuation allowances are used to reduce deferred tax assets to the amount likely to be realized. We intend to distribute approximately $1.5 million of spillover earnings from the year ended December 31, 2012 to our shareholders in 2013.

Net Increase in Net Assets Resulting from Operations and Change in Net Assets per Share

For the three-month periods ended March 31, 2013 and 2012, the net increase in net assets resulting from operations totaled approximately $16.7 million and $17.1 million, respectively. These changes are made up of the items previously described.

Basic and fully diluted net change in net assets per common share was $0.30 and $0.36 for the three-month periods ended March 31, 2013 and 2012, respectively.

Financial Condition, Liquidity, and Capital Resources

Our liquidity and capital resources are derived from our Wells Facility, Union Bank Facility (together the “Credit Facilities”), SBA debentures, Convertible Senior Notes, 2019 Notes, Asset-Backed Notes and cash flows from operations, including investment sales and repayments, and income earned. Our primary use of funds from operations includes investments in portfolio companies and payments of fees and other operating expenses we incur. We have used, and expect to continue to use, our borrowings and the proceeds from the rotation of our portfolio and from public and private offerings of securities to finance our investment objectives. We may raise additional equity or debt capital through both registered offerings off a shelf registration and private offerings of securities, by securitizing a portion of our investments or borrowing, including from the SBA through our SBIC subsidiaries.

At March 31, 2013, we had $75.0 million of Convertible Senior Notes payable, $170.4 million of 2019 Notes, $120.1 million of Asset-Backed Notes and $225.0 million of SBA debentures payable. We had no borrowings outstanding under either the Wells Facility or the Union Bank Facility.

At March 31, 2013, we had $311.9 million in available liquidity, including $206.9 million in cash and cash equivalents. At March 31, 2013, we had available borrowing capacity of approximately $75.0 million under the Wells Facility and $30.0 million under the Union Bank Facility, subject to existing terms and advance rates and regulatory requirements. We primarily invest cash on hand in interest bearing deposit accounts.

At March 31, 2013, we had approximately $810,000 of restricted cash. Our restricted cash consists of collections of interest and principal payments on assets that are securitized. In accordance with the terms of the related securitized Asset-Backed Notes, based on current characteristics of the securitized loan portfolios, the restricted funds may be used to pay monthly interest and principal on the securitized debt and are not distributed to us or available for our general operations. During the three months ended March 31, 2013, we principally funded our operations from (i) cash receipts from interest, dividend and fee income from our investment portfolio and (ii) cash proceeds from the realization of portfolio investments through the repayments of loan investments and the sale of loan and equity investments.

During the three-months ended March 31, 2013, our operating activities used $47.7 million of cash and cash equivalents, compared to $17.7 million used during the three-months ended March 31, 2012. The $30.0 million increase in cash used in operating activities resulted primarily from additional purchases of investments of approximately $74.1 million partially offset by an increase in principal payments received on investments of approximately $40.0 million. During the three months ended March 31, 2013, our investing activities used $864,000 of cash, compared to $12,000 during three months ended March 31, 2012. This $852,000 increase in cash used by investing activities was primarily due to an increase in cash collections of interest and principal payments, classified as restricted cash, on assets that are securitized. During the three-months ended March 31, 2013, our financing activities provided $72.5 million of cash, compared to $1.7 million during the three-months ended March 31, 2012. This $70.9 million increase in cash provided by financing activities was primarily due to an increase in proceeds from issuance of common stock of $47.4 million and a decrease in repayments of credit facilities of $25.6 million.

As of March 31, 2013, net assets totaled $615.6 million, with a net asset value per share of $10.00. We intend to generate additional cash primarily from cash flows from operations, including income earned from investments in our portfolio companies and, to a lesser extent, from the temporary investment of cash in other high-quality debt investments that mature in one year or less as well as from future borrowings as required to meet our lending activities. Our primary use of funds will be investments in portfolio companies and cash distributions to holders of our common stock.

Additionally, we expect to raise additional capital to support our future growth through future equity and debt offerings, and/or future borrowings, to the extent permitted by the 1940 Act. To the extent we determine to raise additional equity through an offering of our common stock at a price below net asset value, existing investors will experience dilution. During our 2012 Annual Shareholder Meeting held on May 30, 2012, our stockholders authorized us, with the approval of our Board of Directors, to sell up to 20% of our outstanding common stock at a net price below our then current net asset value per share and to offer and issue debt with warrants or debt convertible into shares of our common stock at an exercise or conversion price that will not be less than the fair market value per share but may be below the then current net asset value per share. There can be no assurance that these capital resources will be available. We are seeking stockholder approval of this proposal again at our 2013 Annual Meeting of Shareholders.

On July 25, 2012, our Board of Directors approved an extension of the stock repurchase plan under the same terms and conditions that allowed us to repurchase up to $35.0 million of our common stock. The stock repurchase plan expired on February 26, 2013 and no shares were repurchased in 2013.

As required by the 1940 Act, our asset coverage must be at least 200% after each issuance of senior securities. Recent legislation introduced in the U.S. House of Representatives, if passed, would modify this section of the 1940 Act and increase the amount of debt that business development companies may incur by modifying the percentage from 200% to 150%. As of March 31, 2013 our asset coverage ratio under our regulatory requirements as a business development company was 329.1%, excluding our SBA debentures as a result of our exemptive order from the SEC which allows us to exclude all SBA leverage from our asset coverage ratio. Total leverage when including our SBA debentures was 203.7% at March 31, 2013. As a result of the SEC exemptive order, our ratio of total assets on a consolidated basis to outstanding indebtedness may be less than 200%, which while providing increased investment flexibility, also may increase our exposure to risks associated with leverage.

Outstanding Borrowings

At March 31, 2013 (unaudited) and December 31, 2012, we had the following borrowing capacity and outstanding amounts:


	March 31, 2013				December 31, 2012
(in thousands)	Total Available		Carrying Value⁽¹⁾		Total Available		Carrying Value⁽¹⁾
Union Bank Facility	$	30,000	$	—	$	30,000	$	—
Wells Facility		75,000		—		75,000		—
Convertible Senior Notes⁽²⁾		75,000		71,707		75,000		71,436
2019 Notes		170,364		170,364		170,364		170,364
Asset-Backed Notes		120,051		120,051		129,300		129,300
SBA Debentures⁽³⁾		225,000		225,000		225,000		225,000

Total	$	695,415	$	587,122	$	704,664	$	596,100

⁽¹⁾	Except for the Convertible Senior Notes, all carrying values are the same as the principal amount outstanding.

⁽²⁾

Represents the aggregate principal amount outstanding of the Convertible Senior Notes less the unaccreted discount initially recorded upon issuance of the Convertible Senior Notes. The total unaccreted discount for the Convertible Senior Notes was $3.3 million at March 31, 2013 and $3.6 million at December 31, 2012.

⁽³⁾	At March 31, 2013 and at December 31, 2012, the total available borrowings under the SBA was $225.0 million, of which $76.0 million was available in HT II and $149.0 million was available in HT III.

Our net asset value may decline as a result of economic conditions in the United States. Our continued compliance with the covenants under our Credit Facilities, Convertible Senior Notes, 2019 Notes Payable, Asset-Backed Notes and SBA debentures depend on many factors, some of which are beyond our control. Material net asset devaluation could have a material adverse effect on our operations and could require us to reduce our borrowings in order to comply with certain covenants, including the ratio of total assets to total indebtedness. We believe that our current cash and cash equivalents, cash generated from operations, and funds available from our Credit Facilities will be sufficient to meet our working capital and capital expenditure commitments for at least the next 12 months.

Debt financing costs are fees and other direct incremental costs we incur in obtaining debt financing and are recognized as prepaid expenses and amortized into the consolidated statement of operations as loan fees over the term of the related debt instrument. Prepaid financing costs, net of accumulated amortization, as of March 31, 2013 (unaudited) and December 31, 2012 were as follows:


(in thousands)	March 31, 2013		December 31, 2012
Wells Facility	$	789	$	867
SBA Debenture		5,668		5,877
Convertible Senior Notes		1,756		1,900
Asset-Backed Notes		3,809		4,074
2019 Notes		6,046		6,287

	$	18,068	$	19,005

Commitments

In the normal course of business, we are party to financial instruments with off-balance sheet risk. These consist primarily of unfunded commitments to extend credit, in the form of loans, to our portfolio companies. Unfunded commitments to provide funds to portfolio companies are not reflected on our balance sheet. Our unfunded commitments may be significant from time to time. As of March 31, 2013, we had unfunded commitments of approximately $137.1 million. Approximately $83.6 million of these unfunded debt commitments are dependent upon the portfolio company reaching certain milestones before the debt commitment becomes available. These commitments will be subject to the same underwriting and ongoing portfolio maintenance as are the on-balance sheet financial instruments that we hold. Since these commitments may expire without being drawn upon, the total commitment amount does not necessarily represent future cash requirements. Closed commitments generally fund 70-80% of the committed amount in aggregate over the life of the commitment. We intend to use cash flow from normal and early principal repayments, and proceeds from borrowings and notes to fund these commitments. However, there can be no assurance that we will have sufficient capital available to fund these commitments as they come due.

In addition, we had approximately $93.0 million of non-binding term sheets outstanding to seven new and existing companies, which generally convert to contractual commitments within approximately 45 to 60 days of signing. Non-binding outstanding term sheets are subject to completion of our due diligence and final approval process, as well as the negotiation of definitive documentation with the prospective portfolio companies. Not all non-binding term sheets are expected to close and do not necessarily represent future cash requirements.

Contractual Obligations

The following table shows our contractual obligations as of March 31, 2013 (unaudited):


	Payments due by period (in thousands)
Contractual Obligations⁽¹⁾⁽²⁾	Total		Less than 1 year		1 - 3 years		3 - 5 years		After 5 years
Borrowings⁽³⁾⁽⁴⁾	$	587,123	$	—	$	120,051	$	71,707	$	395,365
Operating Lease Obligations⁽⁵⁾		8,555		1,334		2,901		3,063		1,257

Total	$	595,678	$	1,334	$	122,952	$	74,770	$	396,622

⁽¹⁾	Excludes commitments to extend credit to our portfolio companies.

⁽²⁾	We also have a warrant participation agreement with Citigroup. See Note 4.

⁽³⁾	Includes $225.0 million in borrowings under the SBA debentures, $170.4 million of the 2019 Notes, $120.1 million in aggregate principal amount of the Asset-Backed Notes and $71.7 million of the Convertible Senior Notes.

⁽⁴⁾

⁽⁵⁾	Long-term facility leases.

We and our executives and directors are covered by Directors and Officers Insurance, with the directors and officers being indemnified by us to the maximum extent permitted by Maryland law subject to the restrictions in the 1940 Act.

Borrowings

Long-term SBA Debentures

On September 27, 2006, HT II received a license to operate as a SBIC under the SBIC program and is able to borrow funds from the SBA against eligible investments and regulatory capital. Under the Small Business Investment Company Act and current SBA policy applicable to SBICs, a SBIC can have outstanding at any time SBA guaranteed debentures up to twice the amount of its regulatory capital. HT II has a total of $76.0 million of SBA guaranteed debentures outstanding as of March 31, 2013 and has paid the SBA commitment fees of approximately $1.5 million. As of March 31, 2013, we held investments in HT II in 49 companies with a fair value of approximately $128.3 million, accounting for approximately 13.3% of our total portfolio at March 31, 2013.

On May 26, 2010, HT III received a license to operate as a SBIC under the SBIC program and is able to borrow funds from the SBA against eligible investments and additional contributions to regulatory capital. With our net investment of $74.5 million in HT III as of March 31, 2013, HT III has the capacity to issue a total of $149.0 million of SBA guaranteed debentures, subject to SBA approval, of which $149.0 million was outstanding as of March 31, 2013. As of March 31, 2013, HT III has paid commitment fees of approximately $1.5 million. As of March 31, 2013, we held investments in HT III in 37 companies with a fair value of approximately $222.9 million accounting for approximately 23.0% of our total portfolio at March 31, 2013.

SBICs are designed to stimulate the flow of private equity capital to eligible small businesses. Under present SBA regulations, eligible small businesses include businesses that have a tangible net worth not exceeding $18.0 million and have average annual fully taxed net income not exceeding $6.0 million for the two most recent fiscal years. In addition, SBICs must devote 25.0% of its investment activity to “smaller” concerns as defined by the SBA. A smaller concern is one that has a tangible net worth not exceeding $6.0 million and has average annual fully taxed net income not exceeding $2.0 million for the two most recent fiscal years. SBA regulations also provide alternative size standard criteria to determine eligibility, which depend on the industry in which the business is engaged and are based on such factors as the number of employees and gross sales. According to SBA regulations, SBICs may make long-term loans to small businesses, invest in the equity securities of such businesses and provide them with consulting and advisory services. Through its wholly-owned subsidiaries HT II and HT III, we plan to provide long-term loans to qualifying small businesses, and in connection therewith, make equity investments.

HT II and HT III are periodically examined and audited by the SBA’s staff to determine their compliance with SBA regulations. If HT II or HT III fails to comply with applicable SBA regulations, the SBA could, depending on the severity of the violation, limit or prohibit HT II’s or HT III’s use of debentures, declare outstanding debentures immediately due and payable, and/or limit HT II or HT III from making new investments. In addition, HT II or HT III may also be limited in their ability to make distributions to us if they do not have sufficient capital in accordance with SBA regulations. Such actions by the SBA would, in turn, negatively affect us because HT II and HT III are our wholly owned subsidiaries. HT II and HT III were in compliance with the terms of the SBIC’s leverage as of March 31, 2013 as a result of having sufficient capital as defined under the SBA regulations.

The rates of borrowings under various draws from the SBA beginning in April 2007 are set semiannually in March and September and range from 2.25% to 5.73%. Interest payments on SBA debentures are payable semiannually. There are no principal payments required on these issues prior to maturity and no prepayment penalties. Debentures under the SBA generally mature ten years after being borrowed. Based on the initial draw down date of April 2007, the initial maturity of SBA debentures will occur in April 2017. In addition, the SBA charges a fee that is set annually, depending on the Federal fiscal year the leverage commitment was delegated by the SBA, regardless of the date that the leverage was drawn by the SBIC. The annual fees related to HT II debentures that pooled on September 22, 2010 were 0.406% and 0.285%, depending upon the year in which the underlying commitment was closed. The annual fees related to HT III debentures that pooled on March 27, 2013 were 0.804%. The annual fees on other debentures have been set at 0.906%. The average amount of debentures outstanding for the three-months ended March 31, 2013 for HT II was approximately $76.0 million with an average interest rate of approximately 5.30%. The average amount of debentures outstanding for the three-months ended March 31, 2013 for HT III was approximately $149.0 million with an average interest rate of approximately 3.26%.

In January 2011, we repaid $25.0 million of SBA debentures under HT II, priced at approximately 6.63%, including annual fees. In April 2011, the SBA approved a $25.0 million dollar commitment for HT III. In February 2012, we repaid $24.25 million of SBA debentures under HT II, priced at 6.63%, including annual fees. In June 2012, the SBA approved a $24.25 million dollar commitment for HT III. In August 2012, we repaid $24.75 million of SBA debentures under HT II, $12.0 million priced at 6.43%, including annual fees and $12.75 million priced at 6.38%, including annual fees.

As of March 31, 2013, the maximum statutory limit on the dollar amount of outstanding SBA guaranteed debentures issued by a single SBIC is $150.0 million, subject to periodic adjustments by the SBA, and a maximum amount of $225.0 million for funds under common control, subject to periodic adjustments by the SBA. In the aggregate, at March 31, 2013 there was $225.0 million principal amount of indebtedness outstanding incurred by our SBIC subsidiaries, bringing us to the maximum statutory limit on the dollar amount of SBA guaranteed debentures under the SBIC program.

We reported the following SBA debentures outstanding as of March 31, 2013 (unaudited) and December 31, 2012:


(in thousands) Issuance/Pooling Date	Maturity Date	Interest Rate⁽¹⁾			March 31, 2013		December 31, 2012
SBA Debentures:
March 26, 2008	March 1, 2018		6.38	%	$	34,800	$	34,800
March 25, 2009	March 1, 2019		5.53	%		18,400		18,400
September 23, 2009	September 1, 2019		4.64	%		3,400		3,400
September 22, 2010	September 1, 2020		3.62	%		6,500		6,500
September 22, 2010	September 1, 2020		3.50	%		22,900		22,900
March 29, 2011	March 1, 2021		4.37	%		28,750		28,750
September 21, 2011	September 1, 2021		3.16	%		25,000		25,000
March 21, 2012	March 1, 2022		3.05	%		11,250		11,250
March 21, 2012	March 1, 2022		3.28	%		25,000		25,000
September 19, 2012	September 1, 2022		3.05	%		24,250		24,250
March 27, 2013	March 1, 2023		3.16	%		24,750		24,750

Total SBA Debentures					$	225,000	$	225,000

⁽¹⁾	Interest rate includes annual charge

Wells Facility

In August 2008, we entered into a $50.0 million two-year revolving senior secured credit facility with Wells Fargo Capital Finance (the “Wells Facility”). On June 20, 2011, we renewed the Wells Facility. Under this three-year senior secured facility, Wells Fargo Capital Finance has made commitments of $75.0 million. The facility contains an accordion feature, in which we can increase the credit line up to an aggregate of $300.0 million, funded by additional lenders and with the agreement of Wells Fargo Capital Finance and subject to other customary conditions. We expect to continue discussions with various other potential lenders to join the new facility; however, there can be no assurances that additional lenders will join the Wells Facility.

On August 1, 2012, we entered into an amendment to the Wells Facility. The amendment reduces the interest rate floor by 75 basis points to 4.25% and extends the maturity date by one year to August 2015. Additionally, an amortization period of 12 months was added to pay down the principal balance as of the maturity date, and the unused line fee was reduced.

Borrowings under the Wells Facility will generally bear interest at a rate per annum equal to LIBOR plus 3.50%, with a floor of 4.25% and an advance rate of 50% against eligible loans. The Wells Facility is secured by loans in the borrowing base. The Wells Facility requires payment of a non-use fee on a scale of 0.0% to 0.50% of the average monthly outstanding balance. The monthly payment of a non-use fee thereafter shall depend on the average balance that was outstanding on a scale between 0.0% and 0.50%. For the three-month period ended March 31, 2013, this non-use fee was approximately $94,000. On June 20, 2011 we paid an additional $1.1 million in structuring fees in connection with the Wells Facility which is being amortized through the end of the term. At March 31, 2013, there were no borrowings outstanding on this facility.

The Wells Facility includes various financial and operating covenants applicable to us and our subsidiaries, in addition to those applicable to Hercules Funding II, LLC. These covenants require us to maintain certain financial ratios and a minimum tangible net worth in an amount, when added to outstanding subordinated indebtedness, that is in excess of $362.0 million plus 90% of the cumulative amount of equity raised after June 30, 2012. In addition, the tangible net worth covenant will increase by 90 cents on the dollar for every dollar of equity capital that we subsequently raise. As of March 31, 2013, the minimum tangible net worth covenant has increased to $478.5 million as a result of the October 2012 follow-on public offering of 3.1 million shares of common stock for proceeds of approximately $33.6 million and the March 2013 follow-on public offering of 8.1 million shares of common stock for proceeds of approximately $95.8 million. The Wells Facility provides for customary events of default, including, but not limited to, payment defaults, breach of representations or covenants, bankruptcy events and change of control. We were in compliance with all covenants at March 31, 2013.

Union Bank Facility

On February 10, 2010, we entered a $20.0 million one-year revolving senior secured credit facility with Union Bank (the “Union Bank Facility”). On November 2, 2011, we renewed and amended the Union Bank Facility and added a new lender under the Union Bank Facility. Union Bank and RBC Capital Markets (“RBC”) have made commitments of $30.0 million and $25.0 million, respectively. The Union Bank Facility contains an accordion feature, in which we can increase the credit line up to an aggregate of $150.0 million, funded by additional lenders and with the agreement of Union Bank and subject to other customary conditions. We expect to continue discussions with various other potential lenders to join the new facility; however, there can be no assurances that additional lenders will join the Union Bank Facility.

On March 30, 2012 we entered into an amendment to the Union Bank Facility which permitted us to issue additional senior notes relating to the offer and sale of our 2019 Notes. On September 17, 2012, we entered into an amendment to the Union Bank Facility. Pursuant to the terms of the amendment, we are permitted to increase our unsecured indebtedness by an aggregate original principal amount not to exceed $200.0 million incurred after March 30, 2012 in one or more issuances, provided certain conditions are satisfied for each issuance.

On December 17, 2012, we further amended the Union Bank Facility to remove RBC from the Union Bank Facility. Following the removal of RBC, the Union Bank Facility consists solely of Union Bank’s commitment of $30.0 million. In connection with the amendment, the maximum availability under the Union Bank Facility, subject to a borrowing base, was reduced from $55.0 million to $30.0 million. The Union Bank Facility contains an accordion feature, in which we could increase the credit line by up to $95.0 million in the aggregate, funded by commitments from additional lenders and with the agreement of Union Bank and subject to other customary conditions. There can be no assurances that additional lenders will join the Union Bank Facility.

Borrowings under the Union Bank Facility will generally bear interest at a rate per annum equal to LIBOR plus 2.25% with a floor of 4.0%. The Union Bank Facility requires the payment of a non-use fee of 0.50% annually. For the three-month period ended March 31, 2013, this nonuse fee was approximately $37,500. The Union Bank Facility is collateralized by debt investments in our portfolio companies, and includes an advance rate equal to 50.0% of eligible loans placed in the collateral pool. The Union Bank Facility generally requires payment of interest on a monthly basis. All outstanding principal is due upon maturity. At March 31, 2013 there were no borrowings outstanding on this facility.

The Union Bank Facility requires various financial and operating covenants. These covenants require us to maintain certain financial ratios and a minimum tangible net worth in an amount, when added to outstanding subordinated indebtedness, that is in excess of $314.0 million plus 90% of the amount of net cash proceeds received from the sale of common stock after March 31, 2011. As of March 31, 2013, the minimum tangible net worth covenant has increased to $472.8 million as a result of the January and October 2012 follow-on public offerings of 5.0 and 3.1 million shares of common stock, respectively, for total net proceeds of approximately $80.9 million and the March 2013 follow-on public offering of 8.1 million shares of common stock for total net proceeds of approximately $95.6 million. The Union Bank Facility will mature on November 1, 2014, approximately three years from the date of issuance, revolving through the first 24 months with a term out provision for the remaining 12 months. Union Bank Facility also provides for customary events of default, including, but not limited to, payment defaults, breach of representations or covenants, bankruptcy events and change of control. We were in compliance with all covenants at March 31, 2013.

Citibank Credit Facility

We, through Hercules Funding Trust I, an affiliated statutory trust, had a securitized credit facility (the “Citibank Credit Facility”) with Citigroup Global Markets Realty Corp. which expired under normal terms. During the first quarter of 2009, we paid off all principal and interest owed under the Citibank Credit Facility. Citigroup has an equity participation right through a warrant participation agreement on the pool of loans and warrants collateralized under the Citibank Credit Facility. Pursuant to the warrant participation agreement, we granted to Citigroup a 10% participation in all warrants held as collateral. However, no additional warrants were included in collateral subsequent to the facility amendment on May 2, 2007. As a result, Citigroup is entitled to 10% of the realized gains on the warrants until the realized gains paid to Citigroup pursuant to the agreement equal $3,750,000 (the “Maximum Participation Limit”). The obligations under the warrant participation agreement continue even after the Citibank Credit Facility is terminated until the Maximum Participation Limit has been reached.

During the three-months ended March 31, 2013, we reduced our realized gain by approximately $207,000 for Citigroup’s participation in the gain on sale of equity securities which were obtained from exercising a portfolio company warrant which was included in the collateral pool. We recorded a decrease on participation liability and an increase on unrealized appreciation by a net amount of approximately $181,000 as a result of current quarter depreciation of fair value on the pool of warrants collateralized under the warrant participation agreement. The value of their participation right on unrealized gains in the related equity investments was approximately $132,000 as of March 31, 2013 and is included in accrued liabilities. There can be no assurances that the unrealized appreciation of the warrants will not be higher or lower in future periods due to fluctuations in the value of the warrants, thereby increasing or reducing the effect on the cost of borrowing. Since inception of the agreement, we have paid Citigroup approximately $1.6 million under the warrant participation agreement thereby reducing our realized gains by this amount. We will continue to pay Citigroup under the warrant participation agreement until the Maximum Participation Limit is reached or the warrants expire. Warrants subject to the Citigroup participation agreement are set to expire between April 2013 and January 2017.

Convertible Senior Notes

In April 2011, we issued $75.0 million in aggregate principal amount of 6.00% convertible senior notes (the “Convertible Senior Notes”) due 2016. As of March 31, 2013, the carrying value of the Convertible Senior Notes, comprised of the aggregate principal amount outstanding less the unaccreted discount initially recorded upon issuance of the Convertible Senior Notes, is approximately $71.7 million.

The Convertible Senior Notes mature on April 15, 2016 (the “Maturity Date”), unless previously converted or repurchased in accordance with their terms. The Convertible Senior Notes bear interest at a rate of 6.00% per year payable semiannually in arrears on April 15 and October 15 of each year, commencing on October 15, 2011. The Convertible Senior Notes are our senior unsecured obligations and rank senior in right of payment to our existing and future indebtedness that is expressly subordinated in right of payment to the Convertible Senior Notes; equal in right of payment to our existing and future unsecured indebtedness that is not so subordinated; effectively junior in right of payment to any of our secured indebtedness (including unsecured indebtedness that we later secure) to the extent of the value of the assets securing such indebtedness; and structurally junior to all existing and future indebtedness (including trade payables) incurred by our subsidiaries, financing vehicles or similar facilities.

Prior to the close of business on the business day immediately preceding October 15, 2015, holders may convert their Convertible Senior Notes only under certain circumstances set forth in the Indenture. On or after October 15, 2015 until the close of business on the scheduled trading day immediately preceding the Maturity Date, holders may convert their Convertible Senior Notes at any time. Upon conversion, we will pay or deliver, as the case may be, at our election, cash, shares of our common stock or a combination of cash and shares of our common stock. The conversion rate will initially be 84.0972 shares of common stock per $1,000 principal amount of Convertible Senior Notes (equivalent to an initial conversion price of approximately $11.89 per share of common stock). The conversion rate will be subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest. In addition, if certain corporate events occur prior to the Maturity Date, the conversion rate will be increased for converting holders.

We may not redeem the Convertible Senior Notes prior to maturity. No sinking fund is provided for the Convertible Senior Notes. In addition, if certain corporate events occur, holders of the Convertible Senior Notes may require us to repurchase for cash all or part of their Convertible Senior Notes at a repurchase price equal to 100% of the principal amount of the Convertible Senior Notes to be repurchased, plus accrued and unpaid interest through, but excluding, the required repurchase date.

In accounting for the Convertible Senior Notes, we estimated that the values of the debt and the embedded conversion feature of the Convertible Senior Notes were approximately 92.8% and 7.2%, respectively. The original issue discount of 7.2% attributable to the conversion feature of the Convertible Senior Notes has initially been recorded in “capital in excess of par value” in the consolidated statement of assets and liabilities. As a result, we record interest expense comprised of both stated interest expense as well as accretion of the original issue discount resulting in an estimated effective interest rate of approximately 7.9%

As of March 31, 2013, the components of the carrying value of the Convertible Senior Notes were as follows:


(unaudited, in thousands)	As of March 31, 2013
Principal amount of debt	$	75,000
Original issue discount, net of accretion		(3,294	)

Carrying value of debt	$	71,706

For the three-months ended March 31, 2013 and 2012, the components of interest expense, fees and cash paid for interest expense for the Convertible Senior Notes were as follows:


	Three Months Ended March 31,
(unaudited, in thousands)	2013		2012
Stated interest expense	$	1,125	$	1,125
Accretion of original issue discount		271		271
Amortization of debt issuance cost		144		144

Total interest expense	$	1,540	$	1,540

Cash paid for interest expense	$	—	$	—

As of March 31, 2013, we are in compliance with the terms of the indentures governing the Convertible Senior Notes. See Note to our consolidated financial statements for more detail on the Convertible Senior Notes.

2019 Notes

On March 6, 2012, we and U.S. Bank National Association (the “Trustee”) entered into an indenture (the “Base Indenture”). On April 17, 2012, we and the Trustee entered into the First Supplemental Indenture to the Base Indenture (the “First Supplemental Indenture”), dated April 17, 2012, relating to our issuance, offer and sale of $43.0 million aggregate principal amount of 7.00% senior notes due 2019 (the “April 2019 Notes”). The sale of the April 2019 Notes generated net proceeds, before expenses, of approximately $41.7 million.

On September 24, 2012, we and the Trustee, entered into the Second Supplemental Indenture to the Base Indenture (the “Second Supplemental Indenture”), dated as of September 24, 2012, relating to our issuance, offer and sale of $75.0 million aggregate principal amount of 7.00% senior notes due 2019 (the “September 2019 Notes” and, together with the April 2019 Notes, the “2019 Notes”). The sale of the September 2019 Notes generated net proceeds, before expenses, of approximately $72.75 million.

April 2019 Notes

The April 2019 Notes will mature on April 30, 2019 and may be redeemed in whole or in part at our option at any time or from time to time on or after April 30, 2015, upon not less than 30 days nor more than 60 days written notice by mail prior to the date fixed for redemption thereof, at a redemption price of 100% of the outstanding principal amount thereof plus accrued and unpaid interest payments otherwise payable for the then-current quarterly interest period accrued to but not including the date fixed for redemption. The April 2019 Notes bear interest at a rate of 7.00% per year payable quarterly on January 30, April 30, July 30 and October 30 of each year, commencing on July 30, 2012, and trade on the New York Stock Exchange under the trading symbol “HTGZ.”

The April 2019 Notes are our direct unsecured obligations and rank: (i) pari passu with our other outstanding and future senior unsecured indebtedness, including without limitation, the $75.0 million in aggregate principal amount of the Convertible Senior Notes; (ii) senior to any of our future indebtedness that expressly provides it is subordinated to the April 2019 Notes; (iii) effectively subordinated to all our existing and future secured indebtedness (including indebtedness that is initially unsecured to which we subsequently grant security), to the extent of the value of the assets securing such indebtedness, including without limitation, borrowings under our Credit Facilities; (iv) structurally subordinated to all existing and future indebtedness and other obligations of any of our subsidiaries, including without limitation, the indebtedness of Hercules Technology II, L.P. and Hercules Technology III, L.P. and borrowings under our revolving senior secured credit facility with Wells Fargo Capital Finance, LLC.

The Base Indenture, as supplemented by the First Supplemental Indenture, contains certain covenants including covenants requiring our compliance with (regardless of whether it is subject to) the asset coverage requirements set forth in Section 18(a)(1)(A) as modified by Section 61(a)(1) of the 1940 Act to comply with the restrictions on dividends, distributions and purchase of capital stock set forth in Section 18(a)(1)(B) as modified by Section 61(a)(1) of the 1940 Act and to provide financial information to the holders of the April 2019 Notes and the Trustee if we should no longer be subject to the reporting requirements under the Securities Exchange Act of 1934. These covenants are subject to important limitations and exceptions that are described in the Indenture, as supplemented by the First Supplemental Indenture. The Indenture provides for customary events of default and further provides that the Trustee or the holders of 25% in aggregate principal amount of the outstanding April 2019 Notes in a series may declare such April 2019 Notes immediately due and payable upon the occurrence of any event of default after expiration of any applicable grace period.

In July 2012, we reopened our April 2019 Notes and issued an additional $41.5 million in aggregate principal amount of April 2019 Notes, which includes exercise of an over-allotment option, bringing the total amount of the April 2019 Notes issued to approximately $84.5 million in aggregate principal amount.

September 2019 Notes

The September 2019 Notes will mature on September 30, 2019 and may be redeemed in whole or in part at our option at any time or from time to time on or after September 30, 2015, upon not less than 30 days nor more than 60 days written notice by mail prior to the date fixed for redemption thereof, at a redemption price of 100% of the outstanding principal amount thereof plus accrued and unpaid interest payments otherwise payable for the then-current quarterly interest period accrued to but not including the date fixed for redemption. The September 2019 Notes bear interest at a rate of 7.00% per year payable quarterly on March 30, June 30, September 30 and December 30 of each year, commencing on December 30, 2012, and trade on the New York Stock Exchange under the trading symbol “HTGY.”

The September 2019 Notes are our direct unsecured obligations and rank: (i) pari passu with our other outstanding and future senior unsecured indebtedness, including without limitation, the $75 million in aggregate principal amount of the Convertible Senior Notes; (ii) senior to any of our future indebtedness that expressly provides it is subordinated to the September 2019 Notes; (iii) effectively subordinated to all our existing and future secured indebtedness (including indebtedness that is initially unsecured to which we subsequently grant security), to the extent of the value of the assets securing such indebtedness, including without limitation, borrowings under our credit facilities; (iv) structurally subordinated to all existing and future indebtedness and other obligations of any of our subsidiaries, including without limitation, the indebtedness of Hercules Technology II, L.P. and Hercules Technology III, L.P. and borrowings under our revolving senior secured credit facility with Wells Fargo Capital Finance.

The Base Indenture, as supplemented by the Second Supplemental Indenture, contains certain covenants including covenants requiring us to comply with (regardless of whether it is subject to) the asset coverage requirements set forth in Section 18 (a)(1)(A) as modified by Section 61(a)(1) of the 1940 Act to comply with the restrictions on dividends, distributions and purchase of capital stock set forth in Section 18(a)(1)(B) as modified by Section 61(a)(1) of the 1940 Act and to provide financial information to the holders of the September 2019 Notes and the Trustee if we should no longer be subject to the reporting requirements under the Securities Exchange Act of 1934. These covenants are subject to important limitations and exceptions that are described in the Indenture, as supplemented by the Second Supplemental Indenture. The Indenture provides for customary events of default and further provides that the Trustee or the holders of 25% in aggregate principal amount of the outstanding September 2019 Notes in a series may declare such September 2019 Notes immediately due and payable upon the occurrence of any event of default after expiration of any applicable grace period.

For the three months ended March 31, 2013 and 2012, the components of interest expense and cash paid for interest expense for the April 2019 Notes and September 2019 Notes are as follows:


	Three Months Ended March 31,
(unaudited, in thousands)	2013		2012
Stated interest expense	$	2,981	$	—
Amortization of debt issuance cost		240		—

Total interest expense and fees	$	3,222	$	—

Cash paid for interest expense and fees	$	2,998	$	—

As of March 31, 2013, we are in compliance with the terms of the indenture governing the 2019 Notes. See Note 4 to our consolidated financial statements for more detail on the 2019 Notes.

Asset-Backed Notes

On December 19, 2012, we completed a $230.7 million term debt securitization in connection with which an affiliate of ours made an offering of $129.3 million in aggregate principal amount of fixed-rate asset-backed notes (the “Asset-Backed Notes”), which Asset-Backed Notes were rated A2(sf) by Moody’s Investors Service, Inc. The Asset-Backed Notes were issued by Hercules Capital Funding Trust 2012-1 pursuant to a note purchase agreement, dated as of December 12, 2012, by and among us, Hercules Capital Funding 2012-1 LLC, as Trust Depositor (the “Trust Depositor”), Hercules Capital Funding Trust 2012-1, as Issuer (the “Issuer”), and Guggenheim Securities, LLC, as Initial Purchaser, and are backed by a pool of senior loans made to certain of our portfolio companies and secured by certain assets of those portfolio companies and are to be serviced by us. Interest on the Asset-Backed Notes will be paid, to the extent of funds available, at a fixed rate of 3.32% per annum. The Asset-Backed Notes have a stated maturity of December 16, 2017.

As part of this transaction, we entered into a sale and contribution agreement with the Trust Depositor under which we have agreed to sell or have contributed to the Trust Depositor certain senior loans made to certain of our portfolio companies (the “Loans”). We have made customary representations, warranties and covenants in the sale and contribution agreement with respect to the Loans as of the date of their transfer to the Trust Depositor.

In connection with the issuance and sale of the Asset-Backed Notes, we have made customary representations, warranties and covenants in the note purchase agreement. The Asset-Backed Notes are secured obligations of the Issuer and are non-recourse to us. The Issuer also entered into an indenture governing the Asset-Backed Notes, which indenture includes customary representations, warranties and covenants. The Asset-Backed Notes were sold without being registered under the Securities Act of 1933, as amended (the “Securities Act”), to “qualified institutional buyers” in compliance with the exemption from registration provided by Rule 144A under the Securities Act and to institutional “accredited investors” (as defined in Rule 501(a)(1), (2), (3) or (7) under the Securities Act) who in each case, are “qualified purchasers” for purposes of Section 3(c)(7) under the 1940 Act. In addition, the Trust Depositor entered into an amended and restated trust agreement, which includes customary representation, warranties and covenants.

The Loans are serviced by us pursuant to a sale and servicing agreement, which contains customary representations, warranties and covenants. We perform certain servicing and administrative functions with respect to the Loans. We are entitled to receive a monthly fee from the Issuer for servicing the Loans. This servicing fee equals the product of one-twelfth (or in the case of the first payment date, a fraction equal to the number of days from and including December 5, 2012 through and including January 15, 2013 over 360) of 2.00% and the aggregate outstanding principal balance of the Loans, excluding all defaulted Loans and all purchased Loans, as of the first day of the related collection period (the period from the 5th day of the immediately preceding calendar month through the 4th day of the calendar month in which a payment date occurs, and for the first payment date, the period from and including December 5, 2012, to the close of business on January 4, 2013).

We also serve as administrator to the Issuer under an administration agreement, which includes customary representations, warranties and covenants.

At March 31, 2013 and December 31, 2012, the Asset-Backed Notes had an outstanding balance of $120.1 million and $129.3 million, respectively.

Under the terms of the Asset Backed Notes, we are required to maintain a reserve cash balance, funded through interest and principal collections from the underlying securitized debt portfolio, which may be used to pay monthly interest and principal payments on the Asset-Backed Notes. We have segregated these funds and classified them as Restricted Cash. There was approximately $810,000 of Restricted Cash as of March 31, 2013 funded through interest collections. There was no cash segregated at December 31, 2012 due to immaterial monthly interest collections for the period ended December 31, 2012.

Dividends

The following table summarizes our dividends declared and paid or to be paid on all shares, including restricted stock, to date:


Date Declared	Record Date	Payment Date	Amount Per Share
October 27, 2005	November 1, 2005	November 17, 2005	$	0.03
December 9, 2005	January 6, 2006	January 27, 2006		0.30
April 3, 2006	April 10, 2006	May 5, 2006		0.30
July 19, 2006	July 31, 2006	August 28, 2006		0.30
October 16, 2006	November 6, 2006	December 1, 2006		0.30
February 7, 2007	February 19, 2007	March 19, 2007		0.30
May 3, 2007	May 16, 2007	June 18, 2007		0.30
August 2, 2007	August 16, 2007	September 17, 2007		0.30
November 1, 2007	November 16, 2007	December 17, 2007		0.30
February 7, 2008	February 15, 2008	March 17, 2008		0.30
May 8, 2008	May 16, 2008	June 16, 2008		0.34
August 7, 2008	August 15, 2008	September 19, 2008		0.34
November 6, 2008	November 14, 2008	December 15, 2008		0.34
February 12, 2009	February 23, 2009	March 30, 2009		0.32
May 7, 2009	May 15, 2009	June 15, 2009		0.30
August 6, 2009	August 14, 2009	September 14, 2009		0.30
October 15, 2009	October 20, 2009	November 23, 2009		0.30
December 16, 2009	December 24, 2009	December 30, 2009		0.04
February 11, 2010	February 19, 2010	March 19, 2010		0.20
May 3, 2010	May 12, 2010	June 18, 2010		0.20
August 2, 2010	August 12, 2010	September 17,2010		0.20
November 4, 2010	November 10, 2010	December 17, 2010		0.20
March 1, 2011	March 10, 2011	March 24, 2011		0.22
May 5, 2011	May 11, 2011	June 23, 2011		0.22
August 4, 2011	August 15, 2011	September 15, 2011		0.22
November 3, 2011	November 14, 2011	November 29, 2011		0.22
February 27, 2012	March 12, 2012	March 15, 2012		0.23
April 30, 2012	May 18, 2012	May 25, 2012		0.24
July 30, 2012	August 17, 2012	August 24, 2012		0.24
October 26, 2012	November 14, 2012	November 21, 2012		0.24
February 26, 2013	March 11, 2013	March 19, 2013		0.25
April 29, 2013	May 14, 2013	May 21, 2013		0.27

			$	8.16

*	Dividend paid in cash and stock.

On April 29, 2013 the Board of Directors increased the quarterly dividend $0.02, or approximately 8.0%, and declared a cash dividend of $0.27 per share that is to be paid on May 21, 2013 to shareholders of record as of May 14, 2013. This dividend is our thirty-first consecutive quarterly dividend declaration since our initial public offering, and will bring the total cumulative dividend declared to date to $8.16 per share.

Our Board of Directors maintains a variable dividend policy with the objective of distributing four quarterly distributions in an amount that approximates 90 - 100% of our taxable quarterly income or potential annual income for a particular year. In addition, at the end of the year, we may also pay an additional special dividend or fifth dividend, such that we may distribute approximately all of our annual taxable income in the year it was earned, while maintaining the option to spill over our excess taxable income.

Distributions in excess of our current and accumulated earnings and profits would generally be treated first as a return of capital to the extent of the stockholder’s tax basis, and any remaining distributions would be treated as a capital gain. The determination of the tax attributes of our distributions is made annually as of the end of our fiscal year based upon our taxable income for the full year and distributions paid for the full year. Of the dividends declared during the year ended December 31, 2012 and 2011, 100% were distributions of ordinary income. There can be no certainty to stockholders that this determination is representative of what the tax attributes of our 2013 distributions to stockholders will actually be.

Each year a statement on Form 1099-DIV identifying the source of the distribution (i.e., paid from ordinary income, paid from net capital gains on the sale of securities, and/or a return of paid-in-capital surplus which is a nontaxable distribution) is mailed to our stockholders. To the extent our taxable earnings fall below the total amount of our distributions for that fiscal year, a portion of those distributions may be deemed a tax return of capital to our stockholders.

We operate to qualify to be taxed as a RIC under the Code. Generally, a RIC is entitled to deduct dividends it pays to its shareholders from its income to determine “taxable income.” Taxable income includes our taxable interest, dividend and fee income, as well as taxable net capital gains. Taxable income generally differs from net income for financial reporting purposes due to temporary and permanent differences in the recognition of income and expenses, and generally excludes net unrealized appreciation or depreciation, as gains or losses are not included in taxable income until they are realized. In addition, gains realized for financial reporting purposes may differ from gains included in taxable income as a result of our election to recognize gains using installment sale treatment, which generally results in the deferment of gains for tax purposes until notes or other amounts, including amounts held in escrow, received as consideration from the sale of investments are collected in cash. Taxable income includes non-cash income, such as changes in accrued and reinvested interest and dividends, which includes contractual payment-in-kind interest, and the amortization of discounts and fees. Cash collections of income resulting from contractual PIK interest or the amortization of discounts and fees generally occur upon the repayment of the loans or debt securities that include such items. Non-cash taxable income is reduced by non-cash expenses, such as realized losses and depreciation and amortization expense.

We intend to distribute quarterly dividends to our stockholders. In order to avoid certain excise taxes imposed on RICs, we currently intend to distribute during each calendar year an amount at least equal to the sum of (1) 98% of our ordinary income for the calendar year, (2) 98.2% of our capital gains in excess of capital losses for the one year period ending on October 31 of the calendar year, and (3) any ordinary income and net capital gains for the preceding year that were not distributed during such year. We will not be subject to excise taxes on amounts on which we are required to pay corporate income tax (such as retained net capital gains). In order to obtain the tax benefits applicable to RICs, we will be required to distribute to our stockholders with respect to each taxable year at least 90% of our ordinary income and realized net short-term capital gains in excess of realized net long-term capital losses.

We can offer no assurance that we will achieve results that will permit the payment of any cash distributions and, if we issue senior securities, we will be prohibited from making distributions if doing so causes us to fail to maintain the asset coverage ratios stipulated by the 1940 Act or if distributions are limited by the terms of any of our borrowings. Our ability to make distributions will be limited by the asset coverage requirements under the 1940 Act.

We intend to distribute approximately $1.5 million of spillover earnings from the year ended December 31, 2012 to our shareholders in 2013.

We maintain an “opt-out” dividend reinvestment plan for our common stockholders. As a result, if we declare a dividend, cash dividends will be automatically reinvested in additional shares of our common stock unless the stockholder specifically “opts out” of the dividend reinvestment plan and chooses to receive cash dividends.

Critical Accounting Policies

The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and revenues and expenses during the period reported. On an ongoing basis, our management evaluates its estimates and assumptions, which are based on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. Actual results could differ from those estimates. Changes in our estimates and assumptions could materially impact our results of operations and financial condition.

Valuation of Portfolio Investments

The most significant estimate inherent in the preparation of our consolidated financial statements is the valuation of investments and the related amounts of unrealized appreciation and depreciation of investments recorded.

Our investments are carried at fair value in accordance with the 1940 Act and Accounting Standards Codification (“ASC”) topic 820 Fair Value Measurements and Disclosures (formerly known as SFAS No. 157, Fair Value Measurements). At March 31, 2013, approximately 79.9% of our total assets represented investments in portfolio companies that are valued at fair value by the Board of Directors. Value, as defined in Section 2(a)(41) of the 1940 Act, is (i) the market price for those securities for which a market quotation is readily available and (ii) for all other securities and assets, fair value is as determined in good faith by the Board of Directors. Our debt securities are primarily invested in venture capital-backed companies in technology-related markets, including technology, biotechnology, life science and clean technology industries. Given the nature of lending to these types of businesses, our investments in these portfolio companies are generally considered Level 3 assets under ASC 820 because there is no known or accessible market or market indexes for these investment securities to be traded or exchanged. As such, it values substantially all of its investments at fair value as determined in good faith pursuant to a consistent valuation policy and our Board of Directors in accordance with the provisions of ASC 820 and the 1940 Act. Due to the inherent uncertainty in determining the fair value of investments that do not have a readily available market value, the fair value of our investments determined in good faith by our Board may differ significantly from the value that would have been used had a readily available market existed for such investments, and the differences could be material.

Our Board of Directors may from time to time engage an independent valuation firm to provide us with valuation assistance with respect to certain of our portfolio investments on a quarterly basis. We intend to continue to engage an independent valuation firm to provide us with assistance regarding our determination of the fair value of selected portfolio investments each quarter unless directed by the Board of Directors to cancel such valuation services. The scope of the services rendered by an independent valuation firm is at the discretion of the Board of Directors. Our Board of Directors is ultimately and solely responsible for determining the fair value of our investments in good faith.

With respect to investments for which market quotations are not readily available or when such market quotations are deemed not to represent fair value, our Board of Directors has approved a multi-step valuation process each quarter, as described below:

(1) our quarterly valuation process begins with each portfolio company or investment being initially valued by the investment professionals responsible for the portfolio investment;

(2) preliminary valuation conclusions are then documented and business based assumptions are discussed with our investment committee;

(3) the valuation committee of the Board of Directors reviews the preliminary valuation of the investment committee which incorporates the results of the independent valuation firm as appropriate.

We adopted ASC 820 on January 1, 2008. ASC 820 establishes a framework for measuring the fair value of the assets and liabilities and outlines a fair value hierarchy which prioritizes the inputs used to measure fair value and the effect of fair value measures on earnings. ASC 820 also enhances disclosure requirements for fair value measurements based on the level within the hierarchy of the information used in the valuation. ASC 820 applies whenever other standards require (or permit) assets or liabilities to be measured at fair value but does not expand the use of fair value in any new circumstances. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.

We have categorized all investments recorded at fair value in accordance with ASC 820 based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels, defined by ASC 820 and directly related to the amount of subjectivity associated with the inputs to fair valuation of these assets and liabilities, are as follows:

the fair value measurement and unobservable. Generally, assets carried at fair value and included in this category are the debt investments and warrants and equities held in a private company.

In accordance with ASU 2011-04, the following table provides quantitative information about our Level 3 fair value measurements of our investments as of December 31, 2012. In addition to the techniques and inputs noted in the table below, according to our valuation policy we may also use other valuation techniques and methodologies when determining our fair value measurements. The below table is not intended to be all-inclusive, but rather provides information on the significant Level 3 inputs as they relate to our fair value measurements.


Investment Type - Level Three Debt Investments	Fair Value at March 31, 2013 (unaudited, in thousands)		Valuation Techniques/ Methodologies	Unobservable Input^(a)	Range
Pharmaceuticals - Debt	$	264,707	Market Comparable Companies	Hypothetical Market Yield Premium/(Discount)	13.84% - 19.29% (2.0%) - 1.0%
			Option Pricing Model^(b)	Average Industry Volatility^(c) Risk Free Interest Rate Estimated Time to Exit (in months)	57.97% 0.170% 12.17
Medical Devices - Debt		60,674	Market Comparable Companies	Hypothetical Market Yield Premium	16.77% 0.00% - 1.00%

Technology - Debt		164,844	Market Comparable Companies	Hypothetical Market Yield Premium/(Discount)	12.36% - 19.30% (2.00%) - 2.00%
			Liquidation	Investment Collateral	$0.00 - $7.08 million

Clean Tech - Debt		105,436	Market Comparable Companies	Hypothetical Market Yield Premium	13.03% - 17.17% 0.00% - 1.00%
Lower Middle Market - Debt		285,350	Market Comparable Companies	Hypothetical Market Yield Premium	11.07% - 21.85% 0.00% - 1.00%
			Broker Quote^(d)	Price Quotes	81.0% - 100% of par
				Market Comparable Index Yield Spreads	3.50% - 5.93%
				Par Value	$30.0 million

Total Level Three Debt Investments	$	881,011

(a)

Pharmaceuticals, above, is comprised of debt investments in the Specialty Pharmaceuticals, Drug Discovery and Development, Drug Delivery, and Diagnostics and Biotechnology industries in the Schedule of Investments.

Medical Devices, above, is comprised of debt investments in the Therapeutic, Surgical Devices, Medical Devices and Equipment and Biotechnology Tools industries in the Schedule of Investments.

Technology, above, is comprised of debt investments in the Software, Semiconductors, Electronics and Computer Hardware, Internet Consumer and Business Services, Information Services, Media/Content/Info and Communications and Networking industries in the Schedule of Investments.

Lower Middle Market, above, is comprised of debt investments in the Communications and Networking, Software, Electronics and Computer Hardware, Information Services, Internet Consumer and Business Services, Media/Content/Info, and Specialty Pharmaceuticals industries in the Schedule of Investments.

Clean Tech, above, aligns with the Clean Tech industry in the Schedule of Investments.

(b)	An option pricing model valuation technique was used to derive the fair value of the conversion feature of convertible notes.

(c)	Represents the range of industry volatility used by market participants when pricing the investment.

(d)	A broker quote valuation technique was used to derive the fair value of loans which are part of a syndicated facility.


Investment Type -	Fair Value at March 31, 2013		Valuation Techniques/ Methodologies	Unobservable Input^(a)	Range
	(unaudited, in thousands)
Level Three Equity Investments	$	40,106	Market Comparable Companies	EBITDA Multiple^(b)	4.30x - 24.55x
				Revenue Multiple^(b)	0.59x - 16.29x
				Discount for Lack of Marketability^(c)	10.4% - 25.20%

Level Three Warrant Investments		28,030	Market Comparable Companies	EBITDA Multiple^(b)	4.30x - 24.55x
				Revenue Multiple^(b)	0.59x - 16.29x
				Discount for Lack of Marketability^(c)	10.4% - 25.20%

Warrant positions additionally subject to:			Option Pricing Model	Average Industry Volatility^(d)	43.53% - 140.36%
				Risk-Free Interest Rate	0.15% - 0.64%
				Estimated Time to Exit (in months)	12 - 48

Total Level Three Warrant and Equity Investments	$	68,136

(a)

The significant unobservable inputs used in the fair value measurement of our warrant and equity-related securities are revenue and/or EBITDA multiples and discounts for lack of marketability. Additional inputs used in the Black Scholes option pricing model include industry volatility, risk free interest rate and estimated time to exit. Significant increases (decreases) in the inputs in isolation would result in a significantly higher (lower) fair value measurement, depending on the materiality of the investment. For some investments, additional consideration may be given to data from the last round of financing or merger/acquisition events near the measurement date.

(b)	Represents amounts used when we have determined that market participants would use such multiples when pricing the investments.

(c)	Represents amounts used when we have determined market participants would take into account these discounts when pricing the investments.

(d)	Represents the range of industry volatility used by market participants when pricing the investment.

Debt Investments

We follow the guidance set forth in ASC 820 which establishes a framework for measuring the fair value of assets and liabilities and outlines a fair value hierarchy which prioritizes the inputs used to measure fair value and the effect of fair value measures on earnings. Our debt securities are primarily invested in venture capital-backed companies in technology-related markets, including technology, biotechnology, life science and clean-technology industries at all stages of development. Given the nature of lending to these types of businesses, our investments in these portfolio companies are considered Level 3 assets under ASC 820 because there is no known or accessible market or market indexes for these investment securities to be traded or exchanged.

In making a good faith determination of the value of our investments, we generally start with the cost basis of the investment, which includes the value attributed to the OID, if any, and PIK interest which has been accrued to principal as earned. We then apply the valuation methods as set forth below.

We apply a procedure for debt investments that assumes a sale of investment in a hypothetical market to a hypothetical market participant where buyers and sellers are willing participants. The hypothetical market does not include scenarios where the underlying security was simply repaid or extinguished, but includes an exit concept. Under this process, we also evaluate the collateral for recoverability of the debt investments as well as apply all of its historical fair value analysis. We use pricing on recently issued comparable debt securities to determine the baseline hypothetical market yields as of the measurement date. We consider each portfolio company’s credit rating, security liens and other characteristics of the investment to adjust the baseline yield to derive a hypothetical yield for each investment as of the measurement date. The anticipated future cash flows from each investment are then discounted at the hypothetical yield to estimate each investment’s fair value as of the measurement date.

Our process includes, among other things, the underlying investment performance, the current portfolio company’s financial condition and market changing events that impact valuation, estimated remaining life, current market yield and interest rate spreads of similar securities as of the measurement date. We value our syndicated loans using broker quotes and bond indices amongst other factors. If there is a significant deterioration of the credit quality of a debt investment, we may consider other factors than those a hypothetical market participant would use to estimate fair value, including the proceeds that would be received in a liquidation analysis.

We record unrealized depreciation on investments when we believe that an investment has decreased in value, including where collection of a loan is doubtful or if under the in exchange premise when the value of a debt security were to be less than amortized cost of the investment. Conversely, where appropriate, we record unrealized appreciation if we believe that the underlying portfolio company has appreciated in value and, therefore, that our investment has also appreciated in value or if under the in exchange premise the value of a debt security were to be greater than amortized cost.

When originating a debt instrument, we generally receive warrants or other equity-related securities from the borrower. We determine the cost basis of the warrants or other equity-related securities received based upon their respective fair values on the date of receipt in proportion to the total fair value of the debt and warrants or other equity-related securities received. Any resulting discount on the loan from recordation of the warrant or other equity instruments is accreted into interest income over the life of the loan.

Equity-Related Securities and Warrants

Securities that are traded in the over-the-counter markets or on a stock exchange will be valued at the prevailing bid price at period end. We have a limited number of equity securities in public companies. In accordance with the 1940 Act, unrestricted publicly traded securities for which market quotations are readily available are valued at the closing market quote on the measurement date.

We estimate the fair value of warrants using a Black Scholes pricing model. At each reporting date, privately held warrant and equity related securities are valued based on an analysis of various factors including, but not limited to, the portfolio company’s operating performance and financial condition and general market conditions, price to enterprise value or price to equity ratios, discounted cash flow, valuation comparisons to comparable public companies or other industry benchmarks. When an external event occurs, such as a purchase transaction, public offering, or subsequent equity sale, the pricing indicated by that external event is utilized to corroborate our valuation of the warrant and equity related securities. We periodically review the valuation of our portfolio companies that have not been involved in a qualifying external event to determine if the enterprise value of the portfolio company may have increased or decreased since the last valuation measurement date.

Income Recognition.

We record interest income on the accrual basis and we recognize it as earned in accordance with the contractual terms of the loan agreement to the extent that such amounts are expected to be collected. Original Issue Discount (“OID”) initially represents the value of detachable equity warrants obtained in conjunction with the acquisition of debt securities and is accreted into interest income over the term of the loan as a yield enhancement. When a loan becomes 90 days or more past due, or if management otherwise does not expect the portfolio company to be able to service its debt and other obligations, we will generally place the loan on non-accrual status and cease recognizing interest income on that loan until all principal has been paid. Any uncollected interest related to prior periods is reversed from income in the period that collection of the interest receivable is determined to be doubtful. However, we may make exceptions to this policy if the investment has sufficient collateral value and is in the process of collection. At March 31, 2013, we had two loans on non-accrual, one with a fair value of approximately $5.6 million and the other with no fair market value compared to one loan at December 31, 2012 with no fair market value.

Paid-In-Kind and End of Term Income.

Contractual paid-in-kind (“PIK”) interest, which represents contractually deferred interest added to the loan balance that is generally due at the end of the loan term, is generally recorded on the accrual basis to the extent such amounts are expected to be collected. We will generally cease accruing PIK interest if there is insufficient value to support the accrual or we do not expect the portfolio company to be able to pay all principal and interest due. In addition, we may also be entitled to an end-of-term payment that we amortize into income over the life of the loan. To maintain our status as a RIC, PIK and end-of-term income must be paid out to stockholders in the form of dividends even though we have not yet collected the cash. Amounts necessary to pay these dividends may come from available cash or the liquidation of certain investments. We recorded approximately $779,000 and $298,000 in PIK income in the three-month periods ended March 31, 2013 and 2012, respectively.

Fee Income.

Fee income, generally collected in advance, includes loan commitment and facility fees for due diligence and structuring, as well as fees for transaction services and management services rendered by us to portfolio companies and other third parties. Loan and commitment fees are amortized into income over the contractual life of the loan. Management fees are generally recognized as income when the services are rendered. Loan origination fees are capitalized and then amortized into interest income using the effective interest rate method. In certain loan arrangements, warrants or other equity interests are received from the borrower as additional origination fees.

We recognize nonrecurring fees amortized over the remaining term of the loan commencing in the quarter relating to specific loan modifications. Certain fees may still be recognized as one-time fees, including prepayment penalties, fees related to select covenant default waiver fees and acceleration of previously deferred loan fees and original issue discount (OID) related to early loan pay-off or material modification of the specific debt outstanding.

Equity Offering Expenses

Our offering costs are charged against the proceeds from equity offerings when received.

Debt Issuance Costs

Debt issuance costs are being amortized over the life of the related debt instrument using the straight line method, which closely approximates the effective yield method.

Stock-Based Compensation.

We have issued and may, from time to time, issue additional stock options and restricted stock to employees under our 2004 Equity Incentive Plan and Board members under our 2006 Equity Incentive Plan. We follow ASC 718, formally known as FAS 123R “Share-Based Payments” to account for stock options granted. Under ASC 718, compensation expense associated with stock-based compensation is measured at the grant date based on the fair value of the award and is recognized over the vesting period.

Federal Income Taxes.

We intend to operate so as to qualify to be taxed as a RIC under Subchapter M of the Code and, as such, will not be subject to federal income tax on the portion of our taxable income and gains distributed to stockholders. To qualify as a RIC, we are required to distribute at least 90% of our investment company taxable income, as defined by the Code. We are subject to a non-deductible federal excise tax if we do not distribute at least 98% of our taxable income and 98.2% of our capital gain net income for each one year period ending on October 31. At December 31, 2012, 2011, 2010 and 2009, no excise tax was recorded. We intend to distribute approximately $1.5 million of spillover earnings from the year ended December 31, 2012 to our shareholders in 2013. Because federal income tax regulations differ from accounting principles generally accepted in the United States, distributions in accordance with tax regulations may differ from net investment income and realized gains recognized for financial reporting purposes. Differences may be permanent or temporary. Permanent differences are reclassified among capital accounts in the financial statement to reflect their tax character. Temporary differences arise when certain items of income, expense, gain or loss are recognized at some time in the future. Differences in classification may also result from the treatment of short-term gains as ordinary income for tax purposes.

Subsequent Events

Dividend Declaration

On April 29, 2013 the Board of Directors increased the quarterly dividend by $0.02, or approximately 8.0%, and declared a cash dividend of $0.27 per share to be paid on May 21, 2013 to shareholders of record as of May 14, 2013. This dividend would represent our thirty-first consecutive dividend declaration since our initial public offering, bringing the total cumulative dividend declared to date to $8.16 per share.

Closed and Pending Commitments

As of April 29, 2013, we have:

Closed commitments of approximately $20.0 million to new and existing portfolio companies, and funded approximately $28.0 million since the close of the first quarter of 2013.

Pending commitments (signed non-binding term sheets) of approximately $179.0 million.

The table below summarizes our year-to-date closed and pending commitments as follows:


Closed Commitments and Pending Commitments (in millions)
Q1-13 Closed Commitments	$	224.0
Q2-13 Closed Commitments (as of April 29, 2013)	$	20.0
Total year-to-date 2013 Closed Commitments(a)	$	244.0
Pending Commitments (as of April 29, 2013)(b)	$	179.0
Total 2013	$	423.0

Notes:

Not all Closed Commitments result in future cash requirements. Commitments generally fund over the two succeeding quarters from close.

Not all pending commitments (signed non-binding term sheets) are expected to close and do not necessarily represent any future cash requirements.

Company Developments

In April 2013, Kroll Bond Rating Agency (“KBRA”) assigned Hercules an investment grade corporate rating of BBB+. In addition, our two outstanding bond issuances of 7.00% Senior Notes due 2019, which trade on the NYSE under the symbols “HTGZ” and “HTGY,” were assigned a rating of BBB+.

Portfolio Company Developments

In April 2013, Japanese company Ajinomoto Co., Inc. (TYO: 2802) completed its acquisition of our portfolio company Althea Technologies.

In April 2013, Omthera Pharmaceuticals, Inc., (“OMTH”) completed its initial public offering of 8,000,000 shares of its common stock at $8.00 per share.

ITEM 3.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are subject to financial market risks, including changes in interest rates. Interest rate risk is defined as the sensitivity of our current and future earnings to interest rate volatility, variability of spread relationships, the difference in re-pricing intervals between our assets and liabilities and the effect that interest rates may have on our cash flows. Changes in the general level of interest rates can affect our net investment income, which is the difference between the interest income earned on interest earning assets and our interest expense incurred in connection with our interest bearing debt and liabilities. Changes in interest rates can also affect, among other things, our ability to acquire and originate loans and securities and the value of our investment portfolio.

We are subject to financial market risks, including changes in interest rates. During the three month period ended March 31, 2013, approximately 98.8% of the loans in our portfolio had variable rates based on floating Prime or LIBOR, or variable rates with a floor. Assuming no changes to our balance sheet as of March 31, 2013, a hypothetical one percent increase in Prime or LIBOR on our floating rate assets would increase our net investment income by approximately $0.11 per average share over the next twelve months. Assuming no changes to our balance sheet as of March 31, 2013, a hypothetical one percent decrease in Prime or LIBOR on our floating rate assets would have no impact on our net investment income per average share over the next twelve months. This hypothetical result includes additional 1% interest on our idle cash funds as well as additional interest income on our investment portfolio. Our liabilities bear interest at fixed rates. We do not currently engage in any hedging activities. However, we may, in the future, hedge against interest rate fluctuations by using standard hedging instruments such as futures, options, and forward contracts. While hedging activities may insulate us against changes in interest rates, they may also limit our ability to participate in the benefits of lower interest rates with respect to our borrowed funds and higher interest rates with respect to our portfolio of investments. During the three-month period ended March 31, 2013, we did not engage in interest rate hedging activities.

Interest rates on our borrowings are based primarily on LIBOR. Borrowings under our SBA program are fixed at the ten year treasury rate every March and September for borrowings of the preceding nine-months. Borrowings under the program are charged interest based on ten year treasury rates plus a spread and the rates are generally set for a pool of debentures issued by the SBA in nine-month periods. The rates of borrowings under the various draws from the SBA beginning in April 2007 and set semiannually in March and September range from 2.25% to 5.73%. In addition, the SBA charges a fee that is set annually, depending on the Federal fiscal year the leverage commitment was delegated by the SBA, regardless of the date that the leverage was drawn by the SBIC. The annual fees related to HT II debentures that pooled on September 22, 2010 were 0.406% and 0.285%, depending upon the year in which the underlying commitment was closed. The annual fees related to HT III debentures that pooled on March 27, 2013 were 0.804%. The annual fees on other debentures have been set at 0.906%. The average amount of debentures outstanding for the three-month period ended March 31, 2013 for HT II was approximately $76.0 million with an average interest rate of approximately 5.3%. The average amount of debentures outstanding for the three-month period ended March 31, 2013 for HT III was approximately $149.0 million with an average interest rate of approximately 3.26%. Interest is payable semiannually and there are no principal payments required on these issues prior to maturity. Debentures under the SBA generally mature ten years after being borrowed. Based on the initial draw down date of April 2007, the initial maturity of SBA debentures will occur in April 2017.

Borrowings under the Wells Facility will generally bear interest at a rate per annum equal to LIBOR plus 3.50%, with a floor of 4.25% and an advance rate of 50% against eligible loans. The Wells Facility is secured by loans in the borrowing base. The Wells Facility requires payment of a non-use fee on a scale of 0.0% to 0.50% of the average monthly outstanding balance. For the three-month period ended March 31, 2013, this non-use fee was approximately $94,000. On June 20, 2011 we paid an additional $1.1 million in structuring fees in connection with the Wells Facility which is being amortized through June 2014. At March 31, 2013, there was no debt outstanding under the Wells Facility.

Borrowings under the Union Bank Facility will generally bear interest at a rate per annum equal to LIBOR plus 2.25% with a floor of 4.0%. The Union Bank Facility required the payment of an unused fee of 0.50% annually. For the three-month period ended March 31, 2013, this non-use fee was approximately $37,500. The Union Bank Facility is collateralized by debt investments in our portfolio companies, and includes an advance rate equal to 50% of eligible loans placed in the collateral pool. The Union Bank Facility generally requires payment of interest on a monthly basis. All outstanding principal is due upon maturity. There were no outstanding borrowings under this facility at March 31, 2013. On November 2, 2011, we renewed and amended the Union Bank Facility. The other terms of the Union Bank Facility generally remain unchanged, including the stated interest rate. The Union Bank Facility will mature on November 1, 2014, revolving through the first 24 months with a term out provision for the remaining 12 months.

Borrowings under the Convertible Senior Notes mature on April 15, 2016 (the “Maturity Date”), unless previously converted or repurchased in accordance with their terms. The Convertible Senior Notes bear interest at a rate of 6.00% per year payable semiannually in arrears on April 15 and October 15 of each year, commencing on October 15, 2011. The Convertible Senior Notes are our senior unsecured obligations and rank senior in right of payment to the our existing and future indebtedness that is expressly subordinated in right of payment to the Convertible Senior Notes; equal in right of payment to our existing and future unsecured indebtedness that is not so subordinated; effectively junior in right of payment to any of our secured indebtedness (including unsecured indebtedness that we later secure) to the extent of the value of the assets securing such indebtedness; and structurally junior to all existing and future indebtedness (including trade payables) incurred by our subsidiaries, financing vehicles or similar facilities.

The April 2019 Notes and September 2019 Notes will be our direct unsecured obligations and will rank: (i) pari passu with our other outstanding and future senior unsecured indebtedness, including without limitation, the $75 million in aggregate principal amount of the Convertible Senior Notes; (ii) senior to any of our future indebtedness that expressly provides it is subordinated to the Notes; (iii) effectively subordinated to all our existing and future secured indebtedness (including indebtedness that is initially unsecured to which we subsequently grant security), to the extent of the value of the assets securing such indebtedness, including without limitation, borrowings under our credit facilities; (iv) structurally subordinated to all existing and future indebtedness and other obligations of any of our subsidiaries, including without limitation, the indebtedness of Hercules Technology II, L.P. and Hercules Technology III, L.P. and borrowings under our revolving senior secured credit facility with Wells Fargo Capital Finance.

In connection with our $230.7 million Debt Securitization, the Securitization Issuer made an offering of $129.3 million in aggregate principal amount of the Asset-Backed Notes. Interest on the Asset-Backed Notes will be paid, to the extent of funds available, at a fixed rate of 3.32% per annum. The Asset-Backed Notes have a stated maturity of December 16, 2017.

As of the closing date of the Debt Securitization, all of the floating rate Loans sold and/or contributed to the Securitization Issuer are subject to interest rate floors. As of the closing date of the Debt Securitization, all of the floating rate Loans are accruing interest at the applicable interest rate floors specified thereunder, which rate floors are in excess of the fixed rate of interest accruing on the Asset-Backed Notes, which naturally hedges the Securitization Issuer’s assets and liabilities. However, there is no requirement for any Loan to have an interest rate floor and there can be no assurance that any such interest rate floor will fully mitigate any decrease in “excess spread” (i.e. the difference between the interest collected on the Loans and the sum of the interest payable on the Asset-Backed Notes and certain transaction fees and expenses payable by the Issuer) that otherwise would be available to make payments on the Asset-Backed Notes, as credit support, or as otherwise provided in the priority of payments under the documents governing the Debt Securitization. In the unlikely event that a breach of the representations and warranties under the documents governing the Debt Securitization with respect to the Loans in the pool as of the closing date of the Debt Securitization were to occur, a substantial volume of substitutions of Loans in the pool could result. There can be no assurance that the applicable margins and any applicable interest rate floors on such substitute Loans would be in excess of the interest on the Asset-Backed Notes. As a result of such substitutions, and subject in the case of floating rate Loans to changes in the level of LIBOR or any other applicable floating rate index, a mismatch could therefore arise between the rates of interest accruing in connection with the Loans in the pool and the fixed rate of interest accruing on the Asset-Backed Notes. Consequently, amounts payable by the Securitization Issuer could exceed collections on the Loans in the pool, which could delay, reduce or eliminate the ability of the Securitization Issuer to make distributions in respect of the equity interest that we indirectly hold.

Because we currently borrow, and plan to borrow in the future, money to make investments, our net investment income is dependent upon the difference between the rate at which we borrow funds and the rate at which we invest the funds borrowed. Accordingly, there can be no assurance that a significant change in market interest rates will not have a material adverse effect on our net investment income. In periods of rising interest rates, our cost of funds would increase, which could reduce our net investment income if there is not a corresponding increase in interest income generated by variable rate assets in our investment portfolio.

ITEM 4.

CONTROLS AND PROCEDURES

Disclosure Controls and Procedures

Our chief executive and chief financial officers, under the supervision and with the participation of our management, conducted an evaluation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934. As of the end of the period covered by this quarterly report on Form 10-Q, our chief executive and chief financial officers have concluded that our disclosure controls and procedures were effective to ensure that information required to be disclosed by us in reports that it files or submits under the Securities Exchange Act of 1934 is recorded, processed, summarized, and reported within the time periods specified in SEC rules and forms, and that information required to be disclosed by us in the reports that it files or submits under the Securities Exchange Act of 1934 is accumulated and communicated to our management, including its chief executive and chief financial officers, as appropriate to allow timely decisions regarding required disclosure.

Changes in Internal Control Over Financial Reporting

There have been no other changes in our internal control over financing reporting, as defined in Rules 13a-15(f) and 15d-15(f) of the Securities Exchange Act of 1934, as amended, that occurred during our most recently completed fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II: OTHER INFORMATION

ITEM 1.

LEGAL PROCEEDINGS

We may, from time to time, be involved in litigation arising out of our operations in the normal course of business or otherwise. Furthermore, third parties may try to seek to impose liability on us in connection with the activities of our portfolio companies. While the outcome of any current legal proceedings cannot at this time be predicted with certainty, we do not expect any current matters will materially affect our financial condition or results of operations; however, there can be no assurance whether any pending legal proceedings will have a material adverse effect on our financial condition or results of operations in any future reporting period.

ITEM 1A.

RISK FACTORS

In addition to the risks discussed below, important risk factors that could cause results or events to differ from current expectations are described in Part I, Item 1A “Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2012.

Our financial results could be negatively affected if a significant portfolio investment fails to perform as expected.

Our total investment in companies may be significant individually or in the aggregate. As a result, if a significant investment in one or more companies fails to perform as expected, our financial results could be more negatively affected and the magnitude of the loss could be more significant than if we had made smaller investments in more companies. The following table shows the fair value of the totals of investments held in portfolio companies at March 31, 2013 (unaudited) that represent greater than 5% of net assets:


	March 31, 2013
(in thousands)	Fair Value		Percentage of Net Assets
Box, Inc.	$	48,455		7.9	%
Merrimack Pharmaceuticals, Inc	$	43,816		7.1	%
BrightSource Energy, Inc.	$	34,801		5.7	%
Comverge, Inc.	$	33,358		5.4	%

Box, Inc. is an online storage and sharing service that gives users access to their files from anywhere.

Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of serious diseases, with an initial focus on cancer.

Brightsource Energy, Inc. designs, develops and sells solar thermal power systems that deliver reliable, clean energy to utilities and industrial companies.

Comverge, Inc. provides clean energy solutions.

Our financial results could be materially adversely affected if these portfolio companies or any of our other significant portfolio companies encounter financial difficulty and fail to repay their obligations or to perform as expected.

Investing in publicly traded companies can involve a high degree of risk and can be speculative.

We have invested, and expect to continue to invest, a portion of our portfolio in publicly traded companies or companies that are in the process of completing their initial public offering, or IPO. As publicly traded companies, the securities of these companies may not trade at high volumes, and prices can be volatile, which may restrict our ability to sell our positions and may have a material impact on us.

ITEM 2.

UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

During the three-month period ended March 31, 2013, we issued approximately 40,000 shares of common stock to shareholders in connection with the dividend reinvestment plan. These issuances were not subject to the registration requirements of the Securities Act of 1933, as amended. The aggregate value the shares of our common stock issued under our dividend reinvestment plan was approximately $488,000.

ITEM 3.

DEFAULTS UPON SENIOR SECURITIES

Not Applicable

ITEM 4.

MINE SAFETY DISCLOSURES

Not Applicable

ITEM 5.

OTHER INFORMATION

Not Applicable

ITEM 6.

EXHIBITS


Exhibit Number		Description

31.1		Chief Executive Officer Certification Pursuant to Exchange Act Rule 13a-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002*

31.2		Chief Financial Officer Certification Pursuant to Exchange Act Rule 13a-14 (a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002*

32.1		Chief Executive Officer Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002*

32.2		Chief Financial Officer Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002*

*	Filed herewith.

SIGNATURES

Pursuant to the requirements of the Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


						HERCULES TECHNOLOGY GROWTH CAPITAL, INC. (Registrant)

Dated: May 2, 2013						/S/ MANUEL A. HENRIQUEZ
						Manuel A. Henriquez
						Chairman, President, and Chief Executive Officer

Dated: May 2, 2013						/S/ JESSICA BARON
						Jessica Baron
						Vice President, Finance and Chief Financial Officer

EXHIBIT INDEX


Exhibit Number		Description

31.1		Chief Executive Officer Certification Pursuant to Exchange Act Rule 13a-14 (a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002*

31.2		Chief Financial Officer Certification Pursuant to Exchange Act Rule 13a-14 (a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002*

32.1		Chief Executive Officer Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002*

32.2		Chief Financial Officer Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002*

*	Filed herewith.